Hormonal and genetic regulation of prostate cancer in Caucasian and Malaysian Chinese ethnic groups by Kuppusamy, Shanggar
  
HORMONAL AND GENETIC REGULATION OF 
PROSTATE CANCER IN CAUCASIAN AND 
MALAYSIAN CHINESE ETHNIC GROUPS 
 
 
 
SHANGGAR KUPPUSAMY 
 
 
A thesis submitted in partial fulfilment of the requirements of the University of the 
West of England, Bristol for the degree of Doctor of Philosophy 
 
 
 
 
 
Faculty of Health and Life Sciences, University of the West of England, Bristol 
November 2014 
 
 
i 
 
Abstract 
Introduction 
Prostate Cancer (PC) is the most common cancer in men and the second biggest cause of 
cancer-related death of men in the Western world.  There are significant ethnic differences 
in the incidence of PC between African Americans, Caucasians and Asians. At the present 
time, the only method used for PC screening is Prostate Specific Antigen (PSA). Prostate is 
an androgen regulated gland and it can also affect the concentration of growth hormone by 
activation of androgen receptor. The aim of this research was to investigate ethnic group-
specific relationship between PC incidence, concentration of circulating hormones and 
polymorphisms in genes that are involved in regulation of androgen metabolism. Specific 
objectives were:  (i) to determine whether circulating concentration of androgens 
testosterone, dihydrotestosterone (DHT) and a growth hormone insulin-like growth factor-I 
(IGF-I) differ between Bristol Caucasian (BC) and Malaysian Chinese (MC) men; (ii) to 
investigate whether variations in concentration of circulating androgens in control and PC 
cohorts are ethnic group-specific; (iii) to determine whether frequency of  DNA 
polymorphisms in CYP17, SRD5A2 and androgen receptor (AR) genes are ethnic group-
specific; (iv) to investigate the relationship between genetic polymorphisms, concentration 
of circulating androgens and incidence of PC in BC and MC groups. 
Material and Method 
Blood sample were obtained from newly diagnosed PC patients from Caucasian and MC 
ethnic groups whose diagnosis was confirmed by biopsy. Control group consisted of 
patients with confirmed Benign Prostatic Hyperplasia with low risk of PC.  The studied 
populations consisted of 50 Caucasian cancer cases, 50 Caucasian controls, 50 MC cancer 
cases and 49 MC control participants. Analysis of testosterone, DHT and IGF-I 
concentrations was performed on serum using ELISA kits. DNA polymorphisms were 
determined using genomic DNA isolated from whole blood (by PCR amplification) and 
follow-on DNA sequencing. The obtained DNA sequences were aligned with appropriate 
DNA sequences of the reference genes. The software “Geneious” was used to identify 
DNA SNPs and amino acid substitutions in translated protein. Statistical analysis was 
performed using SPSS version 20.0.  
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Results 
This study established ethnic group-specific differences in circulating androgens between 
control and PC groups. In particular, testosterone concentration was significantly lower, 
and DHT/T was significantly higher in the MC cancer patients when compared to 
Caucasians. IGF-I concentration was significantly higher in the Caucasian cancer and 
controls than the MC sub-groups. A1/A2 and A2 + A1/A2 alleles of CYP17 gene were 
associated with a higher risk of PC in both ethnic groups. LL and L/V genotypes of 
SRD5A2 were prevalent in MC cancer and control group when compared to Bristol 
Caucasian PC and controls. These genotypes, when present, were associated with increased 
risk of PC in Caucasians but not in MC group.  No relationship was found between a 
number of CAG-repeats in AR gene and PC in Caucasian or MC populations. No 
significant relationship was found between SNPs in CYP17, SRD5A2 and AR genes and 
circulating concentration of androgens and IGF-I in Caucasian and MC populations. The 
only exception was a positive association between the SRD5A2 polymorphism in the 
position 261C→G and IGF-I concentration in Caucasian control group.    
Conclusions 
This study demonstrated positive relationship between the concentration of circulating 
androgens, namely testosterone, IGF-I growth factor and the severity of the PC in Bristol 
Caucasians and MC groups. It also established ethnic-group specific polymorphisms in 
CYP17 and SRD5A2 genes, but not in the AR gene. It was suggested that the CYP17 and 
SRD5A2 polymorphisms might contribute to the risk of PC development in Caucasians 
and MC. Further evaluation of the results on a larger cohort and a wider range of ethnic 
groups are required in order to make definite conclusions about CYP17, SRD5A2 as 
ethnic-group specific biomarkers for PC.          
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1 Introduction 
Prostate cancer (PC) is the second most common cancer after lung cancer in males. In spite 
of high incidence of PC, the mortality related to PC is lower when compared to other types 
of cancer - PC only ranks 6th with regards to cancer-related deaths (Ferlay et al, 2010b). 
There are clear differences in both, incidence and mortality rates between different regions 
and ethnic groups. Increasing trend in incidence and mortality due to PC has been reported 
over a 20 year period (1978-1997) in the Asian region among the Japanese, Korean, 
Singaporean and Thai populations (Sim and Cheng, 2005) as well as in European or 
Caucasian populations (Baade et al, 2009, American Cancer Society, 2010).  
PC is a unique and unpredictable disease due to its heterogeneous nature i.e. each 
individual with the disease differs in stage and grade giving rise to multiple acceptable 
treatment options for the same stage and grade with very unpredictable response to the 
chosen mode of treatment. PC can be cured successfully when diagnosed and treated early, 
but it is lethal when it has progressed to a metastatic stage (Brawley et al, 2009). At the 
same time, a large number of PC cases do not progress to metastatic stage and might not 
require any treatment as they are very slow to progress to cause any harm to an individual 
(Albertsen et al, 1995). This raises an important question about not only early diagnostics 
but also about effective and accurate prognosis assessment with regards to cancer 
progression in order to advocate the best possible treatment option.  
There are several risk factors that contribute to unpredictable nature of the disease such as 
ethnicity, age, family history (genetics) (Bray et al., 2010). The literature also suggests that 
PC development can be influenced by the diet, lifestyle, and sexual behaviour (Damber 
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and Aus, 2008), although any one or a combination of the above risk factors on PC 
development have not been fully established.  
One of the reasons for the increase in PC incidence in some ethnic groups and regions 
might be improvement in cancer diagnostics over the last 20-30 years.  This is linked to the 
introduction of PC screening in the more effluent western countries like United Kingdom 
(UK), United States (US), Scandinavian countries as well as Asian countries like Japan, 
Singapore and Korea. Prostate Specific Antigen (PSA) test was introduced in 1986 into 
clinical practice to aid the diagnosis of PC and monitor its progression and response to 
treatment. However, reliability and specificity of PSA test has been increasingly 
questioned with regards to over-diagnosis (Etzioni et al, 2002), which raises the need for a 
novel, reliable and more specific test for PC diagnostic and prognosis.  
It is known that predisposition to PC varies between ethnic groups (Hsing et al, 2000) but 
the reasons for these variations have not been fully understood. Therefore, there is extreme 
interest in ethnic-group specific PC screening tests which could be used for diagnostics, 
prognostics and management of PC. This could ensure reduction of unnecessary expensive 
and morbid diagnostic procedures such as an invasive biopsy and aggressive treatment. 
Apart from that, a more ethnic based screening and diagnostic protocol could potentially be 
developed. 
An ideal screening method for a particular disease would be a test that does not require 
obtaining tissues by performing a biopsy. Ideally, this test would use blood, urine or saliva 
which can be obtained with minimally invasive methods. In this respect, blood is of 
particular interest as it contains a large number of proteins which could be used as potential 
biomarkers. Potential biomarkers for PC might be the circulating androgens such as 
testosterone and dihydrotestosterone (DHT) as well as the anabolic hormone, Insulin-like 
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Growth Factor-I (IGF-I). Androgens play an important role in the growth of the prostate 
gland and have been shown to cause a malignant change in studies on rat models (Noble, 
1977). Polymorphisms in genes encoding for enzymes that control testosterone and DHT 
concentration, might also be potential PC markers. CYP17 gene encodes the enzyme 
cytochrome P450c17α-hydroxylase and the gene SRD5A2 encodes for the enzyme 5α-
reductase type 2 which control the biosynthesis of testosterone and conversion of 
testosterone to DHT respectively (Picado-Leonard and Miller, 1987, Wilbert et al, 1983). 
Data of the literature on relationship between CYP17 and SRD5A2 polymorphisms and 
circulating androgen concentration are controversial. This may be the reason for the 
unpredictable nature of the disease and also explain the low incidence in some ethnic 
groups especially from the Asian continent. Androgen in the circulation can act on the 
prostate via regulation of Androgen Receptor (AR) activity.  Binding of androgens to the 
AR and the polymorphism in the AR gene can cause a modification in the function of 
androgenic response element (Singh et al, 2005). One such element that could be affected 
by the AR gene polymorphism could be the IGF-I metabolic pathway affecting the 
circulating concentration of IGF-I. Studies have shown positive relationship between 
circulating IGF-I concentration and PC risk as well as elevated IGF-I level in ethnic groups 
with higher PC incidence (Rowlands et al, 2008, Roddam et al, 2008).  
The overall aim of this project was to investigate ethnic group-specific relationships 
between PC incidence, concentration of androgens in circulation and presence/frequency 
of polymorphisms in the genes that control androgen metabolism. The study was 
conducted on Bristol Caucasians (BC) and Malaysian Chinese (MC) men. These ethnic 
groups were chosen because of large difference in incidence of PC, with the PC incidence 
at least 6 times higher in the BC than MC men (Jemal et al, 2011).  
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The hypotheses for this project are: 
1. The concentration of circulating androgens (testosterone and DHT) and the growth 
hormone Insulin-like Growth Factor-I (IGF-I) are positively related to the incidence 
of PC in BC and the MC men. The serum concentration of all these hormones are 
expected to be significantly higher in the BC compared to the MC men because of 
the higher risk and incidence of PC in the Caucasians compared to Asians.  
2. The presence and frequency of selected polymorphisms in the CYP17, SRD5A2 
and the AR genes are related positively to the higher incidence of PC in the BC but 
not in MC men.  
3. Polymorphisms in CYP17, SRD5A2 and AR genes are associated with increased 
concentration of the hormones testosterone, DHT and IGF-I in the circulation. 
 
Specific Objectives 
1. To compare the concentration of circulating androgens (testosterone and DHT) and 
IGF-I in BC and MC ethnic groups and to investigate ethnic-group specific 
relationship between androgens, IGF-I concentration and PC incidence. 
2. To sequence the specific regions in CYP17, SRD5A2 and AR genes from BC and 
MC ethnic groups in order to identify ethnic-group specific polymorphisms.  
3. To investigate the relationship between ethnic group-specific DNA polymorphisms, 
the circulating androgens and growth hormone concentration and the incidence and 
risk of PC.   
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2 Literature Review 
This section of the thesis aims to give a review of the literature on the following aspects: 
I. Background and important issues in PC management. 
II. Role of androgens in PC.  
III. An overview of involvement of testosterone, DHT and IGF-I in PC development.  
IV. Overview of polymorphisms in CYP17, SRD5A2 and AR genes and their 
association with PC. 
V. Ethnic aspects of hormonal status and genetic polymorphisms in relation to PC risk 
and incidence.  
 
2.1 Background on prostate cancer 
This section gives an overview of PC and discusses the important issues involved in 
management of PC with regards to the incidence, risk factors, problems with diagnostic 
and screening.  
2.1.1 Anatomy and function of prostate gland 
The prostate gland is situated in the male pelvis between the urinary bladder and the penis 
at the bladder neck region (Figure 2.1). It is traversed by the prostatic part of the urethra 
which enables the urine from the bladder to pass through. It is the size of a walnut and 
normally weighs about 18 g. It has anterior, posterior and lateral surfaces with a narrow 
apex inferiorly and a flat base superiorly (Wein et al, 2012). The function of the prostate 
gland is to secrete fluid into the semen to keep it in alkaline state in order to protect the 
spermatozoa. 
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Figure 2.1 Male pelvic anatomy.  
Figure shows the position of the prostate gland in relation to the urinary bladder and 
urethra. 
Netter illustration used with permission of Elsevier, Inc. All rights reserved. 
www.netterimages.com 
 
The enlargement of prostate gland with age is a natural occurrence and starts at the age 
above 40 years which subsequently obstructs the outflow of urine causing lower urinary 
tract symptoms (Garraway et al, 1991) (Figure 2.2). However, the need to initiate 
treatment is based on the severity of the symptoms because not all individuals will be 
affected by the symptoms and only 30% of those in their early 70’s are symptomatic with 
1-2% going into urinary retention (Webber, 2006). As this is a slow progressing condition, 
treatment is only advocated to those whose quality of life is affected by the symptoms. 
This condition is called Benign Prostatic Hyperplasia (BPH).  
Urinary bladder 
Prostate gland 
Prostatic urethra 
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Figure 2.2 Schematic presentation of normal prostate gland and benign prostatic hyperplasia 
(BPH). 
Left- normal prostate gland, right- benign prostatic hyperplasia. Obstructed urinary 
outflow due to the BPH is shown by blue arrows. 
 Adapted from http://en.wikipedia.org/wiki/Benign_prostatic_hyperplasia 
 
The prostate gland can undergo a malignant change due to genetic, hormonal, dietary, life-
style and environmental factors (Damber and Aus, 2008, Kolonel et al, 2004, Parkin et al, 
1992, Kopper and Tímár, 2005). A multi-step mechanism that takes place during the 
transformation from normal prostate to cancer is not well understood. Most researchers 
have agreed that reactive oxygen species (ROS) play an important role in this mechanism 
via oxidative damage which is described in section 2.1.3 of this thesis.  
 
2.1.2 Epidemiology of prostate cancer 
Latest figures from developed countries demonstrate that PC is the most common cancer 
diagnosed in men (Ferlay et al, 2013). In the USA, it has been estimated that 1 in 6 men 
will be diagnosed with PC during their lifetime (American Cancer Society, 2010). 
Obstructed urine flow 
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Estimated new cases of PC diagnosed in 2013 in the USA would exceed that for lung and 
bronchial cancer by more than 100,000 cases in men (Figure 2.3).  
 
Figure 2.3 List of leading causes of cancer in males for the year 2013 in U.S. 
Figure shows the number of cases by organ involved and the percentage (%) of the total 
number of cancer cases. Adapted with permission from WILEY and accessed via  
http://onlinelibrary.wiley.com/doi/10.3322/caac.21166/full#fig1. * Excludes cutaneous 
malignancies and in-situ carcinomas except bladder. 
 
In the UK, PC also leads the way with the highest incidence among males with new case 
rate of 41,736 cases in the year 2011 (Cancer Research UK, 2011). This incidence rate is 
only second to breast cancer in females with and incidence of 49,936 cases for the same 
year. PC is the cause of cancer in 1/4 of males in the UK, ahead of lung and bowel (14% 
each) and all other cancers like bladder, oesophagus, haematological, kidney, brain and 
unknown primary sites of the 167,487 new cancer cases in males diagnosed in 2011 
(Figure 2.4).  
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Figure 2.4 Percentage of all cancer cases in males in the UK in 2011. 
Adapted from: Cancer Research UK, http://www.cancerresearchuk.org/. Accessed 
October 2013. 
 
In spite of the high incidence of PC in some developed countries worldwide, PC is only the 
4th common cancer after lung, breast and bowel cancers (Cancer Research UK, 2011). 
This is likely to be due to the incidence of PC being particularly low in Asia which might 
be related to variation of PC incidence between different ethnic groups in China, India, 
Taiwan, Malaysia and Japan compared to Western countries. The ethnic aspect of PC will 
be described in section 2.1.3.   
Introduction of PSA testing in 1986 for screening of PC has given rise to a tremendous 
increase in recording of incidence of PC. For example, the recorded incidence of PC in the 
UK has significantly increased between 1993 and 2011 (Figure 2.5). In the Asian countries 
All other 
Cancers, 
47%
Lung, 
14%
Bowel, 
14%
Prostate, 
25%
Cancer 
incidence 
in UK men
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such as Japan and Singapore there was a 100% increase in recorded PC cases after 
introduction of PSA testing (Sim and Cheng, 2005). A similar increase in PC cases was 
noted in the USA in early 1990s but there was some reduction in newly diagnosed PC 
cases since the late 1990s. One reason for this might be the selective use of PSA in 
screening, where the clinicians selected the patients appropriately to subject them for this 
test following clinical guidelines (American Cancer Society, 2010).  
 
Figure 2.5 Age-standardised PC incidence rates per year in the UK from 1993 to 2011. 
Y-axis denotes the number of cases diagnosed per 100,000 male population per year. 
Source: Cancer Research UK, http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/prostate/incidence/. Accessed October 2013 
 
One would expect that the steep increase in the number of PC cases over the years would 
normally lead to increased mortality due to this malignancy. However, PC has a high 
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incidence to mortality ratio compared to any other cancer (Hsing et al, 2000) which 
indicates that the increase in PC incidence did not have impact on mortality rates in a 
population. This can be explained by impact of widespread PC screening which led to 
improved diagnostics (especially early stage cancer) (Albertsen et al, 1995). The highest 
mortality was reported in the Caribbean population (26.3 per 100,000 male) and the lowest 
was found in the Eastern Asian region (2.5 per 100,000 male population) (Ferlay et al, 
2010b). Most developed countries report a stable mortality rate or a slight reduction in 
mortality due to extensive screening with PSA as well as improved treatment modalities 
developed for the disease (Figure 2.6).  
 
Figure 2.6 Annual incidence and mortality rates due to prostate cancer in the UK. 
Y-axis shows the number of cases per 100,000 male population per year. X-axis denotes 
the year the data was accumulated. Source: Cancer Research UK, 
http://info.cancerresearchuk.org/cancerstats/faqs/#How. Accessed October 2013.  
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2.1.3 Risk factor for prostate cancer development 
It is very important to establish risk factors of a certain disease in order to be able to 
predict its possible development and progression to map out the strategies in diagnosis, 
prevention and treatment.  
The normal prostatic cells undergo malignant changes in a multistep process with 
progression from a normal epithelial cell to a pre-malignant condition called prostatic 
intraepithelial neoplasia (PIN) (Figure 2.7). This is followed by further progression to a 
histologically confirmed PC which subsequently breaches the prostatic capsule to spread 
either locally or to a distant site (Thompson Jr et al, 2014).  
A combination of either dietary factors like anti-oxidants, androgen imbalances due to 
aging and associated genetic polymorphism can cause oxidative stress leading to 
irreversible changes in prostate cells (Nelson and Montgomery, 2003).  
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Figure 2.7 Prostate gland cell changes associated with PC progression.  
PIN- Prostatic intraepithelial neoplasia. Adapted and modified from Thompson Jr et al 
(2014) with permission from Nature Publishing Group. 
 
The process of oxidative stress leading to PC development has been increasingly gaining 
importance with the probable role of reactive oxygen species (ROS)-mediated oxidative 
stress and PC risk remains one of the most important theories in this disease (Figure 2.8) 
(Khandrika et al, 2009). Many factors like those that are intrinsic to the cell (aging, 
androgen imbalance, anti-oxidant imbalance) and environment factors like inflammatory 
process in the prostate, dietary fat intake and exposure to radiation can cause increased 
ROS production in the prostate. This will lead to prostate dysfunction and subsequently 
increases the ROS levels further. At this point, the anti-oxidant system could act as a 
defence mechanism to regulate the ROS in prostate and return the function to normal and 
Androgens 
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hence arrest the progression from normal to a malignant prostate. Impaired anti-oxidant 
defence mechanism leads to uninhibited oxidative stress. This will lead to further increase 
in mutation of the DNA within mitochondria, the formation of aggressive phenotypes and 
further DNA damage causing proliferation of abnormal prostate cells to undergo malignant 
change (Naka et al, 2008, Sauer et al, 2001).  
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Figure 2.8 Schematic presentation of mechanism of prostate cancer development.   
Prostate cancer development is mediated by increased ROS and cellular response to 
elevated ROS in prostate gland.  ROS- reactive oxygen species, DNA- deoxyribonucleic 
acid. Adapted and modified from Khandrika et al (2009) with permission from Elsevier. 
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PC is a disease of aging with the highest incidence of in the age-group above 55 years old 
and rarely seen below 50 years of age (Ries et al, 2008). The role of aging in the 
development of cancer is thought to be due to accumulation of molecular and DNA 
damage by free radicals (Harman, 1981). Cellular oxidative stress increases with age due 
to age-related mitochondrial DNA mutation leading to increase in ROS generation 
(Khandrika et al, 2009). 
Prostate gland development and its functions in human depend on androgens and its 
derivative. The metabolism of androgens and their actions through the AR is described in 
section 2.2 of this thesis. The theory of increased oxidative damage as a result of ROS 
when there is abnormal and excessive androgen stimulation is probably the likely scenario 
for PC development (Pathak et al, 2008).  
Reduction of ROS level via inclusion of anti-oxidants in the diet has been receiving 
increasing attention as a tool for prevention of not only PC but also other types of cancer. 
An important role of dietary anti-oxidants in cancer prevention was first analysed by Lee et 
al. (2005) who performed a study in the USA to demonstrate the role of vitamin E 
supplement in reducing incidence of cancer and cancer-related deaths. Data from the above 
study did not show any benefit of vitamin E supplement to reduce the incidence of cancer 
(Lee et al, 2005). Data of the literature on effect of dietary anti-oxidants on PC 
development are also controversial. Research by Lippman et al (2009) showed that overall 
risk of PC was not affected by dietary supplementation of vitamin E or selenium. Although 
anti-oxidant supplement can possibly reduce the ROS production and subsequently may 
reduce the ROS level, other strategies aiming at reduction of ROS production are likely to 
be beneficial. In addition to dietary supplementation of vitamin E, other ways to reduce 
ROS production could be reduction of dietary fat, animal protein and sugar intake. The 
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ROS reduction strategy also includes reduction of alcohol consumption, smoking and 
exposure to radiation as well as life-style modification to avoid stress and psychological 
disturbances (Devasagayam et al, 2004).  
Chronic bacterial or non-bacterial prostatitis, which is an inflammatory condition of the 
prostate also can lead to stromal and epithelial cell damage that can result in an increase in 
the level of free radicals (De Marzo et al, 2007) and associated changes in protein 
structure, function and DNA damage (Olinski et al, 2002) , which subsequently increases 
the risk of malignancy. 
Ethnicity remains one of the most important risk factor in PC. This aspect is discussed in 
detail below. Ethnic-group specific difference in incidence of PC can be due to a number 
of factors including differences in life-style, diet and environment. These external factors 
can be modified to reduce oxidative stress and thus, the ROS production. Feaireheller et al. 
(2011) demonstrated ethnic differences in the level of oxidative stress and the 
concentration of inflammatory markers between African-Americans and the Caucasians. 
There was increased plasma superoxide dismutase (SOD) activity in African-Americans 
when compared to Caucasians (Feairheller et al, 2011). However, there were no significant 
differences between African-Americans and Caucasians in the concentration of nitric 
oxide, endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit and interleukin-6 
(IL-6). However, the in vitro experiment conducted by the same group on the umbilical 
vein endothelial cells showed increased level of all the above mentioned parameters except 
for SOD activity in African-Americans compared to the Caucasians. Although, this study 
was conducted on a very small population, it gives important preliminary data for future 
research on ethnic difference in mechanisms of oxidative stress development.   
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Once the normal prostatic epithelial cell has undergone a malignant change, the clinical 
disease progression monitoring is based on the digital rectal examination (DRE), the 
Gleason score (determined by histological analysis of  prostate biopsy), PSA as well as any 
radiological assessment (bone scan or magnetic resonance imaging) (Partin et al, 2001).  
PC is a disease that is quite intriguing in that sense, as the only established risk factors that 
can be consistently associated with PC are non-modifiable factors such as age, ethnicity 
and family history/genetic factors (Damber and Aus, 2008, Patel and Klein, 2009, 
Zangwill, 2011). There has been increasing attention to understand mechanism of action of 
these factors to develop effective prognostic and diagnostic tools. Modifiable risk factors 
like nutrition, obesity, vitamin D profile, medications and hormonal factors have also 
attracted extensive attention but the data regarding their involvement in PC development 
are controversial.  
I. Effect of age on PC development  
PC is known as the disease of the elderly and it is very uncommon to be diagnosed with the 
condition in males of age below 45 years (Figure 2.9). A study assessing the data from five 
continents for age related incidence of PC have shown uniformity in all ethnic groups 
studied and concluded that the incidence of PC is very rare in men under 50 (Quinn and 
Babb, 2002, Jung et al, 2014).  The incidence increases with age reaching a peak rate at the 
age of 70-74 years (Cancer Research UK, 2011, Quinn and Babb, 2002, Hemminki et al, 
2005). Beyond this age, there is a drop in the incidence probably due to the recommended 
guideline for the use of PSA test only in men who are clinically healthy with a life-
expectancy of more than 10 years (Carter et al, 2008, Drazer et al, 2011, Williams et al, 
2011).  
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Figure 2.9 Age-specific incidence rates of prostate cancer in the UK from 2009 to 2011. 
The blue line indicates the number of PC cases per 100.000 male population in the age 
group. The blue bar show the average number of new PC cases diagnosed in the particular 
age group. Source: Cancer Research UK,   
http://info.cancerresearchuk.org/cancerstats/faqs/#How. Accessed October 2013. 
 
II. Effect of ethnicity on prostate cancer 
The ethnic background plays a major role in the risk of PC development. Ethnicity can also 
be a factor in determining the severity of the disease and its prognosis.  PC incidence is 
higher in developed regions such as Western Europe, Northern Europe, Northern America 
and Oceania, and in some of the developing regions such as the Caribbean and Southern 
Africa. The PC incidence rates are particularly low in Asian communities and on the 
majority of the African continent (Figure 2.10). 
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Figure 2.10 Geographical distribution of age-standardised prostate cancer incidence rates. 
Source: GLOBOCAN 2008 (Ferlay et al, 2010a). 
 
Latest figures from GLOBOCAN 2012 have shown that the highest incidence of PC is in 
the USA and Australia with age-standardised rates of 98.2 and 115.2 cases per 100,000 
population respectively (Ferlay et al, 2013). Other countries with high PC incidences were 
Sweden (119.0 per 100,000 population), Trinidad and Tobago (123.9 per 100,000 
population), Barbados (123.1 per 100,000 population) and France (127.3 per 100,000 
population) (Ferlay et al, 2012) .  
 The above data can be partially explained by the increased PC screening in the developed 
countries. However, widely used screening methods alone cannot explain the extreme 
differences in PC incidence in different ethnic groups. 
PC incidence is very low in Asia and Africa but there is an increasing trend of these 
figures. In particular, PC rate per 100,000 population is as follows: 3.9 in India, 6.9 in 
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China, 8.5 in Korea and 22.3 in Japan (Jemal et al, 2010) . Not only PC incidence but also 
the rate of increase of PC incidence differ between countries with a 3.1% average increase 
in the Philippines (1985-2002) and Thailand (1988-2002) compared to a 13.8% increase in 
the Republic of Korea (1999-2007) (Center et al, 2012). The incidence of PC has doubled 
in 1986-1997 in Japanese and Singapore Chinese population from about 7.0 to 14.0 per 
100,000 male population (Sim and Cheng, 2005). The latest PC incidence rate for Japan 
and Singapore showed a further increase to 22.3 and 17.3 per 100,000 respectively (Jemal 
et al, 2010). Malaysia, being a multi-ethnic (Malays, Chinese and Indians) country in Asia, 
shows an overall PC incidence of 6.2 per 100,000 but when ethnicity is taken into 
consideration, the Malays show the lowest PC incidence of 4.9 per 100,000 males when 
compared to the Chinese and Indians (8.7 and 5.8 per 100,000 males respectively) (Zainal 
Ariffin and Nor Saleha, 2011). PC incidence on African continent is also low (Gunderson 
et al, 2011) but this might be an underestimation due to absence of extensive PC screening 
programmes (Odedina et al, 2006). The age-standardised rates of PC incidence are not 
uniformly spread within the African continent. For example, some of the Eastern, Western 
and Southern regions of Africa such as  Uganda (39.0), Ivory Coast (31.0) and South 
Africa (40.0) exhibit a very high rate of PC incidence when compared to other countries on 
African continent such as Senegal (7.5) and Kenya (16.6) (Delongchamps et al, 2007). 
Ethnicity has a role in both, the severity and prognosis of PC. Most of the ethnic studies on 
PC were conducted in the USA due to a high diversity of ethnic groups living in the same 
environment. About 10% of the American population are African-Americans and the 
incidence and mortality of PC among the African-Americans according to the National 
Cancer Institute Surveillance, Epidemiology and End Results Program, are higher when 
compared to Caucasian-American males (Table 2.1) (Brawley, 2012). Table 2.1 also 
demonstrates that PC incidence and PC-related mortality are almost doubled in African-
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Americans when compared to the Caucasian-Americans. In the UK, men of African and 
Caribbean descent had higher age-adjusted incidence rate (166.0 per 100,000) than 
Caucasian men (56.4 per 100,000), although this rate was not as high as the American 
populations (Ben-Shlomo et al, 2008). Ben-Shlomo et al (2008) showed no difference in 
PC incidence between men from African or Caribbean origin in the USA. Several articles 
have shown that the mortality rate of males of African-descent were definitely higher than 
that for Caucasian males (Evans et al, 2008, Bernstein, 2003, Godley et al, 2003). There 
might be a number of reasons for this high mortality rate. 
 
Table 2.1 Incidence rate and mortality (per 100,000) by race in the USA from 2003 to 2007. 
Race/Ethnicity Incidence Mortality 
All races 156.0 24.7 
Caucasian-Americans 149.5 22.8 
African-Americans 233.8 54.2 
Asian/Pacific Islander 88.3 10.6 
American Indian/Alaskan Native 75.3 20.0 
Hispanic 107.4 18.8 
Adapted from Brawley (2012) with permission from Springer. 
One of the reasons might be a lower socio-economic and associated co-morbidity status of 
the black ethnic group. However, according to Robbins et al (2000), the socio-economic 
status cannot fully explain the increase mortality in the black population. The other 
possible reason might be the fact that the white population is more likely to be tested for 
PC with PSA (Gilligan et al, 2004). The black population were also noted to be less likely 
to undergo aggressive treatment for PC which might be another reason for the higher 
mortality rates (Shavers and Brown, 2002, Shavers et al, 2004). Furthermore, genetic 
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predisposition to PC should also be taken into account and this pre-disposition can differ 
between different ethnic groups. This aspect is discussed in the next chapter.  
III. Family history and genetics. 
Family history of PC increases the risk of PC. Studies have shown that presence of one 
first-degree relative (brother or father) with PC increases the risk of PC by 2-3 folds (Platz 
E, 2006, Brandt et al, 2010).  
Hereditary PC gene 1 (HPCG) is known to increase risk of PC. The Ribonuclease L 
(RNASEL) gene variants at HPCG locus 1 has been extensively studied in families with 
history of PC and found to be positively associated with PC risk (Rökman et al, 2002). 
RNASEL gene encodes a component of the interferon-regulated system that functions in 
the anti-viral and anti-proliferative roles of interferon. 
A large breast cancer 2 (BRCA2) gene study, which included screening 1864 men with PC 
from the UK Genetic Prostate Cancer Study (UKGPCS) cohort, had shown that the 
frequency of mutations in BRCA2 is positively associated with PC development in patients 
below 65 years of age. This suggests that the BRCA2 gene mutations might have more 
impact on PC incidence then family history in the younger age group (Kote-Jarai et al, 
2011). This gene is a human tumour suppressor gene that help repair damaged DNA or 
destroy cells if the DNA cannot be repaired. The BRCA2 mutations investigated in the 
mentioned above study were the protein-truncating mutations within exons 10 and 11, 
where 3 were in-frame deletions and 69 were insignificant missense variants. 
Another gene which attracted attention in relation to PC is NKX3.1 gene that encodes for 
protein NKX3.1 in human which functions as a prostatic tumour suppressor in an 
androgen-regulated manner (Abate-Shen et al, 2008). It is located on chromosome 8p21.2 
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that displays loss of heterozygosity in almost 85% of high-grade prostatic intraepithelial 
neoplasia (PIN) lesion and adenocarcinomas of the prostate (Bethel et al, 2006). Earlier 
studies had shown that there is a complete loss of NKX3.1 expression in advanced cancers 
(Bowen et al, 2000). However, more recent studies with the use of specific antibodies 
showed a low level of NKX3.1 expression in almost all the PC cases studied (Gurel et al, 
2010).  
It has also been shown that PC patients exhibit a form of fusion between androgen-
regulated gene transmembrane protease serine 2 (TMPRSS2) and erythroblastosis virus 
E26 transcription factor gene (Tomlins et al, 2009, Mosquera et al, 2009). Mosquera et al 
(2009) and Clark et al (2006) have shown that the most common fusion observed in PC 
patients was TMPRSS2-ERG which was found in 50% of localized PC patients and 15% 
of high-grade PIN patients. The functional significance of TMPRSS2-ERG fusion in PC is 
still unknown with theories suggesting that (i) ERG can bind to AR target genes and 
disrupt the AR signalling which leads to inhibition of prostate epithelial differentiation and 
(ii) Erythroblast transformation-specific (ETS) gene activation promotes tumour invasive 
properties of PC (Yu et al, 2010, Wang et al, 2008).   
 There has been increasing interests in the role of various DNA single nucleotide 
polymorphisms (SNPs) in PC risk and progression (Van den Broeck et al, 2014). Extensive 
genome-wide association studies identified multiple SNPs which, when taken individually, 
have been moderately associated with PC risk. However, this association was higher when 
a combination of SNPs was analysed (Takata et al, 2010, Xu et al, 2012). DNA SNPs may 
play an important role in identifying men who are at high risk of developing PC (Pepe et 
al, 2004). A total of 77 susceptibility loci have been instrumental in explaining about 30% 
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of familial risk of PC (Eeles et al, 2013). The role of specific SNPs in the genes controlling 
androgen metabolism is described in detail in section 2.3. 
 
IV. Relationship between nutrition and prostate cancer  
The role of diet in the development of PC is complicated due to the fact that food is usually 
consumed whole rather than individual nutrients, which resulted in controversial data of 
the literature (Wu et al, 2006, Hori et al, 2011, Masko et al, 2013). Low-fat diet with high 
soy content can contribute to a lower PC incidence in Asian communities compared to the 
western countries. This effect of soy has been attributed to a high content of isoflavones 
(phyto-oestrogens) (Ozasa et al, 2004, Hedelin et al, 2006). The mechanism by which 
phyto-oestrogen protects against PC development is yet to be fully established, but several 
theories suggest that the concentration of serum sex hormone-binding globulin (SHBG) 
can be increased by high intake of tofu which is rich in isoflavones (Habito et al, 2000). 
This subsequently reduces the concentration of the free testosterone due to higher 
availability of SHBG to bind to testosterone (Nagata et al, 2000). This theory favours the 
association of androgens with PC development.  
Another theory is based on laboratory investigations on mice which showed that dietary 
supplementation of isolated soy protein can inhibit an experimentally induced prostate 
tumour. This was suggested to be due to reduction of cellular proliferation and 
angiogenesis together with induction of apoptotic activity (Bylund et al, 2000, Zhou et al, 
2002). The phyto-oestrogens also have anti-oxidant and anti-inflammatory effect that can 
reduce the DNA damage by reactive oxygen species and thus prevents the transformation 
of normal cell to malignant cell in the prostate gland (Thomasset et al, 2007, Surh, 2003).  
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Diet high in anti-oxidant compound like lycopene, and micronutrients like selenium and 
vitamin E might have protective effect against PC development. Lycopene, is the 
carotenoid compound, that can protect against PC development via a number of 
mechanisms including  acting as a scavenger of free radicals (Bravo et al, 2012, van 
Breemen and Pajkovic, 2008), and inhibition of cancerous cell progression at G0-G1 stage 
of cell cycle. High concentrations of lycopene were demonstrated to inhibit cancer cells 
growth in vitro on human mammary cancer cell line (Karas et al, 2000). The scavenging 
property of lycopene provides protection for lipoproteins and prevents DNA damage (Stahl 
and Sies, 2003, Hadley et al, 2003). However, data of the literature on relationship 
between lycopene intake and PC risk are controversial.  Whilst Wei and Giovannucci, 
(2012) did not find significant relationship between dietary lycopene concentration and PC, 
a case-control study in China involving 130 PC patients and 274 controls showed reduction 
of PC risk with increase of lycopene intake. (Jian et al, 2007).  
Another pair of nutritional supplement that have been studied in relation to cancer risk are 
selenium and vitamin E. Mechanisms of their action on PC are not well established. It is 
hypothesized that selenium and vitamin E can inhibit carcinogen-induced oxidative 
damage (El-Bayoumy, 2001). However, no evidence for this hypothesis was found in an 
experiment on dietary selenium and vitamin E intake and PC incidence (Lippman et al, 
2009). Furthermore, a follow-on study even showed a significant increase in PC 
occurrence under dietary regime with vitamin E supplementation (Klein et al, 2011).  
There have been a large number of studies on effect of vitamin D on PC development but 
the results are controversial. It has been suggested that vitamin D deficiency can increase 
PC risk due to anti-proliferative effect of vitamin D in the PC cells (Skowronski et al, 
1993). However, dietary experiments did not produce conclusive evidence that vitamin D 
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supplementation reduces the risk of PC. A meta-analysis (Gilbert et al, 2011) has showed 
no major protective impact of vitamin D on PC risk or progression. Another study has 
shown a positive result i.e. increased risk of PC due to high circulating vitamin D 
concentration (Albanes et al, 2011).   
V. Relationship between obesity or physical activity and prostate cancer 
Obesity is frequently associated with increased oestrogen and decreased testosterone 
concentration in the circulation (Zumoff, 1987). Sex steroids are known to play critical role 
in PC development (Bosland, 2006). Androgens, especially testosterone and DHT, are the 
most important sex steroid hormones involved in PC development. This has been 
demonstrated in the studies on Nb strain rats, when subcutaneous injection of pellets 
containing estrone or testosterone 10mg each (every 6 to 8 weeks) into the rats for 6 
months or more resulted in increased incidence of PC (Noble, 1977). The mechanism by 
which androgens regulate PC development will be discussed in section 2.2.1. 
Body size and parameters (weight, height, waist circumference and the Body Mass Index 
(BMI)) was studied in a meta-analysis which revealed that there is no significant 
relationship between these parameters and PC incidence and death (MacInnis and English, 
2006). At the same time Cao and Ma (2011) found a 15-20% increased risk of mortality 
due to PC and biochemical recurrence for each 5 kg/m2 increase in BMI in 26 pooled 
studies from the USA, Netherlands and Japan with more than 1 million participants. 
However, this study does not take into account the state of participants BMI during the pre-
diagnosis period. Therefore, the impact of hormonal imbalances prior to the diagnosis due 
to obesity cannot be ascertained. The above finding, however, shows that obese males have 
a higher risk of developing more aggressive disease compared to non-obese person and, 
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subsequently have a higher mortality rate as a result of the PC (Buschemeyer III and 
Freedland, 2007). 
In addition to body mass, an effect of physical activity on incidence of PC has also been 
studied. There was a significant inverse relationship between physical activity and PC 
incidence reported in a meta-analysis of 43 studies involving 88,294 cases (Liu et al, 
2011). It has also been demonstrated the overall risk reduction with physical activity can 
be as high as 10-30% (Friedenreich and Orenstein, 2002). Several studies have found no 
association at all between physical activity and PC risk (Dosemeci et al, 1993, Liu et al, 
2000). Taking together, data of the literature do not provide strong evidence of relationship 
between physical activity and PC. At the same time, benefit of increased physical activity 
either in the course of the individual’s occupation or for recreation purposes cannot be 
denied.  
 
2.1.4 Screening, diagnosis and staging in prostate cancer 
In this section, the review will focus on the issues related to the contemporary screening 
test PSA which is used for early detection of PC and to assist treatment decisions. PSA is a 
glycoprotein enzyme secreted by the epithelial cells of the prostate gland. PSA test detects 
the amount of PSA in the serum of man in whom there is a suspicion of PC. PSA is not a 
specific test in detecting PC as it may also be elevated in other benign prostatic disorders 
like prostatitis and benign prostatic hyperplasia. A brief description of the clinical stage, 
diagnostic modality and risk stratification will also be discussed. 
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(i) Screening in prostate cancer 
It is widely accepted that PC is a slow developing disease and most patients diagnosed 
with it may not be affected by the disease in their lifetime (Holman et al, 1999). A 
controversial question is whether screening for PC significantly decreases the mortality 
rate due to the disease. Evidence from meta-analysis of five randomised control trials 
(RCT) suggests that screening does not significantly reduce the PC related mortality (Ilic et 
al, 2006).  
Digital rectal examination (DRE) is the mandatory examination of a patient who presents 
to the clinician with prostatic symptoms to look for prostatic nodules and it is unreliable 
due to evidence suggesting that the DRE alone has a low predictive value in patients with 
PSA below 3.0 ng/ml of serum and also in a large group of people with PSA between 3.0 
to 9.9 ng/ml of serum (Schroder et al, 1998). Therefore, relying on DRE alone to proceed 
for a diagnostic biopsy for PC may lead to a large number of unnecessary procedures.  
This brings us to the advent of PSA test in 1986 into clinical practice. PSA is a blood test 
which identifies patients who are at risk of PC in order to subject the patients to a 
diagnostic biopsy. Generally, a PSA value less than 4.0 ng/ml is accepted as normal 
(Catalona et al, 1994). A biopsy is generally considered when the value is above 4.0 ng/ml. 
The PSA test can also be used to monitor PC progression and its response to treatment. 
However, reliability and specificity of PSA test has been increasingly questioned with 
regards to over diagnosis and unnecessary biopsy (Etzioni et al, 2002, Draisma et al, 
2003). Although the recommended cut-off for PSA is 4.0 ng/ml, almost 2/3 of patients in 
this group do not have PC and the biopsy would have been unnecessary. Almost 15% of 
patients with a PSA level of less than 4.0 ng/ml could have PC (Crawford et al, 1999). It is 
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recommended that the combination of DRE and PSA is used to increase the sensitivity and 
specificity of PC detection by Crawford et al (1999). 
Two large randomised trials studied the effect of PSA screening in the reduction of 
mortality rates due to PC. The USA -based Prostate, Lung, Colorectal and Ovarian (PLCO) 
found that there was no difference in the mortality rates of the screened participants with 
PSA compared to those who did not have PSA follow-up (Andriole et al, 2009). The 
European Randomised study of screening for prostate cancer (ERSPC) showed that there is 
a 20% reduction of mortality rates in the screened population (Schröder et al, 2009).   
 Therefore, there is a strong need for a reliable and more specific diagnostic test for PC. 
Such a test would help to reduce unnecessary biopsies, patient’s anxiety of being 
diagnosed with PC, and unnecessary treatments of PC cases which are unlikely to progress 
to advanced stages.  
(ii) Establishing the diagnosis of prostate cancer 
The definitive diagnosis of PC is made by the Trans-rectal Ultrasound (TRUS) guided 
biopsy of the prostate gland. The biopsy gives the clinician a histological diagnosis and the 
patient selected for the biopsy should either have an abnormal DRE or PSA more than 4.0 
ng/ml. This is a procedure that is very uncomfortable due to the insertion of a rectal 
Ultrasound probe to visualise the prostate to take the biopsy. This biopsy has a risk of 
bleeding in the urine, stool and seminal fluid. Apart from this, there is a risk of infection 
and pain although it is performed under local anaesthesia (Clements et al, 1993). 
In view of the morbid and very uncomfortable nature of the procedure, it will be of utmost 
importance if the biopsy could be reserved only for patients who have a significant risk of 
PC. Therefore, a more effective test to screen the patients for PC would be very useful. 
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(iii) Grade and stage of PC 
The most common grading system used in the assessment of the biopsy or the operated 
specimen of the PC is the Gleason grading system, which assesses the architecture of the 
cells and describes a score from 2 to 10 from well differentiated (least aggressive) to 
poorly differentiated (most aggressive) (Gleason and Mellinger, 1974) (Figure 2.11). This 
scoring is the sum of the 2 most common patterns seen from 2 to 5 with the grade < 7 
being a low-grade cancer and ≥ 7 being a more aggressive cancer. 
 
 
Figure 2.11 Grading of the prostate biopsy/operated specimen. 
Figure shows the various grades of prostate cancer from well differentiated to poorly 
differentiated tumour. Adapted from http://trialx.com/curetalk/2011/07/interpret-your-
gleason-grading-score/. Accessed October 2013. Source: Gleason (1977). 
 
 32 
 
A clinical staging for the PC is still done by careful digital examination of the rectum to 
assess the tumour status (T staging) followed by magnetic resonance imaging (MRI) or 
computerised tomography (CT) scan to assess the nodal status (N) and the metastatic status 
of the cancer (Sobin et al, 2011). The risk group stratification of the newly diagnosed PC 
patients based on DRE, PSA and the Gleason score has been described by Damber and Aus 
(2008). Low risk PC is when the DRE showed no abnormality (T1c) or when a tumour is 
felt involving less than 50% of a single lobe of prostate (T2a), PSA 10 ng/ml or less and 
Gleason score of 6 or less. Intermediate risk PC is noted when the DRE finds a tumour 
involving >50% of a single lobe of prostate (T2b), PSA greater than 10ng/ml but less than 
20 ng/ml, and Gleason score of 7. PC is said to be high risk when tumour felt in both lobes 
of prostate (T2c), PSA of 20 ng/mL or greater, and Gleason score of 8 or greater. Risk 
stratification is an important element of PC management in order to decide on an 
appropriate treatment plan which includes active surveillance, radical surgery, radical 
therapy or androgen deprivation therapy.  
 
2.2 The role of androgens and insulin-like growth factor-I (IGF-I) in 
prostate cancer 
2.2.1 Role of androgen  
The prostate is an androgen-dependent organ, requiring androgens (sex steroid hormones) 
for growth during foetal and pubertal development (Ntais et al, 2003b, Ricke et al, 2006). 
There is large body of evidence to suggest that sex steroids, particularly androgens play a 
major role in the development of PC, but mechanism or their action remains unclear 
(Morgentaler and Traish, 2009, Hoffman et al, 2000, Andersson et al, 1993). 
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Testosterone, the major male androgen in the circulation, and DHT, the principal and 
potent androgen in tissue, are the two most important androgens in adult males (Welén and 
Damber, 2011, Henderson et al, 1982). Testosterone production is regulated via the 
hypothalamic-pituitary-gonadal axis (Figure 2.12) where Gonadotropin-releasing hormone 
which is secreted by hypothalamus, stimulates the pituitary gland to release the luteinizing 
hormone which acts on the Leydig cells in the testis to induce testosterone production. This 
contributes up to 90% of the testosterone production with the remaining 10% produced by 
the adrenal glands under control of adrenocorticotrophic hormone released from the 
pituitary gland (Ntais et al, 2003b, Coffey, 1988). 
 
                             
Figure 2.12 Mechanism of testosterone synthesis.   
Testosterone synthesis regulated by the hypothalamo-pituitary-gonadal axis.  
GnRH-Gonadotropin releasing hormone, Gn-Gonadotropin, ACTH- adrenocorticotrophic 
hormone. Image adapted from Bioscience.org.  
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DHT in the circulation is produced from testosterone in the prostate gland in a reaction 
catalysed by 5α-reductase. About 25% of DHT is produced in other peripheral tissues such 
as skin and scalp (Ntais et al, 2003b). The metabolic pathway of androgen production is 
shown in Figure 2.13 (Li et al, 2013a). 
     
 
Figure 2.13 The androgen pathway. 
Figure shows genes involved in androgen biosynthesis and metabolism. DHEA- 
dehydroepiandrosterone DHT- dihydrotestosterone. Adapted from Li et al (2013) with 
permission from the author. 
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The metabolic pathway above shows that the production of testosterone commences with 
the breakdown of cholesterol in multiple reactions catalysed by various enzymes out of 
which, the most common and essential ones are the 17α-hydroxylase and the 17, 20-lyase 
which are encoded by CYP17. (Li et al, 2013a, Schleutker, 2011). The enzyme 17α-
hydroxylase catalyses the reaction which converts pregnolone and progesterone to 17α-
hydroxypregnenolone and 17α-hydroxyprogesterone respectively (Figure 2.13).   The 
enzyme 17, 20-lyase takes part in the reaction that produces dehydroepiandrosterone and 
androstenedione from 17α-hydroxypregnenolone and 17α-hydroxyprogesterone 
respectively (Figure 2.13). 
The conversion of testosterone to DHT is mediated by 5α-reductase encoded by SRD5A2 
gene. This process takes place in the testis and the prostate gland. DHT is the more potent 
hormone, with five to ten-fold higher binding affinity for androgen receptor (AR) than 
testosterone (Feldman and Feldman, 2001, Wright et al, 1999). Testosterone in circulation 
can be present in three forms: bound to albumin, bound to sex hormone binding globulin 
(SHBG) and free testosterone. Free testosterone is converted to DHT within the prostate 
gland and promotes DNA synthesis and cell replication by binding to the intracellular AR 
which activates gene transcription and cell proliferation. Increased cell division heightens 
the potential for mutations, leading to a higher likelihood of PC (Hsing, 2001, Lindström et 
al, 2006). This takes place via  the formation of an intracellular DHT-AR complex which 
is then translocated to the nucleus and binds to the androgen response element of the 
prostate to induce cellular proliferation (Hsing et al, 2002, Heinlein and Chang, 2004) 
(Figure 2.14). 
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The overall effect of androgens in cells expressing AR is related to increase of cyclin-
dependent kinase activity and stimulation of cells to enter the S phase of the cell cycle, 
thereby inducing cellular proliferation (Ntais et al, 2003b). 
 
 
Figure 2.14 Androgenic action in the prostate gland.  
T-testosterone, SHBG-sex hormone binding globulin, DHT-dihydrotestosterone, AR-
androgen receptor, ARA-androgen receptor-associated proteins, DNA-deoxyribonucleic 
acid. Adapted from Hsing (2001) with permission from Oxford University Press. 
 
Androgen deprivation therapy has been an important mode of treatment for advanced or 
metastatic PC for a long time by either chemical (use of anti-androgens) or surgical 
castration (Bare and Torti, 1998, Damber, 2005). Figure 2.15 shows the various levels of 
androgen blockade that can be administered in order to reduce androgen production. This 
includes oestrogen administration to block the stimulation of anterior pituitary, 
administration of LHRH analogues or antagonists which can block metabolic pathways 
controlling testosterone production. CYP17 is the main gene encoding for enzymes 
involved in biosynthesis of testosterone and therefore it could be an ideal candidate for the 
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blockade therapy. This therapy could also involve the use of anti-androgen drugs inhibiting 
the binding of DHT to the AR, and the use of 5α-reductase inhibitors and thus, reducing 
production of DHT (Welén and Damber, 2011). 
 
 
Figure 2.15 Simplified schematic representation of androgen biosynthesis and metabolism. 
Figure shows options of androgen deprivation therapy that are available at different 
stages of androgen pathway. CYP11A1: cholesterol 20– 22 desmolase; CYP17A1: steroid 
17-alpha-hydroxylase/17, 20 lyase; AKR1C3: 17-β-hydroxysteroid dehydrogenase; 
HSD3B: 3-b-hydroxysteroid dehydrogenase; SRD5A: steroid 5α-reductase. Adapted from 
Welén and Damber (2011) with permission from Elsevier. 
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Data of the literature on the role of androgens in PC development are controversial and is 
described below. An increasing number of DNA polymorphisms that can contribute to 
ethnic differences in PC epidemiology have been identified and noted that allele frequency 
differences at regulatory polymorphisms also account for some population differences in 
prevalence of complex diseases (Spielman et al, 2007). This chapter will also focus on 
discussion of polymorphisms in CYP17, SRD5A2 and AR genes which play significant 
role in the control of testosterone and DHT concentration. It has been described in previous 
sections of this thesis that the prostate gland is an androgen dependent gland. One of the 
PC development hypotheses by Gann et al (1996), namely a hormonal hypothesis, suggests 
that the circulating concentration of androgens should be higher in cancer patients 
compared to the non-cancer participants. Therefore, it is logical to suggest that populations 
with high PC incidence, such as the Caucasian compared to Asians would have a higher 
concentration of circulating androgens. The following review intends to look at literature 
to ascertain the role of androgens in the risk of PC development and ethnic-specific aspects 
of androgen effects on PC incidence.  
Majority of studies in this area were conducted on ethnic groups in the USA (Wu et al, 
1995b, Litman et al, 2006). Population data on hormonal status in European and Asian 
populations mainly studied single ethnic groups within the same environment. Data of the 
literature on association between circulating androgens concentration, PC incidence and 
ethnic variations are inconsistent.  
A large population case-control study (N=1127) involving three different PC risk groups 
(African-Americans, White-Americans and Asian-Americans in USA and Canada) was 
conducted in order to determine the concentration of   testosterone, DHT, the DHT to 
testosterone ratio and sex hormone-binding globulin (SHBG) (Wu et al, 1995a). The risk 
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of PC was highest in the African-Americans, followed by White-Americans and lowest in 
the Asian-Americans (either of Japanese or Chinese origin). This study showed that the 
testosterone concentration in African-Americans was not significantly different from that 
in White-Americans. However, it was noted that the Japanese-American and the Chinese-
American had significantly higher total testosterone concentration than the White-
Americans. The African-Americans and the Asian-Americans of Japanese origin showed a 
significantly higher DHT concentration compared to the White-Americans.  
The Boston Area Community Health (BACH) survey involving almost 1900 participants 
(Black-Americans, White-Americans and Hispanics) investigated the racial/ethnic group 
differences in androgen concentration and also the DHT to testosterone ratio (Litman et al, 
2006). This study showed that the concentration of testosterone did not differ significantly 
between the ethnic groups irrespective of whether the results were adjusted for co-variants 
(physical status, BMI, smoking, alcohol intake etc.). The DHT concentration and the DHT 
to testosterone ratio were found to be significantly elevated in the Black-Americans 
compared to the White-Americans and the Hispanics which might be related to the 
variations in PC incidence and prognosis between these ethnic groups (Litman et al, 2006). 
Another study comparing the Black-American and the White-American populations found 
a decrease in testosterone concentration with age in both populations studied. After 
adjustment for age and BMI, it was noted that the Black-American community had a 3% 
higher testosterone concentration than the White-Americans (Gapstur et al, 2002). No 
differences in androgen concentration were found between Kuwaiti Arabs and Chinese 
groups but a significant 20-50% reduction in the concentration of androgens was observed 
in Kuwaiti Arabs compared to the Black and White Americans, Chinese, Germans and 
Nigerians (Kehinde et al, 2006).  It should be noted that the study by Kehinde et al (2006) 
was not performed in a single lab and therefore the results should be interpreted with 
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caution. A study by Kubricht III et al (1999) compared testosterone concentration in 
White-American (N=264) and Black-American (N=189) men who underwent a prostatic 
biopsy. The study did not find significant differences between the mean concentration of 
testosterone in the PC and control groups or between the two ethnic groups (White-
American and Black-American) (Kubricht III et al, 1999).  
In order to consider androgens (testosterone and/or DHT in particular) as potential 
biomarkers for PC, it is important to have clear understanding of relationship between the 
circulating androgen concentration and occurrence of PC. Data from the literature on this 
issue is controversial. There might be a number of reasons for inconsistency between data 
of the literature including the use of different assay for androgens analyses, different blood 
collection time and difference due to ethnicity. 
The nested case-control study by Nomura et al (1996) in Japanese-Americans in Honolulu 
showed that the testosterone and DHT concentration do not differ significantly between the 
PC and control participants. In this study the androgen concentrations were analysed by 
radioimmunoassay (RIA) technique and the time of day of blood collection was not stated. 
The blood collection time is very important for androgen analysis because of the diurnal 
variation observed in the concentration with peak concentration being in the morning from 
8.00 am to 12.00 noon (Rose et al, 1972, Brambilla et al, 2009). There are other studies on 
different ethnic group which concur with findings of Nomura et al (1996). Dorgan et al 
(1998) did not find significant relationship between testosterone, DHT and the PC risk in a 
Finnish population. The blood collection time in this case was specified to be in the 
morning and RIA was used as the technique for assessment of hormones concentrations. 
The above finding is also consistent with reports of Chen et al (2003) on Caucasian-
Americans, Sawada et al (2010) on Japanese men, Heikkila et al (1999) on Finnish cohort 
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and Mohr et al (2001) on Caucasian-Americans. Mohr et al (2001) also used RIA 
technique and blood collected in the morning for androgen detection. Sawada et al (2010) 
used electro chemiluminescence immunoassay (ECLIA) for testosterone assay and the 
blood drawn could not be ascertained whether it was performed in the morning. Gann et al 
(1996) demonstrated that testosterone (but not DHT) concentration was significantly 
higher in PC cases in USA Caucasian ethnic group. Gann et al (1996) performed the 
hormonal assays by RIA technique but the time of blood collection was not exclusively in 
the morning. Similarly, Hsing et al (1993) found elevated DHT to testosterone ratio but the 
time of blood taking in the report was not indicated. de Jong et al (1991) demonstrated that 
there was no significant association between PC and androgen concentration in the Dutch 
and Japanese population but they showed a non-significant lower testosterone and DHT to 
testosterone ratio in the Japanese men.  
To summarise, data of the literature do not provide a consistent view and strong evidence 
regarding the relationship between androgens concentration in PC incidence and 
development.  Furthermore, there have been a limited number of studies on ethnic-group 
specific aspects of circulating androgen concentration and its correlation with PC, although 
population study suggests a higher androgen concentration in the Black-American 
population when compared to White-Americans and Asian-Americans. The above 
highlights the need for detailed investigation into ethnic-group specific androgen 
concentrations, especially from the Asian region using a well-designed case-control study. 
The Asian region has a very low incidence of PC and data from this region has not been 
widely studied in relation to the role of androgens in PC. Majority of the studies published 
so far, are based on nested case-control study which used blood samples drawn at the time 
of patients recruitment, which were stored and analysed only when PC had been 
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diagnosed. Another important issue appears to be the different methods used in the 
androgen assay and the time at which the samples collected were not consistent.  
2.2.2 Role of insulin-like growth factor-I 
IGF-I hormone is mainly produced in the liver under the regulation of the complex 
mechanism controlled by the hormones and nutritional factors (Livingstone, 2013). A 
schematic presentation of this process is given in Figure 2.16. The rate of production of 
growth hormone (GH) in the pituitary gland plays a key role in this process. GH is 
transported to the liver where it binds to the growth hormone receptor to produce IGF-I 
which is secreted into the circulation (Livingstone, 2013). Almost 99% of IGF-I is bound 
to the IGF binding proteins (IGFBP). Six proteins of IGFBP family have been identified 
and they include IGFBP3 which has the highest affinity to IGF-I and subsequently 
determines the concentration and half-life of IGF-I (Livingstone, 2013, Firth and Baxter, 
2002, Pollak et al, 2004, Lima et al, 2009). The small proportion of unbound IGF-I in 
circulation known as the free IGF-I, is the active component and it can bring out the 
mitogenic activity. The mitogenic activity is initiated by binding of the free IGF-I to the 
IGF-I receptor on target tissues (Livingstone, 2013). Apart from GH that controls the IGF-I 
concentration, nutrition also plays a role in the maintenance of IGF-I concentration in 
circulation. There are evidences showing that IGF-I concentration drops under malnutrition 
and increases again upon feeding, supporting the idea that IGF-I can be used as a potential 
nutritional biomarker (Livingstone, 2013, Counts et al, 1992). The hepatic IGF-I 
production can also be stimulated by the circulating insulin produced by the pancreas in 
relation to the carbohydrate content in the body as well as the nutritional status of the 
individual  (Hanaire-Broutin et al, 1996). This explains the reason for the increase and 
decrease IGF-I concentration as described above due to malnutrition and feeding. 
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IGF-I has various functions in the human body including short-term effects such as 
stimulation of amino acid uptake into skeletal muscle and stimulation of peripheral glucose 
uptake (Jacob et al, 1989, Bilan et al, 1992) which is an important function that mimics 
action of insulin. IGF-I also has long-term effect on cellular proliferation, differentiation 
and anti-apoptotic effect which can all lead to the progression of normal cell to a malignant 
cell (Yu and Rohan, 2000, Jones and Clemmons, 1995) . 
                             
Figure 2.16 Regulation of circulating and tissue concentration of Insulin-like growth factors. 
Positive and negative regulatory effects are shown at “+” and “-” respectively. GHR-
growth hormone receptor, GH-growth hormone, IGF-I-Insulin-like growth factor-I, 
IGFBP-Insulin-like growth factor binding protein, IGF-IR- Insulin-like growth factor-I 
receptor, ALS- acid-labile unit. Source: Livingstone (2013). 
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Although prostate gland is an androgen-regulated tissue, (testosterone and DHT- regulated 
in particular), it cannot be denied that PC can also develop in individuals with low 
testosterone concentration (Morgentaler et al, 1996, Morgentaler and Rhoden, 2006). This 
indicates the involvement of other factors, such as the insulin-like growth factors in PC 
development. 
 
Figure 2.17 Illustration of an overview of downstream signalling from IGF-I receptor. 
IGF-I- Insulin-like growth factor-I, IGF1R- Insulin-like growth factor-I receptor, IRS1- 
Insulin receptor substrate 1, PI3K- phosphatidylinositol 3-kinase, TOR- target of 
Rapamycin, S6K- S6 kinase, MEK- mitogen activated protein kinase, ERK-extracellular 
signal-related kinase. Adapted from Pollak et al (2004) and Aggarwal et al (2011) with 
permission from Nature Publishing Group. 
 
IGF-I acts by binding to the IGF-I receptor found on the cell membrane and causes the 
proliferative effect and anti-apoptotic function by activating the tyrosine kinase pathways 
via 2 routes, namely the PI3K and RAS/RAF protein pathways which activates signal 
transduction molecules as shown in Figure 2.17 (Lima et al, 2009, Aggarwal et al, 2011). 
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Function of tyrosine kinase is to catalyse the phosphorylation of tyrosine residues in 
proteins that can lead to functional changes of the protein (Nelson et al, 2008). This protein 
can be transcriptional factors which control the transfer of genetic information from DNA 
to messenger RNA which can be affected by the abnormal tyrosine kinase activity in 
mitogenesis (Radha et al, 1996). This is the reason for unhindered tyrosine kinase activity 
leading to malignant change in the prostate. Insulin also has proliferative as well as anti-
apoptotic effect as the insulin receptors are structurally similar to IGF-I receptor (Mynarcik 
et al, 1997) and the signalling pathway is the same as for IGF-I once insulin binds to the 
IGF-I receptor. There is a correlation between IGF-I and insulin concentration in the 
circulation with the occurrence of PC. (Cox et al, 2009). 
 It is known that there is relationship between the androgen biosynthesis pathway and the 
growth factor metabolism pathway which may contribute to initiation and progression of 
PC (Hsing, 2001). A review article by Zhu and Kyprianou (2008) reported evidence of 
functional interaction between AR and various growth factors such as epidermal growth 
factor, fibroblast growth factor, IGF-I, vascular endothelial growth factor and transforming 
growth factor-β. The endogenous AR expression and its transcriptional activity that control 
cellular proliferation and apoptosis, are regulated by insulin and IGF-I pathways similar to 
that described in Figure 2.17 (Manin et al, 2000, Manin et al, 2002).  
Various epidemiological studies have been performed to investigate the relationship 
between the circulating IGF-I concentration in the development of PC. The discussion 
below focuses on IGF-I as a potential ethnic group-specific biomarker for PC. IGF-I serum 
concentration is age-dependent; it increases slowly from birth to puberty and thereafter 
declines with age (Moschos and Mantzoros, 2002, Ceda et al, 2005). Increased IGF-I 
concentration in older patients may be a sign of human cancer as a whole (Samani et al, 
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2007). There have been various studies over the years assessing circulating concentration 
IGF-I in relation to PC risk.  
A number of authors linked elevated IGF-I concentration in the circulation with increased 
risk of developing PC. Stattin et al (2004) found a 4-fold increase in the risk of PC in a 
Swedish cohort with high IGF-I concentration using the immunoradiometric (IRMA) 
assay. Chokkalingam et al (2001) demonstrated by ELISA technique a 2.6-fold increase of 
PC risk in patients with higher IGF-I in case-control study in Shanghai. Chan et al (2002) 
and Platz et al (2005) also described positive relationship between PC risk and IGF-I 
concentration using the ELISA technique in a mixed American population (all ethnic 
groups). Wolk et al (1998) concurred with the above authors in a Swedish case-control 
study but they used an IRMA technique for IGF-I assay. Kehinde et al (2005) have shown 
that Arab men have lower IGF-I concentration than Caucasians which may explain a low 
incidence of PC in the Arabs. Positive associations between circulating IGF-I 
concentration and PC development and severity was found in several meta-analysis. 
Renehan et al (2004) demonstrated in a meta-analysis which included 21 eligible studies 
with a case to control ratio of 1 : 2 that high concentrations of IGF-I were associated with 
an increased risk of PC compared to a lower concentration. Another meta-analysis also 
showed that high circulating IGF-I concentration can give a 2-fold increase in PC risk 
(Shaneyfelt et al, 2000). An analysis of individual patient data from 12 prospective studies 
also concluded that the higher IGF-I circulating concentration increases the risk of PC 
(Roddam et al, 2008). 
 At the same time data of other authors do not agree with the mentioned above studies. 
Using the IRMA technique for IGF-I analysis, Chen et al (2004) found that IGF-I 
concentration was not associated positively with risk of PC in a mixed USA population. In 
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the UK, Rowlands et al (2012), using the RIA technique also found no association between 
IGF-I and PC risk. Several studies using ELISA techniques by Borugian et al (2008), Allen 
et al (2007) and Severi et al (2006) was also in agreement that IGF-I concentration does 
not affect the PC risk in mixed USA, multiple European and Australian ethnic groups.  
There may be several reasons for the inconsistency of results between studies done 
previously in different ethnic groups. Firstly, most of the studies done previously were 
mainly based on nested case-control study design. These studies are retrospective and the 
samples are collected before the diagnosis is made and are usually a part of a different 
large population study. Once the follow-up of the participants have confirmed that they 
have developed PC, then the analysis of all such patients are performed for the required 
parameters. The selection of controls is age-matched among those in the same cohort. 
Although this type of studies are cost-effective as samples are already available but the 
selection of controls may be biased due to the possibility of unknown occult PC. The 
samples obtained are also pre-diagnostic samples which have been stored for a long time 
since recruitment which can be up to 20 years in some study. This may impact the results 
as it does not reflect the actual state of the participant in the preceding years before the 
diagnosis of PC due to the effect of factors like diet and lifestyle on the hormone 
concentration.  
 Generally, there has been a lack of well-designed prospective case-control and ethnic-
group based studies comparing multiple ethnic groups from different environment. There is 
also a lack of data from various other low PC incidence cohorts like Asians and Africans. 
It should also be noted that previously conducted studies used different techniques for IGF-
I detection which makes it difficult to interpret results. 
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2.3 DNA polymorphisms in genes controlling androgen pathways and 
their link to prostate cancer 
The importance of androgens in PC development has been described in section 2.2.1. The 
genes involved in the biosynthesis and metabolism of androgens have been extensively 
studied and several key genes, such as SRD5A2, CYP17 and AR have been identified as 
potential candidate genes for PC (Figure 2.13). Specific polymorphisms in these genes in 
relation to PC will be reviewed in the following section of the thesis. 
2.3.1 Polymorphisms in CYP17 gene and their role in prostate cancer 
Sex steroid hormone synthesis follows the conversion of cholesterol to pregnenolone. 
CYP17 enzyme catalyses two key reactions involved in the production of sex steroids from 
cholesterol, which occur sequentially as follows: 17α-hydroxylase converts pregnenolone 
to 17α-hydroxypregnenolone and progesterone to 17α-hydroxyprogesterone, while 
C17,20-lyase converts 17α-hydroxypregnenolone to DHEA and 17α-hydroxyprogesterone 
to androstenedione (Vasaitis et al, 2011, Denisov et al, 2005) (Figure 2.18). The precursor 
DHEA and androstenedione are subsequently converted to testosterone by HSD3B2 and 
HSD17B3. There has been another pathway described in the production of DHT that by-
passes testosterone and is catalysed by enzymes encoded by CYP17 gene (Figure 2.18) 
(Auchus, 2004). Extensive involvement of CYP17-encoded enzymes in the androgen 
metabolism indicates importance of this gene as potential therapeutic targets for PC. 
CYP17-encoded enzymes belong to oxygen-reacting hemeproteins cytochrome P450 group 
which has 40 types of proteins in humans with a diverse list of activities, one of which is 
the biosynthesis of sex steroids (Denisov et al, 2005, Hasler et al, 1999). 
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CYP17 gene is located on chromosome 10 and encodes the cytochrome P450c17α 
enzymes. There has been a lot of interest in studying CYP17 polymorphisms and their 
effects on the CYP17 expression and enzyme activity in relation to the rate of testosterone 
production.  The use of abiraterone acetate, a selective CYP17 inhibitor, demonstrated 
improvement in PC patients as evidenced by PSA test and bone scan (Reid et al., 2010). 
These results are in a line with a report on a randomised phase III trial on metastatic PC 
patients which demonstrated benefit of abiraterone acetate-based drug for overall patient 
survival (Ryan et al, 2013).  
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Figure 2.18 Series of reactions involved in the formation of androgens from cholesterol. 
Red- Enzymes encoded by CYP17 gene, Blue- second pathway for DHT production catalysed 
by CYP17 encoded enzymes. Adapted from Vasaitis et al (2011) with permission from 
Elsevier. 
 
The role of CYP17 gene in biosynthesis of testosterone was first described in a study 
which identified a new single base change (T to C substitution) in 5' promoter region of the 
CYP17 gene (Carey et al, 1994). This SNP creates an additional SP1-type (CCACC box) 
promoter site, presence of which may positively be related to testosterone production. The 
variant C allele (designated as A2) may result in increased transcriptional activity and 
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hence increase testosterone biosynthesis (Carey et al, 1994). CYP17 involvement in PC 
development is supported by finding that CYP17 mRNA expression is up-regulated in 
tumour compared to normal tissues (Stigliano et al, 2007).  The same authors also 
demonstrated increase in CYP17 mRNA expression with the PC grade. Another important 
evidence in support of links between CYP17, testosterone concentration and  PC is a 17-
fold increase in CYP17 mRNA in castrate-resistant PC patients (i.e. in those whose disease 
was progressing despite complete androgen blockade achieved as treatment of PC) 
compared to the patients who had not been treated for their primary tumours (Montgomery 
et al, 2008).  
It is important to highlight that although there has been an increasing number of 
communications about polymorphism in CYP17 promoter the relevance of these 
polymorphisms to PC development is not clear and data of the literature are controversial. 
In particular, this refers to the polymorphism in 5’-untranslated region of the CYP17 gene 
containing a polymorphic T-to-C substitution (rs743572) at position -34T→C that gives 
rise to A1 (T) and A2 (C) alleles (Carey et al, 1994).  There are several other 
polymorphisms that have been identified in CYP17 gene in relation to PC risk. The 
reported CYP17 polymorphisms are in rs284851, rs619824, rs10883782, rs1004467, 
rs17115144, rs2486758 but no significant association was found between these 
polymorphisms and PC but it should be taken into account that information about these 
polymorphisms are limited. (Beuten et al, 2009). The only SNP that has been consistently 
studied in different ethnic groups is the rs743572, although outcomes of these studies are 
inconsistent (Karimpur-Zahmatkesh et al, 2013, Severi et al, 2008). This SNP will be one 
of the focuses of this thesis. One of the reasons for controversial data of the literature 
might be the use of different ethnic groups and a possibility of ethnic group-specific 
variations in the mechanisms controlling PC development. The studies reviewed reported 
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frequency of the above polymorphism and the relationship between different CYP17 
alleles (A1, A2 and A1/A2) and the risk of PC.  
Lunn et al (1999) reported the same frequency of A2 allele in Caucasian-Americans and 
Black-Americans. In Caucasians (but not Black-Americans) this allele was associated with 
increased risk of PC. Gsur et al (2000), Yamada et al (2001) and Sarma et al (2008) 
observed a higher frequency of A2 allele in PC patients compared to the controls in the 
Austrian, Japanese and African-American ethnic groups. Yamada et al (2001) also 
described increased risk of PC in patients with a high frequency of A2 allele compared to 
A1 or A1/A2 alleles.  The A2 allele was noted to increase risk of PC in North Indian, 
Iranian and Tunisian men (Sobti et al 2009, Karimpur-Zahmatkesh et al (2013), Souiden et 
al., 2011).  
 At the same time, a number of authors disagreed on contribution of CYP17 
polymorphisms at the position -34T→C to PC development. These studies were conducted 
on Chinese, Australian-Caucasian, Brazilian and mixed American men (multiple USA 
ethnic groups) by Madigan et al (2003), Severi et al (2008), dos Santos et al (2002) and 
Chang et al (2001) respectively. The most likely explanation for controversial data of the 
literature is the different ethnic groups studied. CYP17 polymorphism may be more 
common and associated with PC risk in some ethnic groups but not in others. To confirm 
this hypothesis, a large population study with the use of different ethnic groups under the 
same experimental conditions is required. It is also important to ensure that such a study 
will have a proper control group. The selection of control participants has been different in 
different papers with some using BPH and some using healthy controls. This is an 
important limitation of all the research and could be one of the reasons for the 
inconsistency of the results.  
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No association between CYP 17 SNP (rs743572) and PC was found in meta-analysis on 
2,404 PC patients and 2,755 controls (Ntais et al, 2003a). However, it should be noted that 
when the data were analysed by ethnic groups, the presence of A2 allele was associated 
with increased susceptibility to PC in subjects of African descent. There was no effect of 
A2 allele on PC risk seen in subjects of European origin or Asian origin. As the number of 
cases and studies involving African origin were low, further research is needed to confirm 
these data (Ntais et al, 2003a). This indicates the need to undertake a well-designed case-
control study in an unreported multi-ethnic society like in Malaysia consisting of Malays, 
Chinese and Indians in direct comparison to the Caucasian group. 
Another important aspect of the CYP17 polymorphism at position -34T→C is its impact 
on the concentration of circulating testosterone. The first published study on this topic 
showed no significant association between the CYP17 polymorphism and total testosterone 
concentration in UK white men (Allen et al, 2001). Another nested case-control study 
within the Physicians’ Health Study cohort in the USA involving 590 PC cases and 782 
matched controls evaluated the association between CYP17 polymorphism at position -
34T→C and circulating steroid hormone concentration in the control group. Among the 
controls, the carriers of the A2 allele of CYP17 gene were found to have no difference in 
the circulating steroid hormone concentration compared to the non-carriers (Haiman et al, 
2001). Research involving 523 participants in the Study of Osteoporotic Risk in Men 
(STORM) established a significantly higher concentration of free testosterone in White-
American men with the A2 allele compared  to A1 genotype, with heterozygous (A1/A2) 
men having  intermediate hormone concentration (Zmuda et al, 2001).  There is not much 
information on the status of Asian population with regards to CYP17 polymorphism at 
position -34T→C in relation to the circulating sex hormone concentration. Therefore, one 
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of the focuses of the present PhD project is to investigate the relationship between CYP17 
polymorphism at the position -34T→C and circulating sex hormone concentration. 
2.3.2 Polymorphisms in SRD5A2 gene and their role in prostate cancer 
SRD5A2 gene encodes 5α-reductase enzyme that catalyses the conversion of testosterone 
into a more powerful prostatic androgen, dihydrotestosterone (DHT) (Coffey, 1993), which 
is responsible for prostate growth and may be considered a potential marker for predicting 
clinical response to the anti-androgen therapy in PC patients (Wilbert et al, 1983, Geller et 
al, 1984).  
There are two types of 5α-reductase enzyme reported with SRD5A1 gene encoding for the 
type I enzyme and SRD5A2 gene encoding the type II enzyme. The type 2 enzyme is the 
key enzyme involved in prostate development and growth (Reichardt et al, 1995). The type 
I enzyme is usually found in the skin and liver and is more important in sexual 
differentiation (Reichardt et al, 1995). 
The conversion of testosterone to the more active intracellular metabolite, DHT, by 5α-
reductase with NADPH as the cofactor takes place within the prostatic epithelial cell 
(Figure 2.19). DHT binds to the androgen receptor (AR), and the DHT-AR complex 
activates a number of genes containing AR-responsive elements (Figure 2.14) (Coffey, 
1993). 
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Figure 2.19 Conversion of testosterone to DHT facilitated by 5α-reductase with NADPH as a 
cofactor. 
Adapted and modified from Andrews et al (1996) with permission from author and 
Bentham Science Publishers. 
 
The human SRD5A2 gene is located on chromosome 2 (2p23) and it spans about 40 kb of 
genomic DNA, with 5 exons and 4 introns and known to be a highly polymorphic gene 
(http://www.ncbi.nlm.nih.gov/SNP) (Reichardt et al, 1995). There have been 10 missense 
substitutions reported in SRD5A2 gene (Makridakis et al, 2000). Most of these 
polymorphisms are extremely rare with an incident rate of less than 2%. The two most  
important polymorphisms in SRD5A2 as far as PC is concerned, are C>G substitution, 
rs523349, which results in amino acid substitution, Val to Leu at codon 89 (V89L), and 
G>A substitution,  rs9282858 which results in Ala to Thr change at codon 49 (A49T) 
(Makridakis et al, 2000, Makridakis et al, 1997, Li et al, 2013b). It has been hypothesised 
that the activity of 5α-reductase enzyme can be controlled by the two polymorphism 
mentioned above.  
The V89L amino acid substitution reduces activity of the enzyme 5α-reductase in vivo and 
in vitro, which might lead to reduction in the circulating DHT. This effect could potentially 
protect against PC development (Makridakis et al, 2000).  In contrast, the A49T 
substitution increases 5α-reductase activity in vitro and might lead to increased production 
of DHT from testosterone (Makridakis et al, 1997). Zeigler-Johnson et al, (2002) 
investigated frequency of V89L and A49T in African-Americans, Caucasian-Americans, 
Testosterone Dihydrotestosterone 
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Ghanaians and Senegalese populations. It was noted that frequency of L genotype at codon 
89 was the highest in Caucasian-Americans followed by the African-Americans. The 
Africans were least likely to carry this polymorphism (Zeigler-Johnson et al, 2002). The 
same study showed that the frequency of the T genotype at codon 49 was highest among 
White-Americans followed by African-Americans and Africans. An interesting 
observation was that the frequency of V89L and A49T in the Asians were reported as 
54.8% and 0% respectively among the cancer-free participants (Li et al, 2010). This 
reiterates the fact that there is a potential in studying ethnic differences of these variants in 
cancer patients. Data from epidemiologic study in various populations and the risk 
associated with PC is described below. The genotypes that are produced in the event of the 
above C>G polymorphism are denoted based on the amino acid change. It can be VV for 
Val (no change), LL (for Leu change) and L/V for a heterozygote type of substitution 
under the V89L variant. Margiotti et al (2000) had shown that the presence of the LL 
genotype reduced the risk of PC non-significantly in Italian men. This was also noted in a 
study by Hsing et al (2001) in a Chinese group but similarly the reduction was not 
statistically significant. Yamada et al (2001) demonstrated that there was a non-significant 
5% increase in the frequency of the LL genotype in the Japanese PC cases than in controls. 
These Asian data may indicate the protective nature of increased frequency of the LL 
genotype that may explain the low incidence of PC in these Asian communities but the 
above study did not assess the risk and therefore was unable to comment on the risk of PC. 
However, larger studies in more Asian communities are required to confirm this finding. 
Torkko et al (2008) in a study among non-Hispanics and Hispanic-whites found that 
Hispanic-white men with the VV genotype had reduced PC risk in the USA.  Giwercman 
et al (2005) did not assess the risk of PC in the Swedish cohort studied but found that the 
frequency of the LL genotype was significantly higher in the PC group than the control 
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group. This data was somewhat contradicting the theory that LL genotype frequency 
should be higher in Asians as shown by Torkko et al (2008). Studies by Salam et al (2005) 
and Cussenot et al (2007) in mixed American men and Caucasian French men respectively 
demonstrated that the homozygous LL genotype increase the risk of PC significantly in 
both the ethnic groups studied compared to the VV or LV genotype. Cussenot et al (2007) 
also reported that the LL genotype is associated with the most aggressive PC. This is in 
keeping with positive impact of this LL variant in the SRD5A2 gene that may play an 
important role in increasing the risk of PC in Western men compared to the Asians 
although data from Asia is limited.  
Several authors did not concur with the findings of the previous research above and have 
reported no association between the V89L variant of the SRD5A2 gene in the frequency or 
risk associated with PC in the presence of VV, LL or L/V genotypes. These studies with 
negative association with this polymorphism were reported by Onen et al (2007) in 
Turkish men, Hayes et al in the Australians and Rajender et al (2009) in South Indian men. 
These findings above confirm the possibility of ethnic difference in the frequency and risk 
of PC incidence and warrants larger studies in other ethnic groups. The heterogeneity in 
the selection of the PC cases and the control groups again may play an important role in 
the inconsistency of the results. This is because the selection of patients was all not of the 
same disease stage and grade and therefore led to small numbers in each stage. As in the 
selection of control group in the polymorphism in the CYP17 gene, there may be a 
difference in the genetics of healthy controls, BPH and population control groups as 
described in section 2.3.1.  
Most authors in our review of literature have reported that the A49T variant was not found 
in any of the cases or control patients in their study. Yamada et al (2001), Hsing et al 
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(2001) and Rajender et al (2009) reported the absence of polymorphism that causes the 
A49T variant in the PC cases and controls studied in Asians of Japanese, Chinese and 
South Indian origin respectively. Onen et al (2007) was also in agreement with the above 
finding in the Asian group and reported the absence of A49T variant in any of their 
samples in Turkish men. Contrasting results were found in some of the Western studies as 
far as frequency and risk associated with PC incidence is concerned. Margiotti et al (2000) 
reported that there was a non-significant increase in PC risk with the TT genotype but none 
of the variant was found in any of the controls who were participants with low risk of PC 
development.  Torkko et al (2008) reported that the TT homozygote was absent in the 
Hispanic and non-Hispanic cohort studied in the USA but the AT heterozygote variant 
found did not increase the risk of PC. Hayes et al (2007) reported the frequency of the 
G>A polymorphism at position 140 from the start codon in SRD5A2 gene in an Australian 
cohort study (amino acid change was not reported). They found that the frequency of A 
nucleotide was about 2% higher in PC cases than controls and the G/A heterogeneous 
nucleotide was also about 3% higher in PC cases than controls. The overall risk of PC in 
the study by Hayes et al (2007) was a significant 60% higher with the presence of either A 
or G/A nucleotide.  Result from the study by Hayes et al (2007) was in agreement with an 
earlier study by Makridakis et al (1999) in African-Americans and Hispanic-Americans 
that showed a significant 7.2 and 3.6-fold increase in PC risk in the two ethnic groups 
respectively. Based on this review, it is noted that an ethnic variation exists in the 
prevalence of this A49T variant of SRD5A2 gene. It appears that the variant is absent in 
Asian population compared to other ethnic groups. The possibility of this variant being one 
of the reasons for ethnic difference in the incidence should be studied further in various 
other ethnic groups in Asia in comparison to the Caucasians and African-origin groups.   
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Information about the described above genetic polymorphisms and their relationship with 
PC risk might be useful for the development of intervention strategies for PC treatment. 
There has been increasing interest in developing drugs for chemoprevention (i.e. 
Finasteride) which act as 5α-reductase inhibitors (Lucia et al, 2007, Thompson et al, 
2003). These drugs are used to treat Benign Prostatic Hyperplasia by shrinking the prostate 
and have been tried as a chemo preventive agent for PC. In a study comparing Finasteride 
and placebo in PC prevention, a preventive effect of Finasteride was demonstrated for low 
grade PC (Lucia et al, 2007). Therefore, the use of this drug is beneficial in the prevention 
of PC and the study of polymorphism in the SRD5A2 gene that encodes for the enzyme 
5α-reductase may be correlated with the benefit of using this drug to reduce the incidence 
of PC. The identification of genetic polymorphism of genes that encode for the enzyme 5α-
reductase could provide an explanation for the success or failure of any chemo preventive 
strategy used. 
In view of these contrasting evidence, the need for data from new groups and an overall 
assessment of the androgen pathway can still establish important information to explain the 
heterogeneity of the PC disease. 
 
2.3.3 Polymorphism in AR gene and its role in prostate cancer 
The biological function of androgens is exerted via activation of the transcriptional activity 
of androgen receptor (AR) (Huang and Tindall, 2002). The AR is capable of binding both, 
testosterone and DHT. DHT has a five-fold higher affinity for the AR than testosterone 
(Heemers et al, 2009). 
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The androgen-induced transcriptional activation of AR is modulated by the interaction of 
AR with co-regulators and by phosphorylation of AR and AR co-regulators in response to 
growth factors (Figure 2.20) (Heinlein and Chang, 2004, Richter et al, 2007). 
 
              
Figure 2.20 Interaction between androgen and AR within the prostate gland. 
T- testosterone, DHT- dihydrotestosterone, AR- androgen receptor, ARAs- AR co 
regulators, AREs- androgen response elements, HSP- heat shock protein, R- membrane 
receptor, P- protein Phosphorylation. Adapted from Heinlein and Chang (2004) with 
permission from the author. 
 
Testosterone and DHT bind to the AR in the prostate and promote the association of AR 
co-regulators (ARAs). AR then translocates to the nucleus and binds to androgen response 
elements (AREs) in the promoter regions of target genes to induce cell proliferation and 
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apoptosis. An example of the target gene is the PSA gene which is up regulated to increase 
the production in case of malignant change (Agoulnik and Weigel, 2009) . Other signal 
transduction pathways, such as those involving TGFβ, IL-6, and IGF-I, can also enhance 
AR activity via phosphorylation of AR and/or ARAs (Heinlein and Chang, 2004, Culig et 
al, 2002). 
AR integrates signals from multiple regulatory pathways described above and disruptions 
in any of the pathway may lead to the loss of AR functional integrity. Increases in cell 
growth-promoting functions and the apparent loss of differentiation properties of AR may 
play important role in the transformation from a benign prostate to a malignant one (Figure 
2.21). This transformation can also be due to mutations in the AR gene which alter ligand 
interaction or increase transcriptional activity leading to abnormal cellular proliferation and 
loss of anti-apoptotic signal (Heinlein and Chang, 2004, Richter et al, 2007). 
 
 
Figure 2.21 The Androgen receptor (AR) balance. 
Figure shows overwhelming cell growth and reduced differentiation due to abnormal AR 
signalling. Adapted from Richter et al (2007) with permission from Nature Publishing 
Group. 
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The AR gene, located on the short arm of X-chromosome (Xq11-12), is known to be 
polymorphic, having a highly variable trinucleotide microsatellite of CAG-repeats and 
GGC-repeats in exon 1 (Kral et al, 2011, Ekman et al, 1999). The numbers of CAG-
repeats can vary in different population groups, with normal numbers ranging from 8–31, 
with an average of about 20 repeats (Ekman et al, 1999, Edwards et al, 1992). The number 
of GGC repeats can vary from 10–30 but the impact of abnormal repeat count on PC is still 
a matter of research in contrast to the more definitive findings in studies related to the 
CAG-repeats (Kral et al, 2011).  The NH2-terminal transactivation domain of AR contains 
two trinucleotide repeat regions (CAG and GGC) both of which are polymorphic in length 
and are separated by 248 amino acids of non-polymorphic sequence (Heinlein and Chang, 
2004, Kral et al, 2011). The CAG trinucleotide encodes for a sequence of glutamine 
(polyglutamine) while the GGC trinucleotide encodes for a sequence of glycine 
(polyglycine) and these amino acid sequence length may also vary based on the length of 
polymorphic CAG and GGC repeat length.  
Studies have shown, although not consistently, that the longer AR variants (due to the 
increased number of CAG-repeats and to a certain extent GGC-repeats) decrease 
transactivation activity and affinity to bind androgen which may lead to a protective effect 
on the prostate. The short variants may increase the risk of PC due to increase AR activity 
(Ekman et al, 1999, Chamberlain et al, 1994). PC patients appear to have shorter CAG-
repeats compared to controls (Irvine et al, 1995, Ingles et al, 1997). African-Americans, 
who have the highest risk of PC, generally have shorter CAG-repeats compared to White-
Americans and Asian-Americans (Kral et al, 2011, Coetzee and Ross, 1994). This PhD 
project will focus on relationship between the number of CAG-repeats and PC incidence. 
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The ethnic differences in PC incidence tend to be inversely related to CAG-repeat number 
in the AR gene. Asian men have the lowest PC incidence and the longest AR gene CAG-
repeats, whereas African Americans (AA) have the highest PC incidence and shortest 
CAG-repeat length (Li et al, 2013a, Kral et al, 2011). However, there are several studies 
that found no evidence that the CAG repeats are linked to PC in Taiwanese, non-Hispanic 
white population, Japanese and Chinese Singaporeans (Edwards et al, 1999, Price et al, 
2010, Huang et al, 2003, Chang et al, 2002). In contrast, studies conducted on the 
Americans (Giovannucci et al, 1997), Nigerians (Akinloye et al, 2011) , Iranians (Ashtiani 
et al, 2011), and South Indians (Krishnaswamy et al, 2006) have shown positive links 
between a number of the repeats and PC. In particular, Giovannucci et al (1997) showed 
that the risk of PC increased in those with CAG-repeat length of less than 18. Akinloye et 
al (2011) used the cut-off length of ≤ 21 and reported that PC risk is increased in shorter 
CAG-repeats in Nigerians. Ashtiani et al (2011) demonstrated significant shorter mean 
CAG-repeat length in PC compared to healthy controls and in PC compared to BPH. The 
South Indian study by Krishnaswamy et al (2006) found that the risk of PC increased 
significantly in men with ≤ 19 CAG repeats compared to those with > 19 CAG repeats 
where the controls were a mixture of healthy and BPH participants. In studies conducted in 
Chinese men, Zhai et al (2014) found that the risk of PC and more aggressive disease was 
higher in CAG-repeat length of < 21, but in an earlier study by Hsing et al (2000), it was 
noted that there was 65% increase risk of PC in CAG-repeat length of < 23. A large study 
in multiple ethnic groups within the same environment in a country like Malaysia could 
possibly establish an ethnic based cut-off for CAG-repeat length to determine risk of PC 
tailored to specific ethnic-groups.      
A meta-analysis confirms association between ethnic differences in predisposition to PC 
and ethnic-group specific length of CAG-repeats. It has been noted that longer repeat (≥ 20 
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repeats) were associated with 11% decreased risk of PC in USA population, 53% 
decreased risk in Europe, and 20% decreased risk in Asia (Gu et al, 2012). There are also 
studies which assessed the circulating concentration of testosterone in relation to the AR 
polymorphism. The data are controversial with some papers reporting elevated testosterone 
concentration in case of longer CAG-repeats (Krithivas et al, 1999, Lindström et al, 2010) 
with other communications not being able to establish any correlation between testosterone 
and CAG-repeats length (Zitzmann et al, 2001, Van Pottelbergh et al, 2001). An important 
issue in majority of the study in different ethnic groups reviewed above showed a striking 
difference on cut-off for CAG-repeat length in each community to assess PC risk. This 
indicates a strong need in determining polymorphic length of CAG in specific ethnic 
groups.    
In this research project, the relationship between the number of GGC repeat and PC was 
not studied due to lack of evidence in the literature regarding the role of this polymorphism 
in PC development. 
 
2.4 Summary of literature review 
2.4.1 Background on prostate cancer 
a) Size of prostate gland increases with age and may cause urinary obstruction 
symptoms called benign prostatic hyperplasia.  
b) Malignant change can take place in the prostate. Mechanism that causes the change 
is unknown but the most likely theory is the increased production of reactive 
oxygen species in the prostate caused by risk factors like diet, lifestyle and 
environmental changes.  
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c) Worldwide incidence of PC is rising and it is the most common cancer in men in 
western countries. Despite increase in PC incidence, mortality due to PC has 
remained quite stable due to diagnosis of clinically insignificant cases that is 
unlikely to lead to mortality in the life–time of the patient. 
d) The only established PC risk factors are the non-modifiable ones such as age, 
ethnicity, family history and genetics  
e) Ethnicity plays a major role in PC incidence. The risk of PC is the highest in 
Africa-Americans followed by Caucasians. Asian ethnic groups have the lowest 
risk of PC. 
f) Modifiable PC risk factors have been extensively studied but the results are 
inconsistent so far. These risk factors include nutritional factors (vitamin E, vitamin 
D, Selenium, and Lycopene), obesity, physical activity, and hormonal factors 
(androgens and growth factor). 
g) PSA is the only established screening test widely used for PC screening.  There is 
an issue with PC over diagnosis due to low sensitivity and specificity of the test. 
This lead to unnecessary diagnostic procedure which are morbid. 
 
2.4.2 Role of androgen in prostate cancer     
a) Prostate gland is an androgen regulated organ. Testosterone and DHT are the major 
sex hormones that play important role in PC development. The mechanism of 
androgens involvement in PC development is not fully understood. 
b) It is suggested that the conversion of testosterone to a more potent DHT takes place 
in the prostate. DHT binds to AR and activates gene transcription and cellular 
proliferation. Uninhibited proliferation can lead to malignant change in the prostate 
gland. 
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c) Data of the literature are inconsistent with regards to relationship between androgen 
concentration and PC risk in different ethnic groups. 
 
2.4.3 Role of insulin-like growth factor-I in prostate cancer  
 
a) IGF-I is produced in the liver. The production is regulated by growth hormone and 
nutrition. 
b) IGF-I binds to IGF-I receptor to bring about metabolic and anabolic activity. Its 
long-term effect includes cellular proliferation, cell differentiation and anti-
apoptosis effect via the tyrosine kinase pathway. 
c) Changes in AR function due to binding of DHT to the receptor can cause functional 
changes in the activity of growth factors such as IGF-I. 
d) Data of the literature is inconsistent with regards to effect of IGF-I on risk of PC, It 
is suggested that higher concentration of circulating IGF-I increases the risk of PC. 
 
2.4.4 Review of genetic polymorphisms      
a) CYP17 and SRD5A2 play an important role in control of androgen metabolism. 
AR gene controls the binding capability of AR to DHT. 
b) CYP17 gene:  
i. Polymorphism at -34T→C is the most studied in relation to PC risk and 
incidence. 
ii. CYP17 gene encodes P450c17α enzyme that catalyses two key reactions 
involved in the production of sex steroids from cholesterol. The two 
reactions are (i) conversion of pregnenolone to 17α-hydroxypregnenolone 
 67 
 
and progesterone to 17α-hydroxyprogesterone, and (ii) conversion of 17α-
hydroxypregnenolone to DHEA and 17α hydroxyprogesterone to 
androstenedione. 
iii. The polymorphism mentioned above is suggested to increase production of 
testosterone via androgen metabolism pathway. 
c) Data of literature on CYP17 polymorphisms are controversial with multiple studies 
from different ethnic groups reporting varying PC risk associated with A1, A2 and 
A1/A2 alleles. 
d) SRD5A2 gene:  
i. SRD5A2 gene encodes for 5α-reductase, an enzyme that catalyses the 
conversion of testosterone into the more powerful prostatic androgen, DHT. 
ii. A49T and V89L are the most extensively studied variants with regards to 
PC. Nucleotide substitution at the position 261C→G causes the amino acid 
change from Val to Leu at codon 89 (V89L) and nucleotide substitution at 
the position 140G→A results in amino acid change from Ala to Thr at 
codon 49 (A49T) in this gene. 
iii. V89L variant reduces activity of 5α-reductase thus reducing the conversion 
of testosterone to DHT. A49T variant increases activity of the above 
enzyme and therefore increases the production of DHT. 
iv. Data of the literature are not conclusive as for association between these 
two polymorphisms and PC risk.  
e) AR gene: 
i. Mutation in AR gene can alter the binding capacity of the receptor with 
DHT or increase transcriptional activity leading to abnormal cellular 
proliferation and loss of anti-apoptotic signal. 
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ii. AR gene is known to be polymorphic, with a highly variable trinucleotide 
microsatellite of CAG-repeats and GGC-repeats in exon 1. Number of CAG 
repeats has been widely studied in relation to PC.  
iii. It is thought that a lower number of CAG-repeat is associated with the 
higher the risk of PC. However, the data differ depending on ethnic groups 
studied.  
 
The hypotheses for this project are: 
1. The concentration of circulating androgens (testosterone and DHT) and the growth 
hormone Insulin-like Growth Factor-I (IGF-I) are positively related to the incidence 
of PC in BC and the MC men. The serum concentration of all these hormones are 
expected to be significantly higher in the BC compared to the MC men because of 
the higher risk and incidence of PC in the Caucasians compared to Asians.  
2. The presence and frequency of selected polymorphisms in the CYP17, SRD5A2 
and the AR genes are related positively to the higher incidence of PC in the BC but 
not in MC men.  
3. Polymorphisms in CYP17, SRD5A2 and AR genes are associated with increased 
concentration of the hormones testosterone, DHT and IGF-I in the circulation. 
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3 Materials and methods 
This study was a coordinated research between University of the West of England (UWE), 
Bristol Urological Institute (BUI) and University of Malaya, Kuala Lumpur (UM), aiming 
to investigate ethnic-group specific mechanisms of PC risk and development. 
This study was conducted on 200 samples of whole blood and serum collected from the 
two ethnic groups, Bristol Caucasian (BC) and Malaysian Chinese (MC) men (100 samples 
from each ethnic group). The samples from each ethnic group comprised of control 
samples and PC patients (50 samples per group).  
The samples from the BC men were collected at the Urology outpatient’s clinic at 
Southmead Hospital, Bristol, UK. Samples from the MC group were obtained at the 
Urology outpatient clinic of the University Malaya Medical Centre Kuala Lumpur 
(UMMC). Some control samples in the Malaysian group were also obtained during 
Prostate Awareness Week. All the sample collection was done in accordance to Ethical 
approvals and following strict participant selection criteria described in Table 3.1. The 
same protocol was used for the sample collection in Malaysia and the UK. 
This study also includes a pilot experiment which was conducted in order to optimize 
laboratory techniques and protocols, particularly in relation to molecular biology and 
genetic experiments. This experiment was conducted on the whole blood samples from 
five healthy volunteers recruited at the University of the West of England.  Ethical 
approval for the recruitment of the volunteers was obtained from the Faculty Ethical 
Committee of the University of the West of England which permits the sample to be stored 
for 5 days at -80°C before being processed as in section 3.1.3. All volunteer samples were 
discarded after 5 days.  
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All the collected blood samples from the participants were immediately processed as 
described in section 3.1.3 and stored at -80°C (up to 3 months) until analysed.  
Schematic presentation of the experimental design is shown in Figure 3.1.  
 
Figure 3.1 Schematic presentation of experimental design 
CYP17A1- cytochrome P-450 steroid 17α-hydroxylase/17,20 lyase, SRD5A2- steroid 5α 
reductase type II, AR- Androgen Receptor, DHT- Dihydrotestosterone, IGF-I- Insulin-like 
growth factor-I. 
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3.1  Study Design 
3.1.1 Ethical Approval 
This research was based on work with human tissue (whole blood and serum) and therefore 
a National Health Service (NHS) ethical approval was required prior to sample collection 
and experimental work. The PC patients and control group recruitment was conducted in 
accordance with UK and local Ethical Regulations (South-West Committee). The protocol 
for PC patients and control group recruitment was approved via the Research and 
Governance System (RAGS) of the University of the West of England for both the main 
study and the pilot study with involvement of volunteers. The South-West ethical approval 
was obtained on 14th May 2012. 
Ethical approval was also obtained from the Medical Ethics committee of the University 
Malaya Medical Centre (UMMC), Kuala Lumpur, for the patient recruitment and samples 
collection at the hospital in Malaysia.  
 
3.1.2 Patients and Controls Recruitment 
This study recruited (i) patients who were newly diagnosed with PC and (ii) a control 
group with Benign Prostatic Hyperplasia (BPH). 
The inclusion and exclusion criteria for recruitment were the same for both ethnic groups 
investigated and are presented in Table 3.1.  All the participants in this study were more 
than 40 years old. The PC group consisted of newly diagnosed PC cases. The diagnosis 
was established based on prostate biopsy. Indications for prostate biopsy were either 
abnormality felt on digital rectal examination or an elevated PSA level (above 4.0 ng/ml). 
Participants in the control group were of similar age with low risk of PC.  
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Table 3.1 Inclusion and exclusion criteria for prostate cancer control groups in BC and MC 
participants. 
Parameters Inclusion  Exclusion 
Prostate 
Cancer Group 
All newly diagnosed prostate 
cancer patients. Diagnosis was 
based on Transrectal 
Ultrasound guided biopsy of 
prostate. 
 
Age above 40 years old. 
 
Bristol Caucasian and 
Malaysian Chinese ethnic 
groups. 
Men of ethnic origin other 
than Bristol Caucasian and 
Malaysian Chinese. 
 
 
 
Age less than 40 years old. 
 
 
Control 
Group 
  
Patients who have been 
diagnosed with Benign 
Prostatic Hyperplasia (BPH). 
 
Normal digital rectal 
examination (DRE) findings. 
 
Prostate specific antigen level 
less than 4.0 ng/ml. 
 
No family history of prostate 
cancer. 
Prostate Specific Antigen level 
more than 4.0 ng/ml 
 
 
Positive family history of 
prostate cancer. 
 
Abnormal digital rectal 
examination finding. 
 
Men of ethnic origin other 
than Bristol Caucasian and 
Malaysian Chinese. 
 
 BC- Bristol Caucasians, MC- Malaysian Chinese. 
 
The Bristol Caucasian (BC) participants with PC were approached regarding the 
recruitment for this study during the counselling visit after the treatment decision has been 
made by the clinicians at Southmead Hospital. This was the second visit where the patient 
had been informed about the diagnosis during the first visit. The patients received a Patient 
Information Sheet prior to the second visit. This approach was adopted so that the anxiety 
of being diagnosed with cancer can be reduced. The Malaysian participants were also 
recruited during (i) outpatient appointments after the treatment decisions for PC have been 
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made and (ii) during outpatient follow-up appointments for consultation and investigation, 
or during awareness campaign for the Benign Prostatic Hyperplasia cases. 
Participant information sheets were given out during appointments for Benign Prostatic 
Hyperplasia consultation/investigation clinics or PC clinics. The participant information 
sheets made it clear that the study was voluntary and that choosing to refuse to participate 
would not in any way affect the patients’ treatment plan. It was also made clear to the 
participants that the samples would be made anonymous, and the nature of the experiments 
to be conducted on the samples was explained. The document also explained the benefit of 
this study to the future of prostate cancer management. A written consent was taken from 
each participant who agreed to participate in the study after at least 24 h going through the 
participant information sheet.  Blood samples were then taken from consenting participants 
by a qualified nurse or a doctor at the clinic.  
The Malaysian collaborating team followed the same recruitment protocol, but also 
included some participants who were diagnosed with Benign Prostatic Hyperplasia and PC 
during the Prostate Awareness Programmes. Recruitment through this additional 
programme was related to a very low incidence of PC in a single hospital. 
 
3.1.3 Blood collection and storage 
The protocol for the collection and storage of blood samples was the same for BC and MC 
participants. The blood sample from all consenting participants was obtained in the 
mornings. This was due to the known fact of diurnal variation in the concentration of 
circulating testosterone with the peak concentration known to be in the mornings 
(Brambilla et al, 2009). 
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The blood sample (12 ml) were drawn by venepuncture by either a phlebotomy trained 
nurse or a clinician at the Urology out-patient clinics at Southmead Hospital, Bristol and 
University Malaya Medical Centre, Kuala Lumpur. The blood samples were then divided 
in three tubes labelled with unique identity number. 3ml of blood each was placed in two 
tubes containing anti-coagulant Ethylenediaminetetraacetic acid (EDTA) and another 6ml 
of blood was placed into a plain tube not containing preservatives or anti-coagulant.    
The sample in the EDTA-tube was transferred immediately to a -80°C freezer at Bristol 
Urological Institute and at University Malaya Medical Centre, Kuala Lumpur facility. 
These samples were used for genetic analysis. It has been previously reported that storage 
of blood samples at -80°C does not compromise the quality and integrity of the DNA in 
blood or serum used for hormonal assay (Peakman and Elliott, 2008). For hormonal assays, 
blood samples were left in plain tubes and were allowed to clot for one hour and 
subsequently subjected to centrifugation at 1500 x g for 15 min at room temperature to 
separate the serum from the cellular components 
(http://www.scienceboard.net/resources/protocols). Equal volumes of serum were carefully 
pipetted out into three 1.5ml Eppendorf tubes, one tube per assay of each hormone. The 
tubes were stored at -80°C until analysed (the duration of storage varied from 1 to 6 
months). Aliquoting in three tubes was necessary to ensure that the samples were not 
subjected to repeated freeze-thaw cycles that can contribute to the potential damage to the 
quality of the serum (Mitchell et al, 2005).  
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3.1.4 Sample transfer 
The BC samples were transferred from Bristol Urological Institute to the Centre for 
Research in Biosciences at the University of the West of England in a biohazard labelled 
cold-storage box containing ice on the day of the analysis.  
The Malaysian samples (isolated DNA from whole blood and the serum) were transported 
to the University of the West of England by courier (World Courier (Malaysia) Pvt. Ltd. 
Petaling Jaya) at -80°C. DNA isolation method was agreed by both parties before hand and 
is described in Section 3.3.1 below. Anonymity of the samples was ensured at all times 
with accurate labelling with unique identity number.  
 
3.1.5 Clinical and demographic data collection 
All clinical and demographic data were collected during interview with the patients or 
from medical records and were entered into a standard proforma. The data collected were: 
age, diagnosis, PSA level, the Gleason score (in cancer cases) and digital rectal 
examination (DRE) findings. The information from the proforma was entered into a 
password secure computer for later use in statistical analysis. A unique identity number 
was generated for each participant and this number cannot be traced back to the patient to 
ensure anonymity of each sample. The Malaysian samples and data were collected with the 
help of the Malaysian collaborators from University of Malaya, Kuala Lumpur following 
the uniform protocol and subsequently transferred to the University of the West of England 
for analysis. 
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3.2 Analysis of serum hormone concentration 
The concentration of circulating testosterone, DHT and IGF-I were analysed in the serum 
samples which were collected, stored and transferred to the University of the West of 
England as described in Sections 3.1.3 and 3.1.4.  
The samples were analysed in batches of 40 for each hormone. Each analysis was 
conducted in duplicates. Intra-assay coefficient of variability (CV) was calculated for 
samples within the same plate to ensure the repeatability of the results and precision in the 
techniques. For the intra-assay CV, the mean of the mean concentration of hormone for 
each sample and the standard deviation (SD) was calculated for each plate. The SD was 
then divided by the mean and multiplied by 100 i.e. SD/ mean of mean concentration X 
100 to give the percentage CV. Acceptable CV percentage is < 10%. The percentage CV 
was calculated for each kit and the average for each test in our study was noted to be 8.7%, 
6.1% and 10.7% for testosterone, DHT and IGF-I respectively. Each batch included equal 
number of samples from Caucasian cancer, Caucasian control, MC cancer and MC control 
groups (10 samples per batch).   
The laboratory analysis of testosterone, DHT and IGF-I concentration were performed 
using commercially available Enzyme-Linked Immunosorbent Assay Testosterone ELISA 
kit (Immuno Biological Laboratories International, Hamburg, Germany), 5alpha-
dihydrotestosterone ELISA (Immuno Biological Laboratories International, Hamburg, 
Germany) and Quantikine® ELISA Human IGF-I Immunoassay (R&D System Europe 
Ltd. Abingdon, UK)  respectively following the recommended protocol. Fig. 3.2 shows the 
work-flow in the analysis of the stored serum obtained from the participants.  
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Figure 3.2 Schematic presentation of the work-flow for hormonal analysis. 
ELISA-Enzyme-linked immunosorbent assay, DHT-Dihydrotestosterone, IGF-I-Insulin-
like growth factor-I. 
 
3.2.1 Analysis of serum testosterone 
The concentration of circulating testosterone in the serum was determined using the 
Testosterone ELISA kit (Immuno Biological Laboratories International, Hamburg, 
Germany).  
All the reagents and serum samples were brought to room temperature. All standard 
solutions, control and cancer samples were run in duplicates concurrently to ensure same 
laboratory conditions and minimise the variations. 25µl of standard solution and 25µl of 
samples were dispensed into marked wells coated with mouse monoclonal anti-testosterone 
antibodies. 200µl of enzyme conjugate (testosterone conjugated to horseradish peroxidase) 
was added to each well. The content of the well was thoroughly mixed and incubated at 
room temperature for 60 min, then briskly shaken out and rinsed with 400µl of wash 
solution (provided in the kit). The washing step was repeated 3 times. A substrate solution 
Participant
•Serum separated from whole blood
Hormone 
analysis
•ELISA test for testosterone, DHT and IGF-I
•Absorbance measurement using microplate reader
Results
•Mean absorbance converted to hormone 
concentration
•Statistical analysis for significance
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(Tetramethylbenzidine, 200µl) was added to each well and incubated again at room 
temperature for 15 min. The enzymatic reaction was stopped by adding 100µl of Stop 
Solution from the kit (0.5M H2SO4) to each well and the optical density was measured 
using a microtitre plate reader (Bio-Tek Synergy 2, Winooski, U.S) at 450nm within 10 
min of adding the Stop Solution. The mean absorbance was determined by calculating the 
average of the duplicates for each sample.  Figure 3.3 shows the flow of the experiment for 
testosterone concentration assessment. 
 
 79 
 
 
Figure 3.3 Schematic presentation of the steps in analysis of testosterone concentration. 
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A standard curve (Fig. 3.4) was constructed using the value of the mean absorbance of 
each of the standard (provided in the kit) plotted against its given concentration. A new 
standard curve was constructed for each kit.  
 
Figure 3.4 An example of a standard curve for testosterone. 
Each point represents the mean optical density of 2 measurements for Standard Solution 
of given concentration. 
 
Concentration of the testosterone in control and experimental serum samples was 
calculated using the standard curve. Regression modelling was used as described by the 
manufacturer to derive the formula for calculation of testosterone concentrations. The 
calibration curve produced a good fit for the observed sample data with an R2=0.983. This 
was simplified using the formula derived statistically as below: 
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Testosterone concentration = Anti-log of [1.616- (2.202 x Mean Optical Density)] 
This formula was used for all the samples for testosterone concentration and tabulated for 
statistical analysis later. 
 
3.2.2 Analysis of serum dihydrotestosterone (DHT) 
The concentration of circulating DHT in the serum was determined using the 5alpha-
Dihydrotestosterone ELISA kit (Immuno Biological Laboratories International, Hamburg, 
Germany). 
All the reagents and serum samples were brought to room temperature. The standard 
solutions, controls and cancer samples were run in duplicates concurrently to ensure same 
laboratory conditions and minimise the variations. A working solution of DHT-
Horseradish Peroxidase conjugate was prepared by diluting the stock solution 1:100 with 
the assay buffer (protein-based buffer with non-mercury preservative). 50 μl standard, 
control and cancer samples were pipetted into marked wells coated with rabbit anti-DHT 
antibody. 100µl of conjugate working solution was dispensed into each well. The plate was 
then incubated on a plate shaker (~200 rpm) at room temperature for 1 h. The wells were 
washed three times with the diluted wash buffer (300μl each time) and tapped against an 
absorbance paper to ensure that the wells are dry. The substrate solution 
(Tetramethylbenzidine 150 μl) was added to each well and incubated at room temperature 
on a plate shaker for 10-15 min. Stop solution (1M H2SO4 50 μl) was added into each well 
after the incubation. The absorbance was then read using a microtitre plate reader (Bio-Tek 
Synergy 2, Winooski, U.S) at the recommended wavelength by the manufacturer which 
was 450nm within 20 min of adding the Stop Solution. The mean absorbance was 
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determined from the optical density by calculating the average of the duplicates for each 
sample. Figure 3.5 shows the flow of the experiment for DHT concentration assessment. 
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Figure 3.5 Schematic presentation of the steps in analysis of DHT concentration. 
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A standard curve (Figure 3.6) was constructed using the value of the mean absorbance of 
each of the standard (provided in the kit) against standard concentration. A new standard 
curve was constructed for each kit.  
 
 
Figure 3.6 An example of a standard curve constructed with a 5alpha Dihydrotestosterone 
ELISA kit for the calculation of DHT concentration. 
 
DHT concentration was determined for each control and experimental (cancer) sample 
using the standard curve. Regression modelling was used to derive the formula for 
calculation as described by the manufacturer. The calibration curve produced a good fit for 
the observed sample data with a R2=0.938. This was simplified using the formula derived 
statistically as below: 
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DHT concentration = Anti-log of [3.462- (1.638 X Mean Optical Density)] 
This formula was used for all the samples for DHT concentration and tabulated for 
statistical analysis later. The unit of the calculated DHT concentration is then converted to 
ng/ml for standardisation purpose by dividing with 1000. 
The DHT/T was then calculated by dividing the obtained concentration for the 
corresponding patient. 
 
3.2.3 Analysis of serum Insulin-like Growth Factor-I (IGF-I) 
IGF-I concentration was measured using the Quantikine® ELISA Human IGF-I 
Immunoassay (R&D System Europe Ltd. Abingdon, UK).   
I. Samples and Reagents Pre-treatment 
The samples were pre-treated with the pre-treatment reagent A (acidic dissociation 
solution) and B (buffered protein with blue dye and preservative) from the kit to release the 
IGF-I from the binding proteins. 20µl of serum sample was added to 380 µl of the pre-
treatment A in a polypropylene tube, mixed by vortex and incubated for 10 min at room 
temperature. 50 µl of the mixture was pipetted into 200 µl of the pre-treatment reagent B, 
mixed and analysed immediately. The substrate solution was prepared by mixing colour 
reagents A and B in equal volumes within 15 min of use. The substrate solution was kept 
protected from light. The standard IGF-I (lyophilised) solution was reconstituted with 1.0 
ml distilled water to produce a stock solution of 60 ng/ml IGF-I. The standard solution was 
allowed to sit for 15 min before use. Calibrator Diluent RD5-22 (360 µl) was pipetted into 
the first tube and 200 µl into subsequent tubes. 40 µl of IGF-I stock solution was added to 
the first Calibrator Diluent tube and after mixing, 200 µl from each tube was transferred to 
the remaining tubes to obtain a serial dilution of the standard (Figure 3.7). 
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Figure 3.7 Serial dilution of the IGF-I standard solution using the Calibrator Diluent RD5-22. 
Adapted with permission from manufacturer insert provided by R&D System Europe 
Ltd. Abingdon, UK.  
 
II. Assay procedure 
Assay diluent RD1-53 (150 µl) was added to each well of microtitre plate coated with 
mouse monoclonal anti-IGF-I antibody. Another 50 µl of the pre-treated standard, serum 
from control and cancer participants were added to each well and covered with an adhesive 
strip provided. This covered unit was then incubated at 2-8oC for 2 h. Thorough washing 
was performed with 400 µl of wash buffer and repeated 4 times. Complete removal of 
liquid ensured by tapping on absorbent paper. 200 µl of cold IGF-I conjugate (polyclonal 
antibody against IGF-I conjugated to Horseradish Peroxidase) was added to each well and 
covered with a new adhesive strip before incubating again at 2-8oC for 1 h. The washing 
was repeated another 4 times as described above before adding 200 µl of Substrate 
Solution to each well. The mixture was incubated at room temperature for 30 min 
 87 
 
protected from light. After this, Stop Solution was added (50 µl per well) and the colour 
change from blue to yellow was noted (Figure 3.8).  
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Figure 3.8 Schematic presentation of steps in the analysis of serum IGF-I concentration. 
 89 
 
Optical density of the samples was determined in duplicates using a microtitre plate reader 
(Bio-Tek Synergy 2, Winooski, U.S) at the wavelength recommended by the manufacture 
within 30 min of adding the Stop Solution. In this case, the recommended reading was 
conducted by subtracting the absorbance at 450nm from that obtained at 570nm. The mean 
absorbance value was calculated for duplicates for each sample. 
A standard curve (Fig. 3.9) was constructed by plotting value of the mean absorbance of 
each of the standard (provided in the kit) against its given concentration. A new standard 
curve was constructed for each kit.  
 
 
Figure 3.9 An example of a standard curve constructed with an IGF-I ELISA kit for the 
calculation of the IGF-I concentration. 
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Corresponding concentration of IGF-I for each sample was determined using the standard 
curve. Regression modelling, as described by the manufacturer, was used to derive the 
formula for calculation. The calibration curve produced a good fit for the observed sample 
data with a R2=0.981. This was simplified using the formula derived statistically as below: 
IGF-I concentration = Anti-log of [0.477 + (log10 Mean Optical Density x 0.746)] 
This formula was used for all the samples for IGF-I concentration and tabulated for 
statistical analysis later. 
 
3.3 Genomic DNA extraction and analysis 
Genomic DNA (gDNA) from Bristol Caucasian group was extracted from blood sample 
stored in EDTA at -80oC.  
gDNA from Malaysian samples was extracted at University of Malaya, Kuala Lumpur and 
transferred to the University of the West of England. The gDNA extraction protocol is 
described in Section 3.3.1 and it was standardised between the 2 collaborating teams to 
ensure uniformity.  
Figure 3.10 represents a flow-chart of experiments involving the whole blood analysis for 
genetic polymorphism.  
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Figure 3.10 Schematic presentation of the work-flow in the analysis of genetic polymorphism 
in the Bristol Caucasians and Malaysian Chinese groups. 
 92 
 
3.3.1 Genomic DNA (gDNA) extraction.  
The QI Amp Blood mini kit (Qiagen Ltd, Crawley, UK) was used for extraction of gDNA 
from human whole blood. The DNA extraction in the Malaysian samples were performed 
using the same kit and protocol by trained technical staff at University of Malaya, Kuala 
Lumpur, under direct my direct supervision. 
The blood samples were defrosted on ice. 20μl of Qiagen Protease (or proteinase K) was 
pipetted into 1.5ml Eppendorf tubes. A volume of 200μl of the whole blood sample and the 
same volume of the buffer AL (which causes cell lysis to expose DNA) was added into the 
same tube, and mixed by pulse-vortexing for 15 sec.  The mixture was then incubated in a 
water bath at 56°C for 10 min. The tubes were briefly centrifuged and 200μl of ethanol 
(96–100%) was added to the samples followed by pulse-vortexing for 15 sec and another 
brief centrifugation to remove the drops from the mixture from inside the rim. This mixture 
was then placed carefully in a QIAamp Mini spin column (in a 2 ml collection tube) and 
centrifuged at 6000 x g for 1 min. The QIAamp Mini spin column was placed in a clean 2 
ml collection tube and the filtrate was discarded. The QIAamp Mini spin column was 
opened and centrifuged twice, once with 500μl Buffer AW1 (prepared by adding 96-100% 
ethanol to the concentrate containing Guanidium chloride- denatures the protein and flows 
through the column) at 6000 x g for 1 min and the second time with 500μl Buffer AW2 
(contains mainly ethanol to remove salts from the column) at full speed (20,000 x g) for 3 
min. The filtrate was discarded. The QIAamp Mini spin column was then placed in a new 2 
ml collection tube and centrifuged at full speed to eliminate the chance of possible buffer 
AW2 contamination. After discarding the filtrate, the QIAamp Mini spin column was 
placed in a clean 1.5 ml Eppendorf tube. Buffer AE (contains Tris-Cl and EDTA- elutes 
the DNA from the membrane and enables long-term storage) was added (75μl) and 
 93 
 
incubated at room temperature for 5 min before centrifuging at 6000 x g for 1 min. 
Resulting gDNA was stored at –20°C for later use. 
This gDNA extraction method was optimised and tested on blood samples from volunteers. 
Quantity and quality of the gDNA isolated from blood of volunteers was checked as 
described in Section 3.3.2 and was demonstrated to be appropriate for the purpose of this 
study.  
 
3.3.2 Genomic DNA Quantification 
Quality and quantity of extracted gDNA was assessed using the NanoDrop 1000 (Thermo 
Scientific, Basingstoke, UK). The gDNA concentration was expressed as ng/μl and the 
absorbance ratio at 260/280 (indicates the amount of protein contamination) was measured 
to evaluate quality of gDNA. The optimal 260/280 ratio of 1.8 or higher is generally 
accepted as an indicator of minimal protein contamination of the gDNA samples. Isolated 
gDNA was stored at –20°C until used for PCR amplification. 
 
3.3.3 Primer Design for genetic polymorphism and tandem repeat analysis 
PCR primers were designed for amplification of the regions of interest in CYP17, SRD5A2 
and the AR genes. The human sequence for each gene of interest derived from the National 
Centre for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/):  
 CYP17: ref|NG_007955.1| Homo sapiens cytochrome P450, family 17, subfamily 
A, polypeptide 1. 
 SRD5A2: ref|NG_008365.1| Homo sapiens steroid-5-alpha-reductase, alpha 
polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2). 
 AR: ref|NG_009014.2| Homo sapiens androgen receptor. 
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The areas of interest in CYP17, SRD5A2 and the AR genes were identified based on the 
data of literature review. The areas selected contained polymorphisms which are likely to 
have an impact on PC development.  
 CYP17: position -34T→C (SNP reference rs743572) (Carey et al, 1994).  
 T to C polymorphism at the 34th base preceding the translation initiation 
point.  
 SRD5A2: A49T and V89L variants (SNP rs523349 and rs9282858) (Makridakis et 
al, 2000). 
 Amino acid Ala to Thr change at codon 49 in Exon 1 due to polymorphism 
at position 140G→A. 
 Amino acid Valine to Leucine change at codon 89 in Exon 1 due to 
polymorphism at position 261C→G. 
 AR: Number of polymorphic CAG repeat in Exon 1 (Ekman et al, 1999). 
The forward and reverse primers were designed to include 400-600 base pairs of the 
specific regions of the genes where polymorphisms of interests were reported. Primer 
designing was done based on the available software Primer 3 
(http://frodo.wi.mit.edu/primer3/) and was checked using the Primer-BLAST to ensure the 
specificity of the amplified region. The primers and their characteristics are as shown in 
Table 3.2. The positions of the primers in DNA sequence are demonstrated in Figure 3.11-
3.13.  
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Table 3.2 Forward and reverse primers with their characteristics. 
Gene Type of 
Primer 
Primer (no. of bp) (5’ to 3’) Annealing Temp. (oC) GC content (%) 
CYP17 
(NG_007955.1) 
Forward GAGCCCAGATACCATTCGCA  (20) 59.4 55.0 
Reverse GCCCCATCTATTCGGTTCGT  (20) 59.4 55.0 
SRD5A2 
(NG_008365.1) 
Forward GCGCTCCATAAAGGGGTTGC  (20) 61.4 60.0 
Reverse GGACGCTAGAGAGTTGACAAGCG (23) 64.2 56.5 
AR 
(NG_009014.2) 
Forward TCCCGCAAGTTTCCTTCTCT (20) 57.3 50.0 
Reverse CCCACTTTCCCCGGCTTAA (19) 58.8 57.9 
 
bp- base pairs, Temp.-Temperature, NG- accession number. 
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Figure 3.11 CYP17 gene primers on gDNA sequence (ref NG_007955.1) for SNP rs743572 
(SNP -34T>C).  
Product size: 535bp. Numbering on the left indicates the reference point from origin of 
sequence of gDNA used for primer design. 
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Figure 3.12 SRD5A2 gene primers on gDNA sequence (ref NG_008365.1) for SNP rs523349 
(261C→G) and rs9282858 (140G→A).  
Product size: 550bp. Numbering on the left indicates the reference point from origin of 
sequence of gDNA used for primer design. 
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Figure 3.13 AR gene primers on gDNA sequence (ref NG_009014.2) for CAG repeats at Exon 
1.  
Product size: 671bp. Numbering on the left indicates the reference point from origin of 
sequence of gDNA used for primer design. 
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3.3.4 Polymerase chain reaction (PCR) 
PCR reactions were performed for all the 200 gDNA samples from the Caucasian and 
Malaysian cancer and control groups. The reactions were conducted for identification of 
SNPs of interests in the CYP17, SRD5A2 and AR genes.  
PCR reactions were performed using a GeneAmp High Fidelity PCR System (Applied 
Biosystems, Cheshire, UK). PCR primers were first diluted with molecular grade water in 
the volume recommended by the manufacturer to obtain a concentration of 100pmol/μl. 
This was further diluted to 1:10 and stored at -20°C before use. A dNTP mix containing 
dATP, dCTP, dGTP and dTTP each at a final concentration of 10mM was purchased from 
Fermentas (Sankt Leon-Rot, Germany). This was also diluted 1:10 with molecular grade 
water and stored at -20°C. On the day of experiment, diluted primers, diluted dNTPs, and 
10 x PCR buffer with MgCl2 (provided in the kit) as well as gDNA (produced in section 
3.3.1) were defrosted on ice. At all times, the batch of gDNA to be amplified, always 
consisted of equal number of samples across all the studied groups. For each PCR, 100ng 
of gDNA and was mixed with molecular grade water to make up a volume of 15μl in a 0.5 
ml PCR tube. A Master mix was made by combining 2μl each of the forward and reverse 
primer, 10μl dNTPs per sample, 5μl 10 x PCR buffer with MgCl2 and 0.5 μl High Fidelity 
Enzyme mix (from kit, taken straight from -20°C freezer to minimise enzyme degradation) 
per sample in a 0.5ml Eppendorf tube. A volume of 35μl was pipetted out from the Master 
mix and added to the above 0.5 ml PCR tube and pipette-mixed. The PCR tubes containing 
50μl of PCR mix each were then placed in an MJ Research PTC-200 thermo cycler (Bio-
Rad, Hertfordshire, UK) and the program was run as follows: 
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 Initialisation: 94°C for 3 minutes. 
 Denaturation: 94°C for 30 seconds. 
 Annealing: 59°C for 30 seconds.    Repeated for 35 cycles. 
 Extension: 72°C for 1 minute. 
 Finalisation: 72°C for 7 minutes. 
 Hold: 4°C until removed from machine. 
PCR experiments for CYP17 gene were conducted with the annealing temperature of 
59°C. Annealing temperature of 62°C and 58°C was used for SRD5A2 and AR gene 
respectively. The annealing temperature for each pair of primers was identified after a 
series of pilot experiments which tested a range of temperature recommended by the 
primer designing software.  
 
3.3.5 Agarose Gel Electrophoresis 
An agarose gel was prepared by dissolving 1.0g of powdered agarose in 100ml of Tris-
acetate-EDTA (TAE) buffer by heating in a microwave. The molten agarose was left to 
cool for 5 min before adding 1μl of ethidium bromide from the stock solution 10 mg/ml 
and gently mixed. The agarose was poured into a gel mould, a comb was placed and the 
gel was left to set at room temperature for 30-40 min. Once the gel has set, 3μl of loading 
dye (Bioline, London, UK) was added to 10μl of the PCR products from the Section 3.3.4. 
The mixture was loaded on the gel. 10μl HyperLadder I (Bioline, London, UK) was loaded 
into a spare well. The gel was run for 40 min at 100 V with TAE buffer. The gel was then 
placed on a UV Transilluminator and strong 500 bp bands were identified (Figs 3.14 to 
3.16). The size of the bands was an expected size of PCR products which confirmed that 
the PCR reaction was successful.  
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Figure 3.14 UV transilluminator image showing successful PCR amplification for CYP17 
gene.  
Blue arrow indicates the size of the DNA markers and the brown arrow indicates PCR 
amplification product of about 500bp size. 
 
 
 
               
Figure 3.15 UV transilluminator image showing successful PCR amplification for SRD5A2 
gene.  
Blue arrow indicates the size of the DNA markers and the brown arrow indicates PCR 
amplification product of about 500bp size. 
Lane 1: DNA marker 
~500 bp 
600 bp 
400 bp 
600 bp 
400 bp 
~500 bp 
Lane 1: DNA marker Lane 2-9: PCR product for CYP17 gene 
Lane 2-5: PCR product for SRD5A2 gene 
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Figure 3.16 UV transilluminator image showing successful PCR amplification for AR gene. 
 Blue arrow indicates the size of the DNA marker and the horizontal yellow arrow 
indicates PCR amplification product of about 500bp size for AR gene. 
 
 
3.3.6 Polymerase chain reaction product purification 
PCR product obtained in the Section 3.3.4 was purified before sending for sequencing to 
Eurofins MWG Operon (Ebersberg, Germany). The purification process was done using 
the Wizard® SV Gel and PCR Clean-up kit (Promega, Southampton, UK). 
Equal volume of Membrane Binding Solution (MBS) (provided in the kit) was added to the 
PCR amplification product (38μl). The DNA binding process was undertaken by 
transferring the PCR preparation above into an SV minicolumn in a collection tube. This 
mixture was incubated at room temperature for 1 min, centrifuged at 16,000 x g for 1 min. 
The flow-through was discarded. The membrane was washed twice with 700µl and 500µl 
Lane 2-9: PCR product for AR gene Lane 1: DNA marker 
~500bp 600 bp 
400 bp 
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of Membrane Wash Solution (MWS) (ethanol added) and follow-on centrifugation at 
16,000 x g for 1 and 5 min respectively. The collection tube was then emptied and the 
assembly re-centrifuged at full speed for 1 min with the microcentrifuge lid open (or off) to 
allow evaporation of any residual ethanol. The minicolumn was transferred to a new 1.5ml 
Eppendorf tube. 50µl of Nuclease-Free water was added to the minicolumn and incubated 
at room temperature for 1 min before centrifuging at 16,000 x g for 1 min. The minicolumn 
was then discarded and the purified gDNA obtained was stored at -20⁰C. 
 
3.3.7 DNA sequencing and analysis 
The purified PCR products were sent for sequencing to Eurofins MWG Operon 
(Ebersberg, Germany) using the on-line Value Read Tube service. Purified PCR products 
were split into two tubes so as to perform a forward and reverse read for each sample using 
the same forward and reverse primers in the PCR reactions for each gene in this study. 
Sequencing results were downloaded from the Eurofins MWG Operon website and 
analysed using licensed Geneious Pro 5.6.4 software for Microsoft Windows 7 (Fig. 3.16). 
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Figure 3.17 Example of DNA sequence presenting the region of CYP17 gene. 
Sequence data is colour-coded from green to black indicating quality of data from 
excellent to poor. Only segment in continuous green segment used for alignment.  
 
The downloaded sequence for each sample was aligned with the NCBI database sequences 
in the region of the studied SNPs and any polymorphism identified were noted (Fig. 3.17). 
 
 
Figure 3.18 An example of alignment of CYP17 experimental sequence with database 
sequence.  
Alignment shows polymorphism from nucleotide T (red arrow) to nucleotide C (black 
arrow).  
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3.4 Statistical method 
The sample size was determined using power calculations and to ensure feasibility and 
practicality, this research consisted of 100 samples from Malaysian Chinese (N = 50 
Prostate Cancer, N = 50 Benign Prostate Hyperplasia) and 100 samples from Bristol 
Caucasian (N = 50 Prostate Cancer, N = 50 Benign Prostate Hyperplasia). The primary 
outcome measures were androgen concentration (testosterone, dihydrotestosterone) which 
are inherently continuous measures. For the proposed sample sizes the appropriate primary 
omnibus analysis had in excess of 95% power for detecting medium sized effects between 
the prostate cancer group and the benign prostate hyperplasia group. The detection of 
hormonal effects between those with and without prostate cancer within each ethnic group 
was of concern. For these a priori reasoned contrasts, the study retained in excess of 85% 
power to detect a medium sized effect (Cohen’s d = 0.5) for an analysis using the 
independent samples t-test.  
Quantitative data analysis was undertaken using standard recognised statistical techniques. 
The wider proposed study took the form of a 2 by 2 fully between-subjects factorial 
balanced design with N = 50 replicates (N = 200 in total) with multiple non-commensurate 
dependent variables. The design had Disease Status (Prostate Cancer, Benign Prostate 
Hyperplasia) as a two level independent factor and ethnicity as a second two level 
independent factor (UK Caucasian, Malaysian Chinese). The dependent variables were 
androgen concentration (testosterone, dihydrotestosterone) and IGF-I concentration and 
polymorphisms in the CYP17, SRD5A2 and AR genes. 
For each hormone, the primary omnibus analysis was an analysis of variance for a 2 by 2 
fully between subjects design. The main effect of Disease Status on androgen 
concentration was of primary concern. Such an analysis made reference to the F-
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distribution on 1 and 196 degrees of freedom and had in excess of 95% power for detecting 
medium sized effects across Ethnic groups. However, the detection of hormonal effects 
between those with and without prostate cancer within each ethnic group was of concern 
and the study needed to be powered for this subgroup analysis. For the subgroup analysis, 
the independent samples t-test was used (N = 50 per group, degrees of freedom = 98). 
Elevated mean hormone concentrations were anticipated in the prostate cancer groups and 
assuming a medium effect size (Cohen’s d = 0.5) the study retained a power in excess of 
85%.  
The efficacy of the hormone data in developing a predictive or diagnostic tool for prostate 
cancer was evaluated using a ROC analysis, and confidence intervals for sensitivity and 
specificity for the optimal use of hormone concentration was derived. 
The presence and absence in the CYP17 and SRD5A2 genes was cross-tabulated against 
disease status and association assessed using the chi-square test of association. The 
significance of the number of CAG repeats was analysed as done in the hormonal analysis 
using the analysis of variance for the 2 X 2 design. The strength of association was 
determined using the odds ratio. Good markers for the disease were sought. The odds ratio 
for good markers was expected to have a value in excess of 1 (i.e. the presence or absence 
of a marker doubles the likelihood of correct disease classification). On this expectation a 
sample of N = 200 (N = 100 for prostate cancer, N = 100 for benign prostate hyperplasia) 
should provide approximately 80% power or greater over a wide range of proportions. All 
statistical analysis was performed using IBM SPSS Statistics package version 20.0. 
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4 Results 
This chapter consists of three sub-chapters which describe results of the following sets of 
experiments:   
i. The participants’ demography: This sub-chapter summarises information about the 
participants’ ethnic group, age and other aspects relevant to this study.   
ii. Evaluation of hormones concentration: This section reports results of analysis of 
the circulating testosterone, DHT and IGF-I in the participants of different ethnic 
groups and with or without prostate cancer. 
iii. Investigation of genetic polymorphisms: This part of results (a) reports ethnic-
groups specific DNA polymorphisms in CYP17, SRD5A2 and AR genes in relation 
to their role in androgen metabolism and (b) investigates whether the 
polymorphisms are related to the incidence of prostate cancer.  
iv. Correlation study: This sub-chapter presents analysis of relationship between 
circulating concentration of testosterone, DHT and IGF-I hormones and DNA 
polymorphisms in the genes encoding for these hormones in control and prostate 
cancer patients.  
 
4.1  Participants demography 
This study recruited a total of 200 participants from the Bristol Caucasian group from 
Southmead Hospital, Bristol, UK and the Malaysian Chinese (MC) participants from the 
Urology and community clinics in UMMC, KL.  
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Table 4.1 shows demographic distribution of the participants. The MC participants (N = 
100) had a mean age higher than the Caucasians (N = 100) by 1.9 years across control and 
cancer groups.  The cancer patients (combined MC and Caucasian ethnic groups, N = 100) 
were also found to have a significantly higher mean age when compared to the combined 
control group (N = 100) by 5.1 years (by about 7%) (P < 0.05). The participants were 
divided into 4 sub-groups: MC cancer, MC control, Caucasian cancer and Caucasian 
control. Each of the sub-groups comprised of 50 participants. It was found that the MC 
cancer participants were older with a mean age of 71.5 years when compared with the 
Caucasian cancer group by 5.5 years (by about 8%) respectively. This difference was 
statistically significant (P < 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 109 
 
Table 4.1 Demographic data of Caucasian and Malaysian Chinese participants. 
Parameters Age PSA Gleason Score 
Mean SD Mean SD Mean SD 
Caucasian Control 64.5 10.35 2.16 0.98 N/A 
Cancer 66 7.39 27.47 65.84 6.84 0.766 
Malaysian 
Chinese 
Control 62.8 8.86 1.71 1.03 N/A 
Cancer 71.5* 8.05 201.42 623.32 7.40 1.278 
Caucasian 
+ MC 
Control 63.7 9.62 N/A N/A N/A 
Cancer 68.8* 8.18 N/A N/A N/A 
SD- Standard Deviation, PSA- Prostate Specific Antigen, N/A-not applicable.                 
* Significant at P < 0.05. 
 
Figure 4.1 shows the age of individual participants in Caucasian control (A) and Caucasian 
cancer (B) sub-groups. The age of participants in both groups varied from 41 to 85 years.  
The mean age of the Caucasian control and cancer patients were 64.5 and 66.0 years 
respectively. 
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Figure 4.1  Age of individual participants in Caucasian control (A) and Caucasian cancer (B) 
group. 
Each bar represents and individual participant. The solid line on the bar shows the 
average age for a given group ± standard deviation.  
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Figure 4.2 shows the age of individual participants in the MC control (C) and MC cancer 
(D) sub-groups. The age of participants in both groups ranged from 45 to 88 years. The 
mean age of the MC control and cancer patients were 62.8 and 71.5 years respectively. 
Table 4.1 also includes data on PSA level and Gleason score. PSA is currently the most 
commonly used test to screen a patient for PC or to identify high risk of PC patients and 
together with Gleason score can be used to make treatment decisions (Brawley et al, 2009).  
MC cancer patients had a mean PSA significantly higher (by 9.5 times) when compared to 
Caucasian cancer group. This might be related to the fact that patients in Malaysia usually 
visit doctors when the symptoms or disease are in more advanced state. In contrast to the 
cancer group, PSA values did not differ significantly between MC and Caucasian control 
groups, where the mean PSA values were 2.16 and 1.71 respectively. This was expected as 
the control group participant recruitment was performed with a predefined PSA level (< 
4.0 ng/ml) as one of the recruitment criteria. It was noted in this study, that the mean 
Gleason score for all cancer patients in MC and Caucasian groups were almost the same 
(Table 4.1). The Gleason score for the control groups were not available as these 
participants were not subjected for a biopsy of the prostate. 
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Figure 4.2 Age of individual participants in Malaysian Chinese control (C) and Malaysian 
Chinese cancer (D) group. 
Each bar represents and individual participant. The solid line on the bar shows the 
average age for a given group ± standard deviation.  
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4.2 Evaluation of the concentration of androgens in Caucasian and 
Malaysian Chinese groups 
This section presents results of experiments on evaluation of concentration of male sex 
hormones testosterone, DHT and the growth hormone IGF-I in the circulation system using 
serum separated from the whole blood of the control and experimental groups. The 
measurements were conducted using commercially available ELISA kits (see Material and 
Methods for details). 
 
4.2.1 Analysis of serum testosterone concentration 
Testosterone is the male sex hormone, also known as androgen, which is produced in the 
testis and adrenal glands in human. Testosterone is the most important circulating male sex 
hormone and plays critical role in the development of prostate and has been suggested to 
be involved in the development of PC (So et al, 2003).   
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Table 4.2 Circulating testosterone concentration (ng/ml) in different ethnic groups, control 
and cancer patients and   interaction between these parameters. 
 Group N Mean SD P value** 
Ethnicity Caucasian 100 3.73 1.45 0.810 
MC 100 3.67 2.38 
Diagnosis Control 100 4.34 1.67 < 0.001* 
Cancer 100 3.07 2.05 
Interaction Ethnicity vs. 
Cancer 
&Control 
200 3.70 1.97 0.008* 
N-number of samples, SD- standard deviation, MC-Malaysian Chinese.* Significant at 
P-value < 0.05. ** ANOVA Test 
 
This study showed that the mean testosterone concentration of the Caucasians was slightly 
higher (by 1.6%) than that in MC men (Table 4.2). This difference was, however not 
significant (P = 0.810). The comparison of mean testosterone concentration between the 
control and the cancer groups, which contained combined data from both ethnic groups, 
showed that the control group had a statistically significant higher mean testosterone value 
(by 34.3%  P < 0.001). There was also a significant effect in the interaction between the 
combined ethnic groups and the diagnosis (cancer and control taken as one data set) on the 
concentration of circulating testosterone (P = 0.008) (Table 4.2).  
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Figure 4.3 Mean testosterone concentration for control and cancer patients in Caucasian and 
MC ethnic groups. 
 
The data are presented as Mean +/- SEM. Each study group consisted of 50 participants. 
 
To gain further insight into ethnic-group specific relationship between cancer and 
circulating testosterone, serum testosterone concentrations were compared between cancer 
and control patients within Caucasian and MC ethnic groups.  Figure 4.3 demonstrates that 
the difference in the mean values for testosterone between control and cancer groups 
within MC population was bigger than the difference in the mean values between control 
and cancer groups within the Caucasian population (P < 0.001 and P = 0.125 respectively). 
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It is known that the concentration of male sex hormones declines with age (Gray et al, 
1991). Taking into consideration that there was a significant difference in the age of the 
participants between ethnic groups investigated, with the MC cancer group having 
significantly higher mean age when compared to Caucasians, it was necessary to conduct 
statistical analysis of testosterone concentration taking into account the age factor. This 
was achieved by using analysis of covariance (ANCOVA). Table 4.3 demonstrates that age 
itself has significant effect on testosterone concentration when the data for both ethnic 
groups were pooled together (P = 0.016). However, when effect of age was analysed in 
relation to ethnicity, the testosterone concentration did not depend on ethnicity (Table 4.3). 
There was a highly significant difference in the mean values (P < 0.001) between the 
control and the cancer groups when adjusted for age between the two ethnic groups in this 
study. There was significant interaction between the ethnicity and diagnosis, even after 
taking the age factor into consideration (P = 0.033) (Table 4.3). 
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Table 4.3 Analysis of covariance for mean testosterone concentration with age. 
 Parameter 
 
Mean square F P value 
Age 
 
19.47 5.86 0.016* 
Ethnicity 
 
0.002 0.001 0.980 
Disease (Control x 
PC) 
 
54.0 16.25 <0.001* 
Ethnicity x Disease 
 
15.32 4.61 0.033* 
*Significant when P < 0.05 (ANCOVA). PC- Prostate cancer 
F- Indicates the ratio of the variance due to the effect of the parameters to the variance 
in the error. The ratio is significant when they are high and less significant when close 
to zero. Age- mean age of all the participants in the study according to their disease 
status and ethnicity. Ethnicity- Caucasian and Malaysian Chinese. Disease- indicates 
either control or PC group, Ethnicity x Disease- interaction between ethnicity and 
disease status.  
 
The study has also demonstrated that Caucasian cancer patients had a significantly higher 
mean testosterone concentration than MC cancer patients (P = 0.041). The mean 
testosterone concentrations were, however, significantly higher in the MC control group 
when compared to MC cancer (P < 0.001). There were no significant difference between 
the Caucasian control and cancer groups and MC control vs. Caucasian control groups 
(Table 4.4).   
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Table 4.4 Comparison of serum testosterone concentration in control and cancer patients of 
Caucasian and Malaysian Chinese ethnic groups. 
Dataset 1 Dataset 2 MD(1-2) SE 
P value 
LSD 
Caucasian 
cancer 
MC cancer 0.759 0.369 0.041* 
MC cancer MC control -1.962 0.369 <0.001* 
Caucasian 
control 
Caucasian 
cancer 
0.569 0.369 0.125 
MC control Caucasian 
control 
0.633 0.369 0.088 
MD- mean difference, SE- standard error, LSD-least significant difference, MC-
Malaysian Chinese. * Significant when P < 0.05 using post-hoc analysis. Caucasian 
cancer (n=50), MC cancer (n=50), Caucasian control (n=50), MC control (n=50) 
 
To summarise, the presented results demonstrate that the cancer patients have a lower 
testosterone concentration compared to the control patients overall. There was no 
difference in the testosterone concentrations between the ethnic groups when control and 
cancer data were pooled together. Age factor did not have significant impact on the 
testosterone concentration. However, there was a significant interaction between age, 
ethnicity and diagnosis. MC cancer patients had lower testosterone concentration than the 
Caucasian cancer group. 
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4.2.2 Analysis of serum dihydrotestosterone concentration 
Dihydrotestosterone (DHT), also known as 5ɑ-dihydrotestosterone is derived from 
testosterone in the prostate. It is 10-times more potent in its effect on the prostatic growth 
compared to testosterone (Deslypere et al, 1992).  
Table 4.5 demonstrates that the Caucasian men had a significantly higher mean serum 
DHT concentration compared to the MC men (by 15.4%) when the cancer and control 
groups were analysed as one dataset (P = 0.027). It was also found that there was a 
significant difference in the mean DHT concentration between the control cancer groups 
when ethnicity was analysed as one dataset (P = 0.005). The control group had the mean 
DHT concentration of 18.8% higher than the cancer group. Despite the significant effects 
of ethnicity and diagnosis on DHT concentration when analysed as individual dataset, this 
significance was lost when the analysis was performed to assess the interaction between 
the ethnicity (Caucasian or MC) and the disease (control or cancer) (P = 0.118) .   
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Table 4.5 Circulating DHT concentration (ng/ml) in different ethnic groups, control and 
cancer patients and interaction between these parameters. 
 Group N Mean SD P value** 
Ethnicity Caucasian 100 0.63 0.26 0.027* 
MC 100 0.54 0.29 
Diagnosis Control 100 0.64 0.25 0.005* 
Cancer 100 0.53 0.29 
Interaction Ethnicity vs. 
Cancer 
&Control 
200 0.59 0.28 0.118 
N-number of samples, SD- standard deviation, MC-Malaysian Chinese, DHT-
dihydrotestosterone. * Significant at P-value < 0.05. ** ANOVA Test 
 
The comparison of mean values of circulating DHT concentration between the 4 
participating groups (MC control, MC cancer, Caucasian control and Caucasian cancer) 
showed that the difference in DHT concentration between the control and cancer group is 
bigger within MC than the Caucasian group (Figure 4.4).  
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Figure 4.4 Mean DHT concentration for control and cancer groups in Caucasian and MC 
ethnic groups. 
DHT- Dihydrotestosterone. The data are presented as Mean +/- SEM. Each study group 
consisted of 50 participants. 
 
Similarly to the study on testosterone, an effect of age on DHT concentration was analysed 
(Gray et al, 1991). When age was taken into account, it cancelled the differences in DHT 
concentration between the Caucasian and MC ethnic groups (P = 0.064) and between 
control and cancer groups (combining Caucasian and MC participants) (P = 0.079).There 
was no significant (P = 0.420) interaction between the ethnicity, diagnosis (cancer or 
control) and DHT concentration when the age factor was taken into account (Table 4.6).   
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Table 4.6 Analysis of covariance for mean DHT concentration with age. 
 Parameter Mean square F P value 
Age 0.990 14.46 <0.001* 
Ethnicity 0.238 3.47 0.064 
Disease (Control x 
PC) 
0.213 3.11 0.079 
Ethnicity x Disease 0.045 0.652 0.420 
*Significant when P < 0.05 (ANCOVA), PC- Prostate cancer 
F- Indicates the ratio of the variance due to the effect of the parameters to the variance 
in the error. The ratio is significant when they are high and less significant when close 
to zero. Age- mean age of all the participants in the study according to their disease 
status and ethnicity. Ethnicity- Caucasian and Malaysian Chinese. Disease- indicates 
control or PC group, Ethnicity x Disease- interaction between ethnicity and disease 
status.  
 
To summarise, result presented in this sub-chapter showed that there was a significant 
difference in the concentration of DHT between the MC and the Caucasian groups (when 
control and cancer were analysed as one dataset) as well as difference between the control 
and the cancer groups (when Caucasians and MC were analysed as one dataset). However, 
when age of the participants was taken into account, no statistical significance in DHT 
concentration was observed. Therefore, in contrast to study on testosterone concentration 
(section 4.2.1), where age of participants did not affect the results, in the study on DHT, 
the participants age was an important confounding factor, which, when included, had 
strong impact on the findings.  
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4.2.3 Analysis of dihydrotestosterone to testosterone ratio 
Testosterone and DHT (which is produced from testosterone) are two male sex hormones 
which play critical role in the development of prostate gland (Deslypere et al, 1992).  It is 
important not only to know the concentration of both hormones but also DHT/Testosterone 
(DHT/T) ratio which gives information about the fraction of DHT produced from the 
testosterone in the circulation.  
Table 4.7 shows that there was a significant (P = 0.001) ethnic group effect on the mean 
value of the DHT/T with the MC group showing a higher ratio than the Caucasian group. It 
was also established that the cancer group had a significantly higher DHT/T (P < 0.001) 
than the control group (when ethnicity was analysed as one data pool). The interaction 
between the ethnicity and the diagnosis was also significant (P < 0.001) (Table 4.7). 
Table 4.7 Comparison of mean DHT/T in different ethnic groups, control and cancer patients 
and interaction between these parameters. 
 Group N Mean SD P-value** 
Ethnicity Caucasian 100 0.18 0.07 0.001* 
MC 100 0.38 0.64 
Diagnosis Control 100 0.16 0.07 <0.001* 
Cancer 100 0.40 0.63 
Interaction Ethnicity vs. 
Cancer 
&Control 
200 0.28 0.46 <0.001* 
N-number of samples, SD- standard deviation, MC-Malaysian Chinese. * Significant at 
P-value < 0.05. ** ANOVA Test 
This study demonstrated that the difference in DHT/T between MC cancer and MC control 
groups were bigger (by 122%) when compared to the difference between the Caucasian 
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cancer and Caucasian control groups (Figure 4.5). In fact, there was no significant 
difference in DHT/T ratio between the Caucasian cancer and control group (P = 0.914). 
 
 
Figure 4.5 Mean DHT/T ratio for control and cancer patients in Caucasians and Malaysian 
Chinese ethnic groups. 
DHT/T- Dihydrotestosterone toTestosterone ratio. The data are presented as Mean +/- 
SEM. Each study group consisted of 50 participants. 
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diagnosis was still highly significant (P < 0.001). These results suggest that DHT/T might 
be potentially used as a predictor of prostate cancer in different ethnic groups.  
Table 4.8 Analysis of covariance for mean DHT/T ratio with age. 
 
 Parameter Mean square F P value  
Age 0.197 1.09 0.297 
Ethnicity 1.921 10.68 0.001* 
Disease (Control x 
PC) 
2.291 12.73 <0.001* 
Ethnicity x Disease 2.30 12.77 <0.001* 
*Significant when P < 0.05 (ANCOVA). PC- Prostate cancer 
F- Indicates the ratio of the variance due to the effect of the parameters to the variance 
in the error. The ratio is significant when they are high and less significant when close 
to zero. Age- mean age of all the participants in the study according to their disease 
status and ethnicity. Ethnicity- Caucasian and Malaysian Chinese. Disease- indicates 
control or PC group, Ethnicity x Disease- interaction between ethnicity and disease 
status.  
 
 
Analysis of effect of ethnicity on DHT/T demonstrated that MC cancer patients had a 
significantly (P < 0.001) higher DHT/T ratio than the Caucasian cancer patients. There was 
no significant difference in DHT/T between Caucasian control and MC control groups (P = 
0.742) (Table 4.9). 
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Table 4.9 Comparison of DHT/T ratio in control and cancer patients of Caucasian and 
Malaysian Chinese ethnic groups  
Dataset 1 Dataset 2 MD(1-2) SE 
P value 
LSD 
Caucasian 
cancer 
MC cancer -0.436 0.085 <0.001* 
MC cancer MC control 0.474 0.085 <0.001* 
Caucasian 
control 
Caucasian 
cancer 
-0.009 0.085 0.914 
MC control Caucasian 
control 
-0.028 0.085 0.742 
DHT/T- dihydrotestosterone to testosterone ratio, MD- mean difference, SE- standard 
error, LSD-least significant difference, MC-Malaysian Chinese. * Significant when P < 
0.05 using post-hoc analysis. Caucasian cancer (n=50), MC cancer (n=50), Caucasian 
control (n=50), MC control (n=50) 
 
One of the most likely factors which might have influenced the DHT/T ratio could be the 
severity of disease. PC severity is the factor which enables the clinician to predict the 
disease progression, to assist in making decisions regarding treatment options, and predict 
responses of patients to chosen treatment protocols. The commonly used indicators of PC 
severity are the PSA level and the Gleason score which are used in combination (Partin et 
al, 1997). 
As the mean DHT/T values in the MC cancer patients were significantly different from the 
MC control participants, the distribution of these values for each participant in both ethnic 
groups for both, cancer and controls were plotted (Figure 4.6). DHT/T ratio were all 
clumped together in the Caucasian groups for both, cancer and the control groups, and the 
difference in the mean DHT/T was insignificant. The severity of the disease in the 
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Caucasians did not alter the DHT/T as much as the MC cancer group. It was noted that the 
MC cancer group had multiple participants with a DHT/T ratio lying outside of normal 
range of distribution compared to the control group (Figure 4.6).  
This is to ascertain whether there is an element of severity of the disease based on the PSA 
value and Gleason score that may give rise to a significant increase in the mean of DHT/T 
ratio in the MC cancer groups. 
 
 
Figure 4.6 Distribution of DHT/T ratio in Caucasian and Malaysian Chinese cancer and 
control groups. 
DHT/T- Dihydrotestosterone to Testosterone.  
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The individual clinical data of the MC cancer patients (data of 4 individuals were omitted 
due to extremely high PSA of > 900 ng/ml) was reviewed as far as their PSA values 
(Figure 4.7) and Gleason scores (Figure 4.8) were concerned. This was to compare the 
severity of the disease in relation to DHT/T ratio between those having higher and lower 
ratio than the mean DHT/T in MC cancer group.   
 
Figure 4.7 Distribution of DHT/T ratio in relation to PSA in MC cancer patients. 
DHT/T- Dihydrotestosterone/Testosterone, PSA-Prostate Specific Antigen. Individuals 
with DHT/T above the average DHT/T ratio indicated in amber and below the average is 
indicated in blue.  
 
It was not clearly established in this study that the higher DHT/T ratio is due to increased 
disease severity as indicated by high PSA and Gleason score. The trend indicates the 
possible ethnic variability in the distribution of individual DHT/T ratio comparing the 
Caucasians to the MC cancer patients. However, this finding needs to be investigated 
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further with larger cohort due to an almost equal number of patients with the same severity 
of disease having lower than average DHT/T ratio in this study.  
 
 
Figure 4.8 Distribution of DHT/T ratio in relation to Gleason score in MC cancer patients. 
DHT/T- Dihydrotestosterone/Testosterone, PSA-Prostate Specific Antigen. Individuals 
with DHT/T above the average DHT/T ratio indicated in amber and below the average is 
indicated in blue.  
  
 
To conclude, analysis of DHT/T ratio looks promising as a tool for aiding the diagnosis of 
PC. In this study, the MC cancer group had a higher DHT/T ratio than Caucasian cancer 
and MC control groups. However, it is important to highlight that these differences may be 
due to ethnic group differences in severity of the disease. MC cancer patients were in more 
advanced stage of PC (according to PSA and Gleason score data) when compared to 
Caucasian cancer. Therefore, the observed differences in DHT/T between MC and 
Caucasian cancer might not be the “true” ethnic differences. In order to elucidate further 
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the ethnic differences, it is critical to ensure that all the cancer patients recruited are of the 
same stages of PC.  
 
4.2.4 Analysis of serum insulin-like growth factor-I 
The endocrine hormone IGF-I has been suggested to play a key role in the development of 
PC, and raised circulating IGF-I concentration has been demonstrated to be positively 
associated with PC risk (Rowlands et al, 2009). Insulin and IGF-I play an important role in 
cellular proliferation and apoptosis and can be related to the dietary habits of individuals 
(Pollak et al, 2004). 
This study showed that the Caucasian participants had a higher mean IGF-I concentration 
in the circulation compared to the MC participants (by 20%) when cancer and control 
groups were combined. (P = 0.007). This study also demonstrated that the control group 
(MC and Caucasian data combined) had a significantly higher mean IGF-I concentration 
compared to the cancer group (MC and Caucasian data combined) by 17.7%. (P = 0.017). 
There was no significant interaction between IGF-I concentration and ethnicity or 
diagnosis (P = 0.146) (Table 4.10).   
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Table 4.10 Comparison of mean IGF-I (ng/ml) in different ethnic groups, control and cancer 
patients and interaction between these parameters. 
 Group N Mean SD P-value** 
Ethnicity Caucasian 100 93.73 52.02 0.007* 
MC 100 76.68 36.62 
Diagnosis Control 100 92.74 36.97 0.017* 
Cancer 100 77.68 52.09 
Interaction Ethnicity vs. 
Cancer 
&Control 
200 85.21 45.68 0.146 
N-number of samples, SD- standard deviation, MC-Malaysian Chinese, IGF-I- Insulin-
like growth factor-I. * Significant at P-value < 0.05. ** ANOVA Test 
 
Difference in circulating IGF-I concentration between control and cancer groups were 
bigger in the MC group when compared to the Caucasians. Comparison of IGF-I 
concentration between the ethnic groups demonstrated MC cancer patients had lower IGF-I 
when compared to Caucasian cancer by 28%, and the MC control group had lower IGF-I 
when compared to the Caucasian control by 8% (Figure 4.9). 
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Figure 4.9 Mean IGF-I concentration for control and cancer patients in Caucasians and 
Malaysian Chinese ethnic groups. 
IGF-I- Insulin-like growth factor-I. The data are presented as Mean +/- SEM. Each study 
group consisted of 50 participants. 
 
IGF-I concentration is known to decline with age (Yamamoto et al, 1991) and therefore  
effect of age on circulating  IGF-I concentration was analysed. The results showed that age 
was a significant confounding factor in the decline of the IGF-I concentration in the study 
(P < 0.001). A significant ethnic difference in IGF-I (P = 0.018) was still present after 
adjusting the data statistically for age between the Caucasians and the MC patients (data 
for the cancer and control were pooled together). As for the cancer and control groups 
(combining the MC and the Caucasians for both disease state), there were no significant 
differences in circulating IGF-I concentration (P = 0.174). There was no significant (P = 
0.463) interaction between ethnicity (MC and Caucasian) and diagnosis (cancer or control) 
after factoring in the age of participants as far as the circulating IGF-I concentrations are 
concerned (Table 4.11). 
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Table 4.11 Analysis of covariance for mean IGF-I concentration with age. 
 Parameter Mean square F P value 
Age 23972.76 12.94 <0.001* 
Ethnicity 10561.08 5.70 0.018* 
Disease (Control x 
PC) 
3448.27 1.86 0.174 
Ethnicity x Disease 1000.30 0.54 0.463 
*Significant when P < 0.05 (ANCOVA). PC- Prostate cancer 
F- Indicates the ratio of the variance due to the effect of the parameters to the variance 
in the error. The ratio is significant when they are high and less significant when close 
to zero. Age- mean age of all the participants in the study according to their disease 
status and ethnicity. Ethnicity- Caucasian and Malaysian Chinese. Disease- indicates 
control or PC group.  
 
 
Difference in the mean IGF-1 concentration between Caucasians and MC participants and 
cancer and control groups were assessed using the post-hoc analysis. It was found that 
IGF-I concentration was significantly higher (P = 0.003) in the Caucasian cancer when 
compared to MC cancer cases (Table 4.12). The MC control group had a significantly (P = 
0.007) higher mean IGF-I concentration than the MC cancer group.  Differences in IGF-I 
between the Caucasian control and cancer group as well as the MC control group with the 
Caucasian control were found to be not significant (P = 0.506 and 0.374 respectively).  
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Table 4.12 Comparison of IGF-I concentration in control and cancer patients of Caucasian 
and Malaysian Chinese ethnic groups 
Dataset 1 Dataset 2 MD(1-2) SE 
P value 
LSD 
Caucasian 
cancer 
MC cancer 26.21 8.87 0.003* 
MC cancer MC control -24.21 8.87 0.007* 
Caucasian 
control 
Caucasian 
cancer 
5.91 8.87 0.506 
MC control Caucasian 
control 
-7.90 8.87 0.374 
IGF-I- Insulin-like growth factor-I, MD- mean difference, SE- standard error, LSD-least 
significant difference, MC-Malaysian Chinese. * Significant when P-value < 0.05 using 
post-hoc analysis. Caucasian cancer (n=50), MC cancer (n=50), Caucasian control (n=50), 
MC control (n=50) 
 
Taken together, results for IGF-I concentration demonstrate that age had an effect on IGF-I 
in the circulation. Nevertheless, IGF-I concentration still significantly differed between 
ethnic groups and it was significantly higher in Caucasian cancer patients when compared 
to MC cancer.  Furthermore, IGF-I concentration also allowed to differentiate between MC 
control and cancer cases even after adjusting for age. 
 
4.2.5 Relationship between hormone concentration and prostate cancer 
Currently PSA analysis is the most commonly and widely used test for PC screening. 
However, there are a number of issues associated with this test including its low sensitivity 
and specificity (Holmstrom et al, 2009). This is associated with the issue of over-diagnosis 
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of PC and unnecessary biopsy. As a result, there has been increasing interest in new 
biomarkers for PC, which could form the basis for developing a new effective PC 
diagnostic test which could be used either in conjunction with PSA or replace PSA. This 
search for new PC biomarkers has been developing in two directions: identification of 
biomarkers in circulation (i.e. hormones) and identification of genetic polymorphisms. 
Research conducted in this study addressed both aspects.  
In the sections 4.2.1, 4.2.2, 4.2.3 and 4.2.4, the circulating concentration of testosterone, 
DHT DHT/T and IGF-I were investigated in control and cancer patients of the 2 ethnic 
groups, Caucasian and MC. In this chapter, a relationship between the hormonal status and 
disease as well as impact of ethnicity of this relationship was further investigated.  
To ascertain whether detection of these hormones can be used to predict the state of 
disease, a Receiver Operating Characteristic (ROC) curve was plotted for each of the 
hormone individually and also by combining two or more hormone marker to assess the 
Area Under the Curve (AUC) for each parameter. A higher AUC in a ROC curve indicates 
a better predictability of the test to differentiate between cancer and non-cancer. 
Furthermore, sensitivity and specificity of hormonal assay was also determined using 
calculation from the ROC curve so as to analyse the possibility of establishing a specific 
cut-off value for the assay in the different ethnic groups and the disease state. High 
sensitivity and specificity of a test will enable its usage for diagnostic purposes. 
This study was not able to achieve significant results in the AUC, sensitivity and 
specificity for testosterone, DHT and IGF-I as individual tests. However, analysis of IGF-I 
in combination with testosterone and the DHT/T ratio alone has shown high levels of 
sensitivity and specificity in this study which has been described below. 
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The use of a combination of testosterone and IGF-I analysis as a diagnostic marker for PC 
was found to be significantly different for the Caucasian and MC groups, based on the 
results of the ROC curve. The ROC curve for the Caucasian men in this study (Figure 
4.10) showed a significantly (P = 0.009) larger AUC.  
 
 
 
Figure 4.10 Receiver Operating Characteristic (ROC) curve for Caucasian participants using 
a combination of testosterone and IGF-I  
ROC for assessment of diagnostic capability of Prostate cancer. 1-specificity indicates the 
false positive rate which is given in the X-axis and the specificity is calculated by 
subtracting this value form 1. IGF-I- insulin-like growth factor-I. 
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The AUC for the MC men was found to be significantly (P < 0.001) larger than the AUC 
for the Caucasian men when data for both cancer and non-cancer participants were taken 
into consideration (Figure 4.11).  Although both ethnic groups had significant findings but 
the AUC, sensitivity and specificity for the test is much higher in the MC group compared 
to the Caucasians (Table 4.13). 
 
 
Figure 4.11 Receiver Operating Characteristic (ROC) Curve for Malaysian Chinese 
participants using a combination of testosterone and IGF-I. 
ROC for assessment of diagnostic capability of prostate cancer. 1-specificity indicates the 
false positive rate which is given in the x-axis and the specificity is calculated by 
subtracting this value form 1. IGF-I- insulin-like growth factor-I. 
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Calculation of sensitivity and specificity from ROC curve for both, the Caucasians and the 
MC groups showed that combination of testosterone and IGF-I might be an effective 
predictor of PC (when the entire data for cancer and control groups were analysed together 
(Table 4.13). 
 
Table 4.13 Comparison of area under the Receiver Operating Characteristic (ROC) curve for 
Caucasian and Malaysian Chinese groups using testosterone and IGF-I combination.  
Ethnic 
group ǂ  
AUC 
(%) 
SE P 
value 
Asymptomatic        
95% Confidence 
Interval 
Sensitivity 
(%) 
Specificity 
(%) 
Lower 
Bound 
Upper 
Bound 
Caucasian 65.2 0.056 0.009 0.542 0.762 72 62 
MC 79.2 0.045 <0.001 0.704 0.880 76 70 
SE- standard error, MC-Malaysian Chinese, AUC- area under the ROC curve. 
*Significant when P < 0.05. ǂ- both cancer and control groups. 
 
In this study we observed difference in DHT/T between Caucasian and MC groups as 
described in section 4.2.3 above. The ROC curve for the Caucasian group for DHT/T was 
just about 50% and this indicates that the sensitivity and specificity of this test was not 
significant (P = 0.741) statistically in PC diagnostics (Figure 4.12).  
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Figure 4.12 Receiver Operating Characteristic Curve (ROC) for Caucasian participants 
using DHT/T. 
ROC for assessment of diagnostic capability of prostate cancer. 1-specificity indicates the 
false positive rate which is given in the x-axis and the specificity is calculated by 
subtracting this value form 1. DHT/T- dihydrotestosterone to testosterone ratio. 
 
It was found that MC group had a much larger AUC (by 17.4%, Figure 4.13) compared to 
AUC of Caucasian group.  
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Figure 4.13 Receiver Operating Characteristic Curve (ROC) for Malaysian Chinese 
participants using a DHT/T. 
ROC for assessment of diagnostic capability of prostate cancer. 1-specificity indicates the 
false positive rate which is given in the x-axis and the specificity is calculated by 
subtracting this value form 1. DHT/T- dihydrotestosterone to testosterone ratio. 
 
Sensitivity and specificity of DHT/T ratio in predicting PC was calculated from the ROC 
curve above for both, Caucasians and MC groups.  As expected, due to a larger AUC in the 
MC group, the sensitivity and specificity of DHT/T test in the MC was higher when 
compared to Caucasians in differentiating PC from the controls (Table 4.14). 
 
 
 141 
 
Table 4.14 Comparison of area under the Receiver Operating Characteristic (ROC) curve for 
Caucasian and Malaysian Chinese groups for DHT/T  
Ethnic 
group ǂ  
AUC 
(%) 
SE P- 
value 
Asymptomatic              
95% Confidence 
Interval 
Sensitivity 
(%) 
Specificity 
(%) 
Lower 
Bound 
Upper 
Bound 
Caucasian 51.9 0.058 0.741 0.405 0.633 50 48 
MC 69.3 0.054 0.001 0.587 0.798 68 64 
SE- standard error, MC-Malaysian Chinese, AUC- area under the ROC curve. 
*Significant when P < 0.05. ǂ- both cancer and control groups. 
This study has shown that it might be possible to use testosterone in combination with 
IGF-I or the DHT/T for improving diagnosis of PC even in this small study group. Such a 
test would be particularly important for MC group where the incidence of PC is lower. 
 
4.3 Investigation of DNA polymorphisms 
This section presents results of experiments on (i) identification of ethnic group-specific 
polymorphisms in CYP17 (rs743572), SRD5A2 (rs523349 and rs9282858) and AR genes 
and (ii) relationship between these polymorphisms and PC development.  These genes 
were chosen because they encode for enzymes and receptors that are important in androgen 
metabolism described in section 2.3. The study was conducted on genomic DNA (gDNA) 
isolated from the whole blood of participants recruited for this study from Caucasian and 
MC ethnic groups.  
This research consisted of (i) a pilot study and (ii) ethnic groups study. The pilot study 
aimed to optimise a protocol for isolation of gDNA from blood and optimise DNA 
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amplification, and it was conducted on blood from 4 volunteers (see section 4.3.1. for 
details). The ethnic group study was conducted on 100 cancer and 100 control patients of 
Caucasians and MC populations (see section 4.3.2 for details).  
 
4.3.1 Genomic DNA isolation from whole blood samples of volunteers 
gDNA isolation was optimised using samples of whole blood (10 ml) from 4 volunteers. 
The blood from each volunteer was aliquoted into several tubes and frozen at -80o C. 
Optimisation of gDNA isolation was performed as describe below:   
i. Isolation of gDNA following the manufacture protocol using the QI Amp Blood 
mini kit (Qiagen Ltd, Crawley, UK). DNA quality was assessed using NanoDrop 
1000 (Thermo Scientific, Basingstoke, UK) as described below.  
ii. If the gDNA quality was found to be unsatisfactory (if the absorbance 260/280 ratio 
of < 1.8), the gDNA isolation conditions were modified (the elution buffer was   
replaced with water). 
iii. If the gDNA concentration was low (below < 50 ng/µl), the volume of elution 
buffer was reduced in order to concentrate gDNA.   
Table 4.15 presents results of evaluation of gDNA concentrations and quality (measured as 
260/280 ratio). The results demonstrate that in a pilot study, gDNA concentration was 
generally low (< 50 ng/µl) but the 260/280 absorbance ratio was within acceptable limits 
of > 1.8 with exception of 3 sub-samples of the split volunteer samples.  
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Table 4.15 Concentration and quality of gDNA isolated from blood of volunteers. 
 Sampleǂ DNA 
identity a 
gDNA concentration 
(ng/µl) (Average of 
the 2 sub-samples) 
260/280  
Volunteer 1 V1A1 17.9 2.06 
V1A2 1.79 
Volunteer 2 
 
V2A1 27.05 2.01 
V2A2 1.88 
Volunteer 3 V3A1 42.75 1.91 
V3A2 1.66 
Volunteer 4 
 
V4A1 42.1 1.84 
V4A2 1.67 
 a DNA identity: anonymised sample identification number, gDNA: genomic 
Deoxyribonucleic acid, 260/280: Absorbance ratio. Single measurement for each sample 
performed. ǂ Each volunteer blood sample were divided into two tubes for two 
independent gDNA isolation and measurements.  
 
To increase gDNA yield and improve 260/280 ratio, DNA isolation procedure was 
modified. In particular, water was used instead of the elution buffer for the final elution of 
purified gDNA. This was recommended by the manufacturer in the protocol attached with 
the kit. However, this modification did not improve gDNA quality and, in fact, the 
absorbance ratio and the gDNA concentration were not significantly different when either 
buffer or water was used for elution (P = 0.14 and 0.07 respectively) (Table 4.16). 
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Table 4.16 gDNA concentration and 260/280 ratio   
Sample ǂ Elution gDNA 
concentration 
(ng/µl) 
Mean 
gDNA 
± SEM 
P 
value 
260/280 Mean 
260/280 
± SEM 
P 
value 
Volunteer 1 
 
Buffer 8.2 18.0 
±6.46 
0.14* 1.74 1.70 
±0.72 
0.07* 
Volunteer 2 
 
15.6 1.56 
Volunteer 4 
 
30.2 1.80 
      
Volunteer 1 
 
Water 19.3 18.9 
±2.03 
1.60 1.63 
±0.17 
Volunteer 2 
 
22.2 1.66 
Volunteer 4 
 
15.2 1.63 
 
gDNA concentration obtained with a modified protocol (substituting the buffer with 
water for elution). gDNA: genomic Deoxyribonucleic acid, 260/280: Absorbance ratio. ǂ 
Each volunteer blood sample was divided into two tubes for gDNA isolation and two 
independent measurements was done. Sample from volunteer 3 was not used due to 
insufficient volume. * denotes independent T-test and significant when P < 0.05. 
 
The other approached used to improve gDNA yield and quality was changing the elution 
buffer volume in the first elution step (from 200 µl to 25, 50 and 100 µl). This 
modification allowed production of gDNA of best quality and acceptable concentration 
(Table 4.17). Based on these findings, a decision was made to use 100 µl and 50 µl of 
elution buffer for the first and second elution respectively in future experiments.  
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Table 4.17 DNA concentration and 260/280 ratio in experiments using various volume of 
elution buffers. 
Sample ǂ  DNA 
identity a 
Remarks DNA 
concentration 
(ng/µl) 
260/280  
1a V1C1 Elute with buffer 25µl 79.2 2.06 
1b V1C1 2nd elution with buffer 
50µl 
40.4 2.17 
1c V1C2 Elute with buffer 50µl 43.5 1.99 
1d V1C2 2nd elution with buffer 
50µl 
45.8 2.09 
1e V1C3 Elute with buffer 100µl 39.4 2.13 
1f V1C3 2nd elution with buffer 
50µl 
39.3 2.12 
4a V4C1 Elute with buffer 25µl 135.1 1.98 
4b V4C1 2nd elution with buffer 
50µl 
65.1 2.04 
4c V4C2 Elute with buffer 50µl 100.6 2.01 
4d V4C2 2nd elution with buffer 
50µl 
25.9 2.24 
4e V4C3 Elute with buffer 100µl 63.8 1.87 
4f V4C3 2nd elution with buffer 
50µl 
80.0 2.03 
a DNA identity: anonymised sample identification number, gDNA: genomic 
Deoxyribonucleic acid, 260/280: Absorbance ratio. ǂ Each volunteer blood sample was 
divided into two tubes for gDNA isolation and two independent measurements was 
done. Sample from volunteer 2 and 3 were not used due to insufficient volume.  
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4.3.2 Analysis of quantity and quality of genomic DNA from blood of control and 
cancer patients of Caucasian and Malaysian Chinese groups. 
The optimised protocol (section 4.3.1) was used uniformly for isolation of gDNA from the 
blood of Caucasian and MC groups.  
Table 4.19 presents mean values for 260/280 ratio and gDNA concentration. For all the 
groups investigated, 260/280 values were above 1.8. The mean concentration of gDNA 
obtained in the MC group was lower than the Caucasian group by almost 50% (Table 
4.18). However, the lower concentration of isolated gDNA in MC ethnic group was not an 
issue for PCR amplification and subsequent DNA sequencing as the concentration of 
gDNA used as a template for PCR was standardise to a concentration of 100 ng/µl in all 
the cases.  
 
Table 4.18 gDNA concentration and 260/280 ratio in blood samples from Caucasian and 
Malaysian Chinese groups 
Parameters N Mean gDNA 
concentration 
(ng/µl) 
Mean 260/280 
ratio 
Caucasian Control 50 66.1 1.85 
Cancer 50 63.9 1.87 
Malaysian 
Chinese 
Control 49 35.2 1.90 
Cancer 50 25.5 1.82 
N- number of participant in each group. One sample in the Malaysian Chinese control 
group omitted due to absent gDNA. gDNA- genomic Deoxyribonucleic acid. 
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Some of the patients in the cancer and control groups from both, Caucasians and MC 
groups had absorbance ratio below the 1.8 (but not by more than 10%). However, the 
number of these individuals was only 3 in Caucasian cancer, 8 in Caucasian control, 10 in 
MC cancer and 4 in MC control group. In this study, PCR amplifications were conducted 
on the samples with both, high and lower 260/280 ratio to check whether it is possible to 
obtain a sufficient quality product from samples with lower ratio. The quality of all PCR 
products was satisfactory (evidenced by high quality PCR band of the correct size, absence 
of non-specific bands and correct DNA sequences).   
 
4.3.3 Identification of CYP17 polymorphism 
Prostate is an androgen-regulated organ. It has been suggested that polymorphisms in 
genes encoding for enzymes controlling androgen biosynthesis and metabolism or 
androgen receptor functions may be related to the risk of prostate cancer (Henderson and 
Feigelson, 2000). One such enzyme is 17α-hydroxylase/17, 20 lyase which is encoded by 
CYP17 gene. This enzyme acts at multiple points in the androgen metabolism pathway that 
lead to the formation of testosterone (see Figure 2.14 in section 2.2.1). It has been reported 
in the literature that a single  base pair (bp) change in the 5’-transcribed but untranslated 
region of CYP17 (rs743572) (position: -34T→C) is positively associated  with excessive  
androgen production (Carey et al, 1994).  
Research presented in this chapter investigated the presence or frequency of the above 
CYP17 polymorphism in control and cancer patients in the Caucasian and MC ethnic 
groups.  Furthermore, this study investigated not only CYP17 polymorphism reported in 
the literature but also any coincidental SNPs present in the DNA region amplified during 
PCR.  
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DNA regions of interest were amplified and the size of PCR products was checked using 
agarose gel electrophoresis. The UV transilluminator image showed strong bands of 
500bp. Each gel contained samples from the Caucasian cancer, MC cancer, Caucasian 
control and MC control groups (Figure 4.14). 
 
                                
Figure 4.14 Horizontal agarose gel electrophoresis output for PCR product of CYP17 gene 
fragment. 
Lane 1 DNA markers, Lane 2 & 6: Caucasian cancer, Lane 3 & 7: Malaysian Chinese 
cancer, Lane 4 & 8: Caucasian control, Lane 5 & 9: Malaysian Chinese control. bp- base 
pair.   
 
The position of SNP -34T→C (rs743572) in CYP17 is shown in Figure 4.15. This figure 
also presents a position of a coincidental polymorphism that was found in these 
experiments.  
~500bp 
600 bp 
400 bp 
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Figure 4.15 Position of SNP -34T→C and 135C→T (coincidental) in CYP17 gene gDNA 
sequence (ref NG_007955.1). 
SNPs -34T→C (rs743572) and 135C→T (coincidental) is located 34 bases preceeding and 
135 base from the start codon in Exon 1. Numbering on the left indicates the reference 
point from origin of sequence of gDNA used for primer design. ATG indicates the position 
of the start codon. 
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4.3.3.1 Single nucleotide polymorphism at position -34T→C of CYP17 5’ untranslated 
region. 
The -34T→C SNP in the CYP17 gene was identified by DNA sequencing. This SNP is 
denoted as A1 which represents a homozygote individual where both alleles contain a T 
nucleotide whilst A2 represents a homozygous for C nucleotide at both alleles whils T/C 
heterozygote is represented by A1/A2.  
Table 4.19 Frequency of CYP17 gene polymorphism among Caucasians and Malaysian 
Chinese (MC) groups 
Ethnic 
Group 
N Type of polymorphism (Allele) P-value 
A1 A2 A1/A2 
n  n  n  
Caucasian  100 59 (59%) 18 (18%) 23 (23%) 0.333* 
0.381** MC 99 65 (65.7%) 22 (22.2%) 12 (12.1%) 
A1-T nucleotide (homozygote), A2- C nucleotide (homozygote), A1/A2- T or C 
nucleotide (heterozygote). N- number of participant in the ethnic group. n- number of 
participant with polymorphism. Ethnic group- combination of cancer and control 
cases. *Pearson Chi-Square test   **Fisher’s Exact test. 
 
It was found that frequency of A1 and A1/A2 allele was by 6.7% and 10.9% higher in 
Caucasian group, whilst frequency of A2 allele was 4.3% higher in MC group. However, 
Pearson Chi-Square and Fisher’s exact tests showed that the difference was not statistically 
significant in the frequency profile of the different alleles in the different ethnic groups (P 
= 0.333 and 0.381) (Table 4.19). 
This -34T→C SNP in CYP17 was present in cancer and control cases of both ethnic 
groups in this study. Frequency of polymorphisms (A2 + A1/A2) was 45% (n=45) in the 
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cancer group and 30.3% (n=30) in the control group when men from Caucasians and MC 
ethnic groups were considered together.  Comparison between the control and cancer cases 
overall showed that there was a statistically significant increase (by 14.7%) of 
polymorphism incidence  in the cancer group compared to control group when  data for  
Caucasian and MC participants were analysed as one dataset (P = 0.032 and 0.041 using 
Pearson Chi-Square test and Fisher’s Exact test) (Table 4.20). Frequency of A2 allele was 
no different between the cancer and control groups but there was a 15% increase in the 
prevalence of A1/A2 allele in the cancer group. This higher frequency was statistically 
significant (P = 0.029). 
 
Table 4.20 Frequency of different alleles of CYP17 gene at position -34T→C in cancer and 
control groups. 
Group N Type of polymorphism (Allele) P-value 
A1 A2 A1/A2 A2 + A1/A2 
n (%) n (%) n (%) n (%)  
Control 99 69 (69.7) 20 (20.2) 10 (10.1) 30 (30.3) 0.032* 
0.041** Cancer 100 55 (55) 20 (20) 25 (25) 45 (45) 
A1-T nucleotide (homozygote), A2- C nucleotide (homozygote), A1/A2- T or C 
nucleotide (heterozygote). N- number of participant in the ethnic group. n- number of 
participant with polymorphism. Group- All men combined (Caucasian + Malaysian 
Chinese). *Pearson Chi-Square test   **Fisher’s Exact test. 
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Risk of PC development was assessed by calculating the odds ratio (OR) with 95% 
confidence interval (95% CI). The OR was calculated for A2, A1/A2 and a combination of 
A1 + A1/A2 compared to the baseline OR for A1 which was considered as a reference 
point. OR of > 1.0 was considered to have higher risk of PC but the significance was 
assessed with the range of 95% CI. 95% CI was considered significant if the lower limit 
was > 1.0 due to the fact that OR of the reference in case of A1 was considered to be 1.0. 
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Table 4.21 Association of SNP -34T→C in CYP17 gene with the risk of prostate cancer. 
 
A1-T nucleotide (homozygote), A2- C nucleotide (homozygote), A1/A2- T or C nucleotide (heterozygote). CI- Confidence interval, given in 
brackets for each allele or allele combination.  “Reference” presents OR ratio for A1 allele. MC- Malaysian Chinese. OR- Odds ratio. *- 
significant. 
 
 
Type of 
polymorphism 
All ethnic groups Caucasian MC 
Control Cancer OR (95% CI) Control Cancer OR (95% CI) Control Cancer OR (95% CI) 
A1 69 55 1.0 (reference) 33 26 1.0 (reference) 36 29 1.0 (reference) 
A1/A2 10 25 3.14 (1.39-
7.08) * 
6 17 3.6 (1.24-
10.41) * 
4 8 2.48 (0.68-
9.07) 
A2 20 20 1.25 (0.61-
2.56) 
11 7 0.81 (0.27-
2.37) 
9 13 1.79 (0.67-
4.78) 
A2 + A1/A2 30 45 1.88 (1.05-
3.37) * 
17 24 1.79 (0.8-4.01) 13 21 2.01 (0.86-
4.68) 
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This study has shown that there is significantly increased risk of PC in participants with 
A1/A2 allele compared to the A1 allele when data for men from both the ethnic groups 
were combined (OR = 3.14; 95% CI = 1.39-7.08). This significance was also present in the 
combination of A2 + A1/A2 alleles compared to the A1 allele (OR = 1.88; 95% CI = 1.05-
3.37). Risk of PC was more prominent and statistically significant in the Caucasians (OR = 
3.6; 95% CI = 1.24-10.41) than the MC (OR = 2.48; 95% CI = 0.68-9.07) with A1/A2 
allele.  Comparing the risk of PC in the presence of A2 allele  to the baseline A1 allele, 
there is a non-significant increase in risk in the MC group (OR = 1.79; 95% CI = 0.67-
4.78) compared to the Caucasians. A2 + A1/A2 allele showed a non-significant increase 
risk in both ethnic groups (Table 4.21). 
In summary, this study showed that (i) A1/A2 or a combination of A2 + A1/A2 alleles of 
the SNP -34T→C in CYP17 gene increases the risk of PC in Caucasians and MC overall 
(ii) there is increasing trend in the risk of PC in MC in presence of A2 allele (iii) there is 
significant increase in PC risk in Caucasians in presence of A1/A2 allele. All the 
comparison was against the reference A1 allele. 
 
4.3.3.2 Coincidental polymorphism at position 135C→T of CYP17 gene  
Section 1.3.3 described amplification and sequencing of 500bp of CYP17 gene. Within this 
500 bp, we were able to investigate not only ethnic-group specific occurrence and 
frequency of CYP17 SNP -34T→C, but also identify coincidental polymorphisms. This 
study identified a coincidental polymorphism at the position 135C→T consistently in 
gDNA. This polymorphism occurred in the CYP17 coding region but it did not result in an 
amino acid change and therefore was denoted as a ‘silent’ polymorphism. CYP17 DNA 
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sequence in our study contained either nucleotide C, nucleotide T or a dual peak indicating 
presence of both, C and T which is a wild-type heterogeneous polymorphism. 
Difference in the frequency of the 3 variants in the Caucasian and the MC groups was not 
statistically significant when the data of both, cancer and control groups were combined. 
The MC group had a 2% higher prevalence of C and T allele whereas the Caucasians had 
about 4 % increased frequency of the C/T allele. The frequency profile was not significant 
statistically (Pearson Chi-Square and Fisher’s exact tests of P = 0.768 and 0.875 
respectively) (Table 4.22). 
Table 4.22 Association of variant on ethnicity in the CYP17 gene at position 135C→T. 
 
Ethnic 
Group 
N Type of polymorphism (Allele) P-value 
C T C/T 
n  n  n  
Caucasian  88 59 (67%) 18 (20.5%) 11 (12.5%) 0.768* 
0.875** MC 97 67 (69.1%) 22 (22.7%) 8 (8.2%) 
C-C nucleotide (homozygote), T- T nucleotide (homozygote), C/T- C or T nucleotide 
(heterozygote). N- number of participant in the ethnic group. n- number of participant 
with polymorphism. Ethnic group- combination of cancer and control cases. *Pearson 
Chi-Square test   **Fisher’s Exact test. 
 
This coincidental SNP in the CYP17 gene was present in cancer and control cases of both 
ethnic groups in this study. Frequency of polymorphism (C + C/T) was 33.7% (n=31) in 
the cancer group and 30.1% (n=28) in the control group when Data men from Caucasians 
and MC ethnic groups were analysed together.  Comparison between the control and 
cancer cases overall showed that there was a non-significant increase (by 3.6%) in  
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frequency of the polymorphism in the cancer group compared to control group when 
Caucasian and MC participants were analysed as one dataset (P = 0.601 and 0.638 using 
Pearson Chi-Square test and Fisher’s Exact test) (Table 4.23). Except for the frequency of 
the C/T allele which was almost double the frequency in cancer cases compared to 
controls, the other allele were not significantly different between the two groups (Table 
4.23).  
 
Table 4.23 Frequency of different alleles of the SNP in the CYP17 gene at position 135C→T 
in cancer and control groups. 
Group N Type of polymorphism (Allele) P-value 
C T C/T T + C/T 
n (%) n (%) n (%) n (%)  
Control 93 65 (69.9) 21 (22.6) 7 (7.5) 28 (30.1) 0.601* 
0.638** Cancer 92 61 (66.3) 18 (19.6) 13 (14.1) 31 (33.7) 
C-C nucleotide, T- T nucleotide, C/T- C or T nucleotide. N- number of participant in 
the ethnic group. n- number of participant with polymorphism. Group- All men 
combined (Caucasian + Malaysian Chinese). *Pearson Chi-Square test   **Fisher’s 
Exact test. 
 
As in SNP -34T→C above, the OR and 95% CI was calculated to determine association 
between risk of PC and this polymorphism. It was noted that, there were no statistically 
significant risk associated with any of the allele at position 135C→T of the CYP17 gene 
(Table 4.24). It should be noted that the above data should be treated with caution due to a 
relatively small number of participants in this study.  
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Table 4.24 Association of SNP 135C→T in CYP17 gene with risk of prostate cancer. 
 
 
C- C nucleotide, T- T nucleotide, C/T- C or T nucleotide. CI- Confidence interval, given in brackets for each allele or allele combination.  
“Reference” presents OR ratio for A1 allele. MC- Malaysian Chinese. OR- Odds ratio. 
 
 
Type of 
polymorphism 
All ethnic groups Caucasian MC 
Control Cancer OR (95% CI) Control Cancer OR (95% CI) Control Cancer OR (95% CI) 
C 65 61 1.0 (reference) 29 30 1.0 (reference) 36 31 1.0 (reference) 
T 21 18 0.91 (0.44-
1.88) 
11 7 0.62 (0.21-1.8) 10 12 1.39 (0.53-
3.66) 
C/T 7 13 1.98 (0.74-
5.29) 
4 7 1.69 (0.45-6.4) 3 5 1.94 (0.43-
8.76) 
T + C/T 28 31 1.18(0.64-
2.19) 
15 14 0.9 (0.37-2.2) 13 17 1.52 (0.64-
3.61) 
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To summarise, results presented in this chapter demonstrate that: 
(i) A heterogeneous A1/A2 SNP in CYP17 gene at the position -34T→C was more 
frequent in Caucasians. There was increased risk of PC in case of A1/A2 and/or A2 
+ A1/A2 alleles when data for men from both ethnic groups were combined. 
Caucasians had a higher risk of PC in the presence of A1/A2 allele whilst MC 
ethnic group had higher risk of PC in the presence of A2 allele.   
(ii) A new polymorphism was identified at the position 135C→T of CYP17 gene. Data 
of this study do not allow to conclude whether this polymorphism is associated 
with PC or whether it is ethnic-group specific due to a relatively low number of 
participants.  
 
4.3.4 Identification of SRD5A2 polymorphism 
SRD5A2 gene encodes the enzyme steroid 5α-reductase type 2 which mediates irreversible 
conversion of testosterone to a more metabolically active DHT (Hsing et al, 2001). This 
chapter focuses on determining whether the presence and frequency of SRD5A2 DNA 
polymorphisms reported in the literature are ethnic-group specific and whether frequency 
of these polymorphisms varies between control and cancer groups. A specific focus was on 
two polymorphisms as detailed below. 
It is known that SRD5A2 DNA polymorphism at position 261C→G of the coding region 
results in amino acid substitution. Namely, Val is replaced for Leu at codon 89, and this 
has been defined as V89L variant. This amino acid change has been reported to reduce 
activity of SRD5A2 enzyme (Makridakis et al, 1997).  
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SRD5A2 DNA polymorphism at position 140G→A of the coding region induces another 
amino acid substitution. The A49T variant is produced where conversion of the amino acid 
Ala to Thr at codon 49 takes place due to the above 140G→A polymorphism. This amino 
acid change results in increased SRD5A2 enzymatic activity (Makridakis et al, 2000). 
PCR reaction resulted in 500bp band which is consistent with the size of amplified 
SRD5A2 region.  The amplification was performed on samples from the Caucasian cancer, 
MC cancer, Caucasian control and MC control participants. The PCR products from 
different groups were run on the same gel (Figure 4.16) 
 
                     
Figure 4.16 UV transilluminator image showing successful PCR amplification of a region of 
SRD5A2 gene. 
Lane 1 DNA markers, Lane 2 & 6: Caucasian cancer, Lane 3 & 7: Malaysian Chinese 
cancer, Lane 4 & 8: Caucasian control, Lane 5 & 9: Malaysian Chinese control. bp- base 
pair.   
 
The position of the polymorphism in the coding region in exon 1 of the SRD5A2 gene for 
the 140G→A (rs9282858) and 261C→G (rs523349) is shown in Figure 4.17 below.  
 
~500 bp 600 bp 
400 bp 
 1         2        3         4         5         6          7        8         9 
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Figure 4.17 Position of SNP 140G→A and 261C→G in SRD5A2 gene gDNA sequence (ref 
NG_008365.1).  
SNPs 140G→A (rs9282858) and 261C→G (rs523349) is located 140 bases and 261 bases 
from the start codon in Exon 1. Numbering on the left indicates the reference point from 
origin of sequence of gDNA used for primer design. ATG indicates the position of the start 
codon. 
 
4.3.4.1 Analysis of polymorphism 261C→G (rs523349) in SRD5A2 gene 
The SRD5A2 SNP studied here was referenced to as rs523349, which is 261C→G 
substitution at the coding region in exon 1 resulting in amino acid Val to Leu substitution 
(Makridakis et al, 1997).  
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This study identified the presence of a baseline homozygote with nucleotide C (no 
polymorphism), a polymorphic homozygote with nucleotide G and heterozygote C or G 
nucleotide in the DNA sequence. Both, the G nucleotide and C or G nucleotides were 
denoted as polymorphic in this study which is in agreement with data of the literature 
(Reichardt et al, 1995, Makridakis et al, 1997). Frequency of polymorphisms at the 
position 261C→G (rs523349) of SRD5A2 gene in the Caucasians and the MC groups 
(combining cancer and control cases) is shown in Figure 4.18. 
 It was noted that frequency of G nucleotide was almost 33% higher in the Caucasian 
group compared to MC group. The study also showed that the MC ethnic group had 21.6% 
and 11.3% higher frequency of C nucleotide and C or G nucleotides respectively when 
compared to the Caucasians.  
 
         
Figure 4.18 Frequency of polymorphism at position 261C→G of SRD5A2 gene in the 
Caucasian and Malaysian Chinese groups. 
Data for Caucasians and Malaysian Chinese cancer and control groups pooled together. G 
and C nucleotide are homozygotes, and C and G peak is heterozygote. 
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When results for men from both ethnic groups were analysed together, it was found that 
frequency of C to G polymorphism in SRD5A2 in control group was only 1.3% higher 
than in cancer patients. The cancer group had a 12.6% higher frequency of C nucleotide 
compared to the control group .The frequency of C or G nucleotide was 11.3% higher in 
the control group when compared to cancer (Figure 4.19).  
 
         
Figure 4.19 Frequency of polymorphism at position 261C→G of SRD5A2 gene in the cancer 
and control groups. 
Data for both Caucasian and MC groups pooled together. G and C nucleotide are 
homozygotes, and C and G peak is heterozygote. 
 
 
The SRD5A2 DNA sequence obtained in this study was translated into amino acid 
sequence using Geneious software as described in section 3.3.7. The amino acid sequence 
was then aligned with SRD5A2 protein sequence reported in the database. It was shown 
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that polymorphism at the position 261C→G results in amino acid substitution Val (V) to 
Leu (L) at the codon 89. Depending on the nature of changes in nucleotides in the position 
261, three variants of amino acids were noted (i) Val (denoted as VV genotype), (ii) Leu 
(denoted as LL genotype) or (iii) a heterozygote L/V type of amino acid change for a case 
when both C and G nucleotide peak were observed.  
Comparison between the 2 ethnic groups investigated revealed that Caucasians had a 33% 
higher frequency of VV genotype than the MC men. They also had a 20% and 10% lower 
frequency of the LL and the heterozygote L/V genotype than the MC group. This ethnic-
groups difference in the frequency of DNA polymorphism resulting in amino acid 
substitution was found to be highly significant statistically (P < 0.001). However, the 
above polymorphism was not significant for cancer and control groups when ethnic groups 
were pooled together (Table 4.25).   
Table 4.25 Frequency of genotypes due to functional 261C→G polymorphism of SRD5A2 in 
Caucasians, MC, control and prostate cancer groups.  
Group  VV LL L/V  P-value 
N % N % N % 
Caucasianǂ 42  42.0 38  38.0 20  20.0 <0.001* 
MCǂ 9  9.1 59  59.6 31  31.3  
        
Cancer° 25  25.0 55  55.0 20  20.0 0.127* 
Control° 26  26.3 42  42.4 31  31.3  
N- number of participants, MC-Malaysian Chinese, VV- Val change, LL-Leu change, 
L/V- Leu or Val. ǂ indicates data for both cancer and control cases. ° indicates data for 
men of both Caucasian and MC groups pooled together. Significant when P-value < 
0.05. *Pearson Chi-Square test 
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It was also noted that the Caucasian cancer group had a significantly (P < 0.001) higher 
frequency of functional polymorphism resulting in VV genotype when compared to the 
MC cancer group. However, no significant difference was found between the Caucasian 
cancer and the Caucasian control group. The incidence of the VV genotype was also very 
low in the MC control group compared to the Caucasian controls and it was almost at the 
same frequency as for MC cancer patients. The LL genotype frequency did not differ 
significantly between the MC cancer and Caucasian cancer groups and the L/V genotype 
was higher in frequency in the MC cancer patients compared to the Caucasian cancer 
patients (Table 4.26). 
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Table 4.26 Association of V89L genotype with risk of prostate cancer. 
 
 
 
 
 
  
VV- 
Vali
ne, 
LL- Leucine, L/V- heterozygote with both Leu or Val. CI- Confidence interval, given in brackets for each allele or allele combination.  
“Reference” presents OR ratio for A1 allele. MC- Malaysian Chinese. OR- Odds ratio. 
 
 
Genotype All ethnic groups Caucasian MC 
Control Cancer OR (95% CI) Control Cancer OR (95% CI) Control Cancer OR (95% CI) 
VV 26 25 1.0(reference) 22 20 1.0 (reference) 4 5 1.0 (reference) 
L/V 31 20 0.67 (0.31-
1.47) 
17 3 0.19(0.05-
0.76) 
14 17 0.97 (0.22-
4.32) 
LL 42 55 1.36 (0.69-
2.69) 
11 27 2.7 (1.07-6.82) 31 28 0.72 (0.18-
2.96) 
L/V + LL 73 75 1.07 (0.57-
2.02) 
28 30 1.18 (0.53-
2.61) 
45 45 0.8(0.2-3.17) 
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The OR and 95% CI was calculated to analyse impact of the polymorphism in SRD5A2 
gene at the position 261C→G, that results in V89L genotype, on the risk of PC. The 
polymorphic genotypes were compared to baseline VV genotype which was used as a 
reference. It was noted that the L/V genotype was not associated significantly with the risk 
of PC when results for all the men in this study were considered together. A significant 
reduced risk of PC was observed in the Caucasian group with L/V genotype (OR = 0.19; 
95% CI = 0.05-0.76) when compared to the MC group (OR = 0.97; 95% CI = 0.22-4.32). 
The LL genotype was noted to be associated with increased risk of PC in all the men but 
the results were not statistically significant (OR = 1.36; 95% CI = 0.69-2.69).  However, 
there was a significant increase in risk of PC with in the Caucasians with LL genotype (OR 
= 2.7; 95% CI = 1.07-6.82) compared to the MC.  In case of polymorphic genotypes (L/V 
or LL), it was noted that there was  only small and non-significant increase in the risk of  
PC in  the case when Caucasian and MC data were analysed together and in the  
Caucasians men when compared to the MC. 
In summary, the results presented in this chapter demonstrated that: 
(i) LL and L/V genotypes are more common in the MC compared to the Caucasians 
when the data for all the participants were pooled together. 
(ii) There were no differences in the frequency of any of the genotypes between cancer 
and control participants when data for both ethnic groups were analysed as one 
dataset.  
(iii) LL genotype and L/V genotype were associated with higher and low risks of PC 
respectively in Caucasians but not in MC.  
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4.3.4.2 Analysis of polymorphism 140G→A (rs9282858) in the SRD5A2 gene  
The second SNP in the SRD5A2 gene that has been extensively studied in relation to PC, 
is A49T variant which resulted in Ala to Thr substitution at codon 49 due to the SNP at 
position 140 from nucleotide G to A. Presence of this polymorphism is supposed to 
increase the rate of conversion of testosterone to DHT due to increased activity of 5-ɑ 
reductase type 2 (Makridakis et al, 1997).  
In this study, the mentioned above polymorphism was not detected neither in control, 
cancer, Caucasian nor MC groups.   
 
4.3.5 Assessment of number of CAG repeats in androgen receptor gene  
The number of CAG repeats in Exon 1 of AR gene is known to be inversely related to the 
risk of PC development (Giovannucci et al, 1997). Prostatic cell division and possibility of 
carcinogenesis are controlled by interaction between testosterone and DHT with the 
androgen receptor which, in turn, affects function of AR gene (Chamberlain et al, 1994). 
This chapter presents results of study on a number of polymorphic CAG repeats in Exon 1 
and the relationship between the number of CAG repeats, ethnicity and PC incidence. 
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Table 4.27 Association between mean number of CAG repeats in AR gene with ethnicity, 
disease status and interaction between these parameters. 
 Group N Mean SD P-value 
Ethnicity Caucasian 100 21.80 3.13 0.212 
MC 100 22.37 3.37 
Disease 
status 
Cancer 100 22.36 3.15 0.236 
Control 99 21.81 3.35 
Interaction Ethnicity vs. 
Cancer 
&Control 
199 85.21 45.68 0.111 
* Significant at P-value <0.05. N-number, SD- standard deviation, ANOVA- analysis of 
variance, MC-Malaysian Chinese, AR- Androgen Receptor. 
 
This study showed that a mean number of CAG repeats was not significantly (P = 0.212) 
different between the Caucasian and MC groups when control and cancer data were 
considered as one dataset. Comparison between the cancer group and control groups (when 
Caucasians and MC were considered as one data set) did not reveal significant differences 
in mean numbers of CAG repeats  either (P = 0.236). The number of CAG repeats in each 
ethnic group was noted to be in the range of 18 to 29 in Caucasian cancer, 8 to 27 in 
Caucasian control, 12 to 31 in MC cancer and 15 to 30 in MC controls. There was no 
significant interaction between ethnicity and the disease status (Table 4.27). 
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4.4 Relationship between hormone concentration and DNA 
polymorphisms.   
This chapter provides analysis of relationship between (i) polymorphisms in the CYP17 (-
34T→C and 135C→T) and SRD5A2 at position 261C→G (V89L variant) genes and 
concentration of sex hormones. The A49T variant genotype was not analysed as it was not 
present in any of the participants in this study.  (ii) number of CAG repeats in the AR gene 
and the concentration of sex hormones.  
 
4.4.1 Relationship between testosterone concentration with genetic polymorphism. 
The mean concentration of testosterone in the circulation in presence or absence of 
polymorphism in CYP17 and SRD5A2 genes are shown in Table 4.30. This study did not 
establish significant relationship between circulating testosterone concentration and 
presence or absence of polymorphism in both the positions of CYP17 gene (-34T→C and 
135C→T) across all the groups investigated.  
Presence of SRD5A2 (261C→G) SNP was only significantly related to the mean 
circulating testosterone concentration in Caucasian control group (P = 0.038). There was 
no significant relationship between this polymorphisms and testosterone concentration in 
Caucasian cancer, MC cancer and control groups (Table 4.28).  
No significant relationship has been found between the number of CAG repeats and 
circulating testosterone concentration in all the sub-groups in this study. 
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Table 4.28 Relationship between polymorphisms and circulating testosterone concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes- one and/or two allele/genotype present, No- absence of polymorphism, SD- standard deviation, MC- Malaysian Chinese. * significant 
when < 0.05 (Independent t-test). Mean in ng/ml. 
Group Presence of 
polymorphism 
-34T→C (CYP17) 135C→T (CYP17) 261C→G (V89L variant) 
Mean SD P-value Mean SD P-value Mean SD P-value 
Caucasian 
Cancer 
Yes 3.71 1.87 0.234 3.40 1.46 0.881 3.35 1.07 0.386 
No 3.22 0.88 3.48 1.53 3.59 1.75 
Caucasian 
Control 
Yes 3.89 1.33 0.652 3.99 1.29 0.966 4.51 1.42 0.038* 
No 4.09 1.47 3.97 1.49 3.38 1.39 
MC 
Cancer 
Yes 3.05 2.98 0.394 2.66 2.56 0.911 4.11 1.07 0.28 
No 2.44 2.04 2.75 2.50 2.78 2.64 
MC 
Control 
Yes 4.51 1.39 0.746 4.38 1.46 0.551 3.16 1.21 0.086 
No 4.71 2.03 4.75 2.01 4.92 1.93 
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4.4.2 Relationship between dihydrotestosterone concentration with genetic 
polymorphism 
This study did not find significant relationship between CYP17 (-34T→C) polymorphism 
and the concentration of circulating DHT in Caucasians cancer, Caucasian controls, MC 
cancer and MC control groups (Table 4.31). A significant relationship was noted in 
Caucasian controls in the 135C→T position of CYP17 gene but the significance of this 
finding needs further evaluation. 
SRD5A2 polymorphism at the position 261C→G (V89L variant) was not positively related 
to DHT concentration in the groups studies (Caucasian cancer, Caucasian control, MC 
cancer and MC control) (Table 4.29).  
There was no relationship between the number of CAG repeats and the hormones studied 
in the sub-groups in this study.  
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Table 4.29 Relationship between polymorphisms and circulating DHT concentration 
 
 
 
 
 
 
 
 
Yes- one and/or two allele/genotype present, No- absence of polymorphism, SD- standard deviation, MC- Malaysian Chinese. * significant 
when < 0.05 (Independent t-test). Mean in ng/ml. 
 
Group Presence of 
polymorphism 
-34T→C (CYP17) 135C→T (CYP17) 261C→G (V89L variant) 
Mean SD P-value Mean SD P-value Mean SD P-value 
Caucasian 
Cancer 
Yes 0.62 0.28 0.684 0.63 0.24 0.758 0.64 0.27 0.545 
No 0.59 0.28 0.60 0.32 0.59 0.30 
Caucasian 
Control 
Yes 0.57 0.28 0.098 0.50 0.23 0.008* 0.67 0.25 0.903 
No 0.70 0.23 0.72 0.27 0.66 0.22 
MC 
Cancer 
Yes 0.49 0.34 0.503 0.47 0.26 0.718 0.54 0.22 0.696 
No 0.44 0.27 0.44 0.37 0.48 0.33 
MC 
Control 
Yes 0.74 0.19 0.076 0.69 0.20 0.357 0.60 0.27 0.820 
No 0.59 0.27 0.61 0.28 0.63 0.26 
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Table 4.30 Relationship between polymorphisms and circulating IGF-I concentration 
Group Presence of 
polymorphism 
-34T→C (CYP17) 135C→T (CYP17) 261C→G (V89L variant) 
Mean SD P-value Mean SD P-value Mean SD P-value 
Caucasian 
Cancer 
Yes 104.5 77.1 0.131 103.8 85.6 0.269 110.3 82.1 0.040* 
No 78.1 40.0 81.7 45.8 72.9 36.2 
Caucasian 
Control 
Yes 112.8 53.4 0.043* 90.4 45.0 0.802 108.1 51.9 0.289 
No 88.3 30.3 93.6 30.0 89.8 28.5 
MC 
Cancer 
Yes 55.7 25.6 0.152 61.9 25.6 0.697 67.1 53.4 0.586 
No 70.9 42.3 66.3 41.7 58.3 28.2 
MC 
Control 
Yes 85.3 24.5 0.600 80.2 21.5 0.236 72.4 23.6 0.289 
No 90.9 35.1 92.7 35.3 87.9 27.4 
Yes- one and/or two allele/genotype present, No- absence of polymorphism, SD- standard deviation, MC- Malaysian Chinese.                                         
* significant when < 0.05 (Independent t-test). Mean in ng/ml. 
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4.4.3 Relationship between insulin-like growth factor-I with genetic polymorphism 
No significant relationship was established between the mean circulating concentration of 
IGF-I in Caucasian cancer, Caucasian controls, MC cancer and MC control groups and  
CYP17 polymorphism at the position 135C→T (Table 4.30). Caucasian control was the 
only group that showed significant positive relationship between IGF-I concentration and 
CYP17 -34T→C polymorphism (P = 0.043). 
Circulating IGF-I concentration was significantly elevated in the presence of SRD5A2 
261C→G polymorphism in the Caucasian cancer group (P = 0.040) (Table 4.32). No 
relationship was found between the SRD5A2 polymorphism and IGF-I concentration in 
Caucasian control, MC cancer and MC control.  
The mean number of CAG repeats was not significantly related to the concentration of 
IGF-I in any of the sub-groups in this study. 
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5 Discussion 
This thesis explored ethnic group-specific differences in PC development with regards to 
the concentration of hormones and genetic polymorphisms that play active role in 
androgen metabolism. The hormones studied were testosterone, DHT and IGF-I in the 
circulation. The genes investigated were CYP17, SRD5A2 and AR. The ethnic groups 
investigated were Bristol Caucasians and Malaysian Chinese men. 
The hypotheses tested in this project were: (i) circulating concentrations of androgens and 
IGF-I should be elevated in participants with PC compared to non-cancer participants 
within the same ethnic group; (ii) circulating concentration of androgens and IGF-I should 
be higher in a population with higher incidence of PC, such as Bristol Caucasians 
compared to the Malaysian Chinese; (iii) frequency of polymorphisms in CYP17, SRD5A2 
and AR genes is associated with increased risk of PC. This study also included 
investigation of relationship between presence/frequency of DNA polymorphisms and the 
concentration of circulating hormones.  
Our study was a case-control study with all the blood samples collected under similar 
condition for both ethnic groups. PC samples were obtained from patients who have been 
newly diagnosed with PC and the control group were selected from BPH patients with low 
risk of PC (see section 3.1.2) Blood storage conditions and experimental protocols were 
strictly uniform for all the samples. It should be highlighted that this is the first study 
which compared two completely different ethnic group tested under uniform conditions in 
contrast to most studies reported in the literature which are based on nested case-control 
studies for hormonal analysis (Dorgan et al, 1998, Sawada et al, 2010, Allen et al, 2007, 
Rowlands et al, 2012). Design of genetic part of our study was comparable to designs in 
majority of case-control studies  (Karimpur-Zahmatkesh et al, 2013, Torkko et al, 2008, 
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Price et al, 2010) with a difference in blood storage time which was much longer in  nested 
case-control studies, ranging from 8 to 20 years (Dorgan et al, 1998, Nomura et al, 1996). 
This project provides important knowledge on androgens and growth hormone status of 
Malaysian Chinese group in comparison with the Caucasians which can form basis for a 
larger ethnic-group specific study. This study will be, for the first time launched in 
Malaysia in 2015/2016.  The planned larger scale study will extend to participants from the 
other two major ethnic groups in Malaysia, namely Malays and Indians. Understanding 
ethnic-group specific mechanisms regulating PC is critical for effective PC diagnostics, 
management and avoiding unnecessary cost-consuming and stressful investigation and 
procedure for patients.  
The discussion chapter consists of a number of sub-chapters which discuss different 
aspects of finding presented in this dissertation as follows:  
i. Participants’ demography: demography of participants from Caucasian and MC 
ethnic groups and ethnic group-related differences.  
ii. Effect of hormonal concentration: discussion of results on hormonal status in 
different ethnic groups and in PC and control participants. 
iii. Effect of genetic polymorphisms: this sub-chapter discusses results of 
identification of polymorphisms in CYP17, SRD5A2 and AR genes in MC and 
Caucasian cancer and control groups.  
iv. General discussion: This sub-chapter critically discusses limitations and inferences 
which could influence results of this study. 
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5.1 Participants Demography 
The participants in this study comprised of 100 Caucasians from Bristol and 100 
individuals from the Malaysian Chinese ethnic group (50 individual in each group, with 
newly diagnosed PC and the other 50 were controls). The participants were all carefully 
selected based on strict inclusion and exclusion criteria discussed in section 3.1.2 of this 
thesis.  
The Malaysian population is known to be heterogeneous and consisting of the three major 
ethnic groups, Malays, Chinese and Indian (Hirschman, 1987). For the purpose of this 
study, only Malaysian Chinese group was selected. The reason for this was the location of 
the University Malaya Medical Centre (a collaborator on this project) at the boundary of 
Petaling Jaya and Kuala Lumpur which is a catchment area for an urban group comprising 
more of the Chinese group. This ethnic group selection enabled us to conduct a quicker 
sample collection for this study.  
In our study, it was noted that participants’ age distribution significantly differed in some 
groups. The Caucasian participants were approximately of the same age with no significant 
difference between PC and the control groups. MC cancer group had higher mean age 
compared to the Caucasian cancer and MC control groups in our research. Overall, taking 
both ethnic groups into consideration, mean age of the PC patients was higher than the 
control group. The main reason for discrepancy in the age in different groups in our study 
is likely due to the effect of the age of MC cancer participants which was the highest. It 
should be noted that in the case of nested case-control studies reported in the literature, the 
age of participants was always well-matched between control and cancer groups (Chen et 
al, 2003, Gann et al, 1996). Margiotti et al (2000) grouped the PC and the recruited control 
participants into age ranges e.g. 51 to 60 years, 61 to 70 years, 71 to 80 years etc. 
However, a research paper by Giwercman et al (2005) on Swedish population, similarly to 
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our study, noted cancer patients group having much higher average age compared to 
control group. Therefore having age differences between participating groups is not an 
unusual situation. 
In the present study, one reason for a higher average age of MC cancer group might be the 
fact that in Malaysia, an uptake of screening tests by the community is low due to various 
reasons including poor information received from doctors, language barrier with leaflets 
not written in languages of the minority ethnic groups, poor socio-economic status, fear of 
the unknown and also religious reasons (Farooqui et al, 2013). One of the studies 
conducted at Hospital Kuala Lumpur, Malaysia demonstrated that patients with PC usually 
seek consultation at later stage of the disease. Majority of the patients undergoing biopsy 
of the prostate in Malaysia are above 70 years of age (Selvalingam et al, 2007) which had 
made it very difficult to recruit participants of the same age across all the groups for the 
present study.   
However, it is important to highlight that in our study, in case of age-difference between 
groups, adjustments for age were made during statistical analysis. These adjustments are 
important due to the fact that the concentration of sex steroids testosterone and DHT as 
well as IGF-I are known to decline with age (Gray et al, 1991) and these steroids are 
thought to be important in regulation of PC development  
Our study also noted that there was difference in PSA level between the groups. The mean 
PSA level of our MC cancer group was very high compared to Caucasian cancer group (by 
9.5 times). This could be due to the fact that MC cancer group included more patients with 
advanced PC compared to the Caucasian cancer patients. This indicates the early and 
localised stage of PC being frequently diagnosed in Caucasians in the UK, which is likely 
to be due to successful PSA screening programme and the high uptake of screening by 
Caucasians (Melia, 2005). Higher socio-economic status with excellent access to 
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healthcare can also contribute to the success of screening programmes in developed 
countries. This is in sharp contrast to Asian countries, where PC patients usually seen at 
hospital late and at more advanced stage of PC (Selvalingam et al, 2007). Higher grade 
(Gleason score) of PC in MC cancer patients can also be due to the same reason of late 
presentation of the cases in this ethnic group. PSA of MC control and Caucasian control 
groups were similar as they were deliberately matched as selection criteria (only those with 
PSA of less than 4 ng/ml were included in the study)  
 
5.2 Effect of androgens and insulin-like growth hormone-I on prostate 
cancer  
5.2.1 Effect of serum testosterone concentration 
It is well known that androgens play an important role in regulation of normal proliferation 
and differentiation of prostate cells, as well as in aetiology of PC (Wu et al, 1995b, 
Buttyan et al, 2000, Takizawa et al, 2010). Wu et al (1995) demonstrated difference in 
concentration of androgens in different ethnic groups in their study in African-Americans, 
White-Americans and Asian-Americans. Buttyan et al (2000) and Takizawa et al (2010) 
showed that PC treatment outcome may be related to androgen status which can be 
manipulated by treatment with androgen deprivation therapy (ADT).  Although there have 
been multiple studies on androgen concentration in different ethnic groups, including 
Americans, European Caucasians and Japanese, data of the literature on relationship 
between PC and androgen concentration  are controversial. (Dorgan et al, 1998, Hsing and 
Comstock, 1993, Sawada et al, 2010). Gann et al (1996) found significant elevation in 
testosterone concentration and DHT/T in relation to PC as also Hsing and Comstock 
(1993).  
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In the study conducted in this thesis, the mean testosterone concentration of Caucasians 
and MC were not significantly different when both cancer and control groups were 
analysed together. Testosterone concentration between the control groups of both, 
Caucasian and MC, were also not significantly different. Therefore results of this study do 
not support the hypothesis that an ethnic group with a higher risk of PC has a higher 
testosterone concentration.  
It is important to highlight that the 2 ethnic groups used in our study were from 2 countries 
(UK and Malaysia) which significantly differ in environmental condition, diet and 
lifestyle. We are aware of only one other study that had an experimental design similar to 
ours, namely comparing two ethnic groups (Dutch and Japanese) from different countries 
(de Jong et al, 1991). The majority of ethnic studies reported in the literature were 
performed on different ethnic groups within the same population which had the same 
environmental exposure. Among these studies, de Jong et al showed that there was no 
significant difference in testosterone concentration between control groups in the Dutch 
and Japanese populations. Litman et al (2006) found no ethnic difference in testosterone 
concentration between Black, Hispanic and White men in the USA. No difference in 
testosterone concentration was observed in the study by Kubricht III et al (1999) who 
analysed testosterone concentration in African-American and White-American patients 
undergoing PC assessment. Results of our study are in agreement with de Jong et al 
(1991), Litman et al (2006) and Kubricht III et al (1999). In contrast to our finding, Wu et 
al (1995) showed that African-Americans had the highest testosterone concentration 
compared to White-Americans, Japanese-Americans and Chinese-Americans. It is known 
that African-Americans have the highest risk of PC followed by the White-Americans and 
the lowest PC risk in Asian-Americans. It has also been reported that the Arabs and 
Chinese have significantly lower mean testosterone concentration compared to Black and 
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White Americans, Germans and Nigerians (Kehinde et al, 2006). One of the reasons for 
controversial data regarding ethnic group difference in testosterone concentration can be 
different age of participants which varied  from 15 years old in the study by Kehinde et al 
(2006) to 60 or above in studies by Wu et al (1995) and Litman et al (2006). It must also 
be taken into consideration that the study by Kehinde et al (2006) on different ethnic 
groups were not performed in a single laboratory using the same laboratory techniques 
which might have affected outcomes of experiments. Therefore, the ethnic group 
differences in testosterone concentration observed by Kehinde et al. (2006) should be 
treated with caution.   
It should be noted that our study was conducted on 100 participants per ethnic group. This 
number was adequate for statistical analysis but it was a relatively small number when 
compared to majority data of the literature based on data collected from up to 300 
participants (Wu et al, 1995b, Kubricht III et al, 1999). Therefore we are not in a position 
to conclude whether ethnic-group differences in testosterone concentration would have 
been observed if the study was conducted on a larger number of samples.  
It was noted in our study that testosterone concentration was able to differentiate PC from 
control cases when data for MC and Caucasian groups were pooled together, with cancer 
patients having a lower mean testosterone concentration compared to the control group. 
When our data were adjusted for age, the MC cancer patients still had a higher average 
testosterone concentration when compared to MC control but this was not the case for 
Caucasians where testosterone concentration was similar in cancer and control groups. Our 
finding on MC group is consistent with a report by Hoffman et al (2000) who analysed 
testosterone concentration in American patients undergoing PC treatment. Hoffman et al 
(2000) showed that low testosterone concentration was positively related to a higher 
Gleason score of 8 or above (i.e. positively related to a more advance stage of PC). As the 
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MC cancer group in our study had more patients with advanced stage of PC then 
Caucasians, this might be an explanation for testosterone concentration differences 
between control and PC in MC but not in Caucasians. Our results suggest that a low 
testosterone concentration might be an indicator of advanced PC.  
In contrast to the mentioned above papers, a substantial number of publications did not 
observe significant variations in testosterone concentration between PC and non-cancer 
cases in Japanese-American man (Nomura et al, 1996), Finnish population (Dorgan et al, 
1998), mixed-American population (Hsing and Comstock, 1993) and Japanese population 
(Sawada et al, 2010). There might be a number of reasons for controversial data of the 
literature regarding relationship between testosterone concentration and PC. These reasons 
could include (but not limited to) differences in the size of groups studies, the use of 
different laboratory techniques for testosterone analysis (radioimmunoassay (RIA) and 
electro chemiluminescence immune assay (ECLIA)). For example, Gann et al (1996) 
showed a significant positive relationship between PC risk and a higher circulating 
testosterone concentration in a nested case-control study in USA using the RIA laboratory 
technique. Chen et al (2003) showed that no significant testosterone association with PC in 
a study using the RIA technique. Severi et al (2006) showed no significant association of 
testosterone with PC in a study of more than 500 participants using the ECLIA technique 
in Australians.    
Another reason for a lower testosterone concentration in MC cancer group in our study 
when compared to MC control might be a higher rate of conversion of testosterone to DHT 
in the prostate gland in MC cancer patients and thus, reduction in circulating testosterone 
concentration. Further investigation is needed into this hypothesis. However, there are 
some data of the literature which suggest different rate of steroid metabolism in different 
ethnic groups as indicated by a research in a mixed USA population where the estradiol 
 183 
 
concentration was found to be highest in non-Hispanic blacks followed by non-Hispanic 
whites compared to Mexican-Americans (Rohrmann et al, 2007). Another global ethnic 
study found that Black men (from USA and Tobago) had higher oestrogen levels than 
Caucasians and Asian men (Orwoll et al, 2010). Different pathological condition like 
breast cancer can influence sex steroids metabolism and the level of hormones such as 
estrogens and their derivatives (Hankinson et al, 1998). Hankinson et al (1998) described 
that there was strong positive relationship between post-menopausal oestrogens level and 
breast cancer. Increased risk of breast cancer was also noted with elevated concentrations 
of testosterone, androstenedione and dehydroepiandrosterone sulphate (Kaaks et al, 2005).  
 
5.2.2 Effect of serum dihyrotestosterone and dihydrotestosterone to testosterone 
ratio  
DHT is the other principal prostatic androgen which is produced from testosterone in a 
reaction catalysed by 5ɑ-reductase (Feldman and Feldman, 2001). In this study, we 
analysed not only DHT concentration in control and PC groups of Caucasian and MC 
populations, but also the ratio of DHT to testosterone. This ratio indicates the amount of 
DHT which has been produced from available testosterone in the circulation. It can be used 
as an indicator of hormones interaction and as an indicator of 5α-reductase activity 
(Feldman and Feldman, 2001). Our research demonstrated that unadjusted (for age) mean 
DHT concentration was higher in the Caucasians than the MC when the cancer and control 
cases were analysed together. However, the mean DHT/T ratio in the MC ethnic group was 
higher than in Caucasians. We expected both, DHT concentration and DHT/T ratio to be 
elevated in the ethnic group with higher risk of PC, i.e. in Caucasians. Our result was in 
agreement with Litman et al (2006) who showed that DHT concentration was higher in 
black men when compared to Hispanics and white men in USA population which is 
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consistent with the higher incidence of PC in the black community in USA. This is not 
consistent with results of our study where DHT/T was lower in a population with higher 
incidence of PC (Caucasians compared to MC). Wu et al (1995) also reported that the 
DHT concentration was highest in African-Americans, followed by Japanese-Americans 
with the lowest values in white Americans and that these differences were statistically 
significant. On the other hand, de Jong et al (1991) group observed significant differences 
in DHT/T but not in DHT concentration in study on Dutch and Japanese man.  
Our study also found that unadjusted (for age) DHT concentration was significantly higher 
in the controls than in the cancer group when results for men from both ethnic groups were 
pooled together. Similar to situation described above with testosterone, age factor played a 
very important role as confounding factor in the study on DHT. After adjusting for age, the 
noted above differences in DHT between control and PC and between the ethnic groups 
were not significant.  
In our study, cancer patients had a higher DHT/T compared to controls when data of both 
ethnic groups pooled together. We also found that DHT/T was higher in the MC cancer 
patients compared to the Caucasian cancer group and the MC control group. This finding is 
not in agreement with some literature reports. Mohr et al (2001) did not find differences in 
DHT and DHT/T between cancer and control groups in a USA -based study using  
prediagnostic blood samples (i.e. samples collected during patients recruitment and 
analysed after establishing PC ) from participants who were under observation for potential 
PC development for  up for 8 years. A study by Dorgan et al (1998) in a Finnish 
population also did not show any difference in DHT and DHT/T between control and PC 
cases. Furthermore, Nomura et al (1996) did not find significant association between DHT 
and DHT/T with PC in a study on Japanese-Americans. Another study by Gann et al 
(1996) also showed no difference in DHT concentration among Caucasian-Americans. Our 
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study showed a significant increase in DHT/T in the MC cancer group but it remains 
unclear whether this is due to ethnic reasons. The presence of more advanced PC cases in 
the MC cancer group when compared to Caucasians (rather than ethnicity as such) could 
have influenced DHT/T ratio. This is an important finding in an ethnic group with low PC 
incidence like the MC. Future larger multi-ethnic studies may be needed to confirm effect 
of ethnicity and advanced PC on DHT and DHT/T and to evaluate suitability of DHT and 
DHT/T as potential markers for PC.  However, there are also publications which did not 
find significant relationships between DHT concentration and PC but observed relationship 
between DHT/T and PC. For example, Hsing and Comstock (1993) demonstrated that 
there was no significant difference in the concentration of DHT but there was a non-
significant increase in risk of PC with increasing DHT/T. DHT and testosterone are usually 
analysed together and the probable reasons for the inconsistency in the results by different 
authors are the same for both hormones as described in section 5.2.1 above. Some generic 
differences across all the studies above are also described in detail in section 5.5 below.  
 
5.2.3 Effect of insulin-like growth factor-I 
In addition to testosterone, IGF-I is viewed as an important factor which can be associated 
with PC. An association between circulating IGF-I concentration and PC was first 
documented in 1997 by (Mantzoros et al, 1997) followed by studies in larger population 
(Wolk et al, 1998, Harman et al, 2000). Results reported in this project has shown that 
there was an inverse relationship between IGF-I concentration and PC cases with lower 
IGF-I concentration in cancer cases when data for both the ethnic groups were pooled 
together. At the same time we observed a significantly higher mean IGF-I concentration in 
the Caucasian groups compared to the MC but this is likely to be an effect of age as the 
ethnic differences were not observed after adjusting for age. No significant differences 
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were observed between Caucasian controls and MC controls in our study. It is difficult to 
compare our findings with data of the literature as publications were scarce on direct 
comparison of non-cancer groups from population with different ethnic background. Most 
of the studies compared only cancer vs. controls by clumping the population together 
without ethnic breakdown. . The only study available on comparison of control groups is 
from Arab population which showed that the IGF-I concentration in control Arab group 
was lower when compared to control Caucasians (Kehinde et al, 2005). However, it should 
be taken into account that this study by Kehinde et al (2005) was not performed in a single 
laboratory and the comparison was based on information available in the literature. 
Caucasian cancer patients in our study had a statistically significant higher mean IGF-I 
concentration compared to the MC cancer. Although the mean IGF-I concentration was 
lower in PC patients of both the Caucasian and MC groups compared to their counterparts 
in the non-cancer groups, this IGF-I test was able to significantly differentiate the cancer 
cases in the two ethnic-groups from the controls in the same ethnic group. The results in 
this study did not concur with most of the studies published where there seem to be 
multiple evidences to show that increased circulating IGF-I is a good indicator of PC risk 
in the population studied (Stattin et al, 2004, Price et al, 2012, Platz et al, 2005, Chan et al, 
2002, Chokkalingam et al, 2001). In particular, Chan et al (2002) showed in a mixed USA 
population that high IGF-I is a good predictor of advanced PC which is in contrast to our 
finding that showed lower IGF-I concentration in MC group which had the higher number 
of patients with advanced PC. Chokkalingam et al (2001) demonstrated positive 
association between PC risk and IGF-I in the same ethnic group (Chinese). A Swedish 
study by Stattin et al (2004) also reported similar strong positive association between PC 
and circulating concentration of IGF-I. Another USA study by Platz et al (2005) and a 
European study involving multiple countries concurred with the above literature reports. 
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Our study did not find significant difference in IGF-I concentration between PC and 
control in Caucasians. Furthermore, in the MC group we observed an inverse relationship 
between these two parameters. This is consistent with results of a number of publications 
that did not find positive association between IGF-I concentration and PC (Borugian et al, 
2008, Chen et al, 2005, Allen et al, 2007). In particular, Chen et al (2005) and Borugian et 
al (2008) demonstrated that circulating IGF-I concentration was not associated with 
increased risk of PC in a mixed USA population. A multinational European study by Allen 
et al (2007) also did not find any relationship between increased IGF-I concentration and 
PC risk.  
In our study, the statistical analysis were extended to investigate whether any of the 
hormonal assays (testosterone, DHT and IGF-I), either individually or in combination 
could be used to aid PSA as a screening tool and to establish ethnic-group specific 
screening test. Results of our study suggest that detection of testosterone in combination 
with IGF-I might potentially be useful for PC detection in Caucasians and MC groups. 
DHT/T also has a potential for being used as a PC screening test in MC ethnic group (but 
not in Caucasians). However, these results need to be treated with caution as they are true 
for a relatively small cohort used in the present study but need to be confirmed on a larger 
cohort. To the best of our knowledge, there are not data of the literature that analysed 
diagnostic capability of concentration of hormones either individually or in combination. 
 
5.3 Effect of genetic polymorphisms on prostate cancer  
Genes that are known to be polymorphic can be analysed to determine whether the 
presence or frequency of their variants are related to hormonal profiles (Wirén and Stattin, 
2008). Experiments conducted in this thesis evaluated polymorphisms in the three genes 
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that encode for key enzymes controlling androgen metabolic pathway (Figure 2.12) as 
follows: 
i. CYP17 gene that encodes for the enzyme cytochrome P450 17ɑ-hydroxylase which 
is involved in the regulation of testosterone biosynthesis. 
ii. SRD5A2 gene that encodes for the enzyme 5ɑ-reductase which is important in the 
regulation of the conversion of testosterone to DHT. 
iii. The number of CAG repeats in AR gene which affects activity of this gene. 
The following part of the thesis will discuss the findings in our thesis and compare them to 
data of the literature and address the issues related to inconsistencies in the findings 
between studies.  
5.3.1 Polymorphism in the CYP17 gene and its association with prostate cancer risk  
In this experiment, the presence of genetic polymorphism in CYP17 gene at position -
34T→C was examined in Caucasian and the MC groups. The presence of homozygous A1 
allele and A2 allele or a heterozygous A1/A2 allele was determined. Our study 
demonstrated that there were no significant difference in the frequency of the above three 
alleles in the Caucasians and MC when the cancer and control cases were analysed 
together.  The A1, A2 and A1/A2 alleles were seen in 59%, 18% and 23% of Caucasians 
compared to 65.7%, 22.2% and 12.1% of MC participants respectively when data for 
cancer and control participants were combined. These data suggest that -34T→C 
polymorphism in CYP17 gene cannot be considered as a good marker for ethnicity. Most 
of the studies reported in the literature investigated frequency of -34T→C polymorphism 
in CYP17 gene amongst PC and control within the same ethnic group. One of the studies 
on USA populations compared frequency of CYP17 polymorphism at position -34T→C 
between the American-Caucasians and American-Blacks (Lunn et al, 1999). Data of this 
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study were similar to our finding that there was no ethnic difference in the frequency of 
CYP17 polymorphism at position -34T→C. 
A study in an Austrian population showed that A2 allele was more frequent in PC cases 
(23.8%) compared to the BPH control group (9.5%) (Gsur et al, 2000). Yamada et al 
(2001) also demonstrated in Japanese ethnic group that the A2 allele was more frequent in 
PC group (18.8%) than in control group (14.5%). Results of our  study noted that MC PC 
patients had higher frequency of A2 allele (26%) compared to control participants (18.4%) 
in agreement with findings of Gsur et al (2000) and Yamada et al (2001). Our data are also 
in agreement with reports by Lunn et al (1999) who showed higher frequency of A2 allele 
in the Caucasian PC patients compared to the Caucasian control participants in USA, and 
with data of Karimpur-Zahmatkesh et al (2013) who reported higher frequency of A2 
allele in the PC group compared to the control group in Iranian population. However, the 
Caucasians in our study exhibited higher frequency of the A2 allele in the control group 
(22%) compared to the PC group (14%). The frequency of A1/A2 allele in both the 
Caucasians and the MC PC groups in our study were higher compared to the control 
groups. These results was not in agreement with Lunn et al (1999), Gsur et al (2000) and 
Yamada et al (2001) who found no significant difference in the A1/A2 frequency between 
PC and control groups.   
The present study established that presence of A1/A2 was associated with a significantly 
increased risk of PC development compared to the men with A1 allele only when data for 
Caucasian and MC groups were analysed together. Men with A2 allele, showed a non-
significant increase risk of PC compared to those with A1 allele. When the data were 
analysed for each ethnic group investigated, it was found that association between A1/A2 
allele and PC risk was significant in the Caucasians. We noted that the risk of PC in the 
MC group non-significantly increased in association with A1/A2 allele. In men with A2 
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allele, the risk of PC was non-significantly increased in the MC but not in the Caucasians. 
We also found that the combination of A2 or A1/A2 alleles increases the risk of PC in both 
Caucasians and MC but this association was not significant.  
There are multiple epidemiological studies indicating that the polymorphism in the -
34T→C position of CYP17 is associated with an increased risk of PC as detailed below. A 
study on Japanese population demonstrated that presence of A2 allele was positively 
associated with risk of PC development (Yamada et al, 2001). Association of A2 allele 
with increased risk of PC was also reported by Lunn et al (1999) in USA Caucasian 
population when compared to USA Black population. A significant association of A2 
allele with PC was demonstrated by Karimpur-Zahmatkesh et al (2013) in a study on PC 
patients and healthy controls in Iran. Gsur et al (2000) reported a significant association 
between A2 allele and PC risk on Austrian population.  
Our study did not find significant association between A2 and PC risk in MC and 
Caucasians. This does not agree with results reported by Sobti et al (2009) on positive 
association between A2 allele frequency and PC risk in a South Indian population. A study 
in a Tunisian population comparing PC patients and healthy controls showed that presence 
of A1/A2 or A2 allele increases the risk of PC by two-fold in this community (Souiden et 
al, 2011).  
A study in a Chinese cohort (Madigan et al, 2003) did not find significant association 
between PC risk and any of the CYP17 genotypes but suggested an increasing trend in PC 
risk with increasing frequency of A1 and A1/A2 alleles. Our study partially agree with 
Madigan et al (2003) as we also found a significant association of A1/A2 allele with PC 
risk in the Caucasians and an increasing trend in MC group.  
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It should be noted that majority of the studies reported in the literature have been 
performed on control and cancer cases in a single population with an exception of Lunn et 
al (1999) who compared the American Caucasians and Black populations. This thesis is 
the first report when analysis of genetic polymorphisms was performed in two different 
communities from different living environment simultaneously. This might form a basis 
for further study on ethnic group-specific PC genetic markers.  
It is important to highlight that Severi et al (2008) in study on Australian Caucasian group, 
dos Santos et al (2002) in study on Brazilian population and Chang et al (2001) in study on 
a mixed American population did not find association between the mentioned above 
CYP17 polymorphisms and PC risk. Two large meta-analyses have been published on 
association of CYP17 gene at -34T→C with PC risk among studies conducted in 
Caucasians, Asians and of African descent. The first report by Ntais et al (2003) showed 
no significant risk of PC associated with any of the alleles in this gene as was also 
described by another larger meta-analysis (Wang et al, 2011)when data from all ethnic 
groups were pooled together. In contrast, we found significant risk of PC in the presence of 
A2 or A1/A2 alleles in combination in our study. When the results were analysed by ethnic 
groups, Ntais et al (2003) and Wang et al (2011) concluded that A2 allele was associated 
with significant increase of PC risk in population of African descent and not the 
Caucasians and Asians. A1/A2 allele was reported to have no association with PC risk in 
any of the ethnic groups in the above two reports. Our study agrees that A2 allele was not 
associated with PC risk in Caucasians and MC but and increasing trend suggested in the 
MC needs to be looked at in future study to make a definite conclusion. Our report also 
contradicts the finding of the two meta-analyses above in that the A1/A2 allele in our 
Caucasian cohort was significantly associated with PC risk,  
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In our research, a coincidental SNP in CYP17 coding region were indentified during 
amplification and sequencing of a 500bp segment of CYP17 gene. The coincidental 
polymorphism was identified at the position 135C→T. There was no significant increase in 
the frequency of the C, T or C/T allele in the Caucasians compared to the MC in our 
experiments. When data from both ethnic groups were pooled together, no difference in 
frequency of the polymorphism was found between PC and control groups. As far as PC 
risk was concerned, no association was found with C, T or C/T allele in Caucasians and 
MC in our study. To the best of our knowledge, this polymorphism at 135C→T of the 
CYP17 gene has not been reported in any study in relation to the incidence or risk of PC. 
Therefore, we were unable to discuss our finding with data of the literature. 
CYP17 gene is a highly polymorphic gene and other SNPs that have been studied with 
regards to PC risk  including that analysed by Beuten et al (2009) at 5’-untranslated region 
rs284851, rs619824, rs10883782, rs1004467, rs17115144, rs2486758). No association 
between these SNPs and with PC risk was found in the Hispanic Caucasians, non-Hispanic 
Caucasians and African-Americans. Another African-American study also showed no 
significant association between PC risk and SNPs rs10883783 at intron 7, rs6163 at codon 
65 of exon 1 (Sarma et al, 2008). There has also been interest in studying polymorphism at 
the position -34T→C of CYP17 gene in relation to its association with other diseases such 
as breast cancer. The study by Feigelson et al (1997) reported positive association between 
advanced breast cancer and frequency of CYP 17 A1/A2 and A2 allele. Further evaluation 
of relationship between coincidental polymorphism identified in our study and PC risk is 
required on a larger number of samples.  
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5.3.2  Polymorphisms in the SRD5A2 gene and their association with prostate 
cancer  
 
5.3.2.1 Polymorphism at position 261C→G 
SRD5A2 gene has been considered as one of the most important genes in PC development. 
It encodes for a key enzyme in the prostate gland (5ɑ-reductase) that catalyses the 
conversion of testosterone to DHT in androgen metabolism (Coffey, 1993). The 
substitution of amino acid Val to Leu at codon 89 due to the SNP C to G nucleotide at 
position 261 is supposed to give protection from PC development (Makridakis et al, 2000). 
This is due to the postulation that this polymorphism reduces activity of the enzyme that 
converts testosterone to DHT thus reducing the circulating DHT concentration (Makridakis 
et al, 2000). It is therefore expected that a population with a higher incidence of PC should 
have a higher prevalence of Val whereas, population with low incidence should have a 
higher frequency of Leu. 
 Our study demonstrated that in control groups the frequency of VV genotype was higher 
in the Caucasians than the MC group. LL and L/V genotype was more frequent in MC than 
Caucasians. This ethnic difference was statistically significant. Our data are in agreement 
with a report by Ziegler-Johnson et al (2002) which demonstrated that LL or L/V genotype 
is most likely in Asians and least likely to be carried by the Africans. Intermediate 
frequency of the genotype was noted in Caucasians and African-Americans. Frequency of 
LL and L/V genotype follows the same ethnic group pattern as PC incidence with the 
lowest frequency observed in Asia (Ferlay et al, 2010a). Based on the finding of lowest 
frequency of the LL or L/V genotype in the Africans, the incidence of PC should ideally be 
the highest in African population but it is not the case because of the possible large 
underestimation of the number of cases reported in Africa (Osegbe, 1997). Comparison of 
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LL and L/V genotypes frequency in Asians, Caucasian and Black-Americans showed that 
American (Caucasian and Black) ethnic group had the world highest incidence of PC this 
ethnic group. Results of our work is also consistent with data of Li et al (2010) who 
reported the frequency of the LL or L/V genotype to be higher in Asians than in Caucasian. 
The risk assessment for PC development in our study showed  that LL or the LL + L/V 
genotype had a non-significantly higher PC risk compared to VV genotype  when data for 
all the participants were pooled together. Salam et al (2005) demonstrated the risk of PC 
was significantly higher in Hispanics and non-Hispanic Americans with the presence of the 
LL or L/V genotypes. Our findings showed an increasing trend in the risk of PC but it may 
be inappropriate to compare our finding with Salam et al (2005) because of the use of 
different ethnic groups in these two studies. A study in French Caucasian population 
(Cussenot et al, 2007) also demonstrated increased PC risk in men with LL genotype. 
Results of our study are consistent with data of Giwercman et al (2005) who reported an 
increased frequency of LL genotype in PC patients in Swedish-Caucasians and with results 
of meta-analysis undertaken by Wang et al. (2010) who observed increased risk of PC in 
European population (with higher frequency of LL) compared to the Asians and Africans. 
In contrast to our data, Margiotti et al (2000) had shown a reduced PC risk in an Italian 
population with high frequency of LL genotype. One of the reasons for this disagreement 
can be the fact that Margiotti et al (2000) worked on a smaller number of participants and 
that the participants were older (70-110 years) than in our study (40-80 years). 
As far as Asian population is concerned, it was shown in a Japanese cohort that frequency 
of LL genotype was higher in PC cases than in controls (Yamada et al, 2001). This is in 
contrast to our study where a trend toward reduction of PC risk in the case of LL or LV 
genotypes was observed in MC group. A trend of PC risk reduction for LL or LV genotype 
was also described by Hsing et al (2001). This might be an indication of a protective nature 
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of this genotype in Asian groups as suggested by Makridakis et al (2000), Ziegler-Johnson 
et al (2002) and Li et al (2010). 
In addition to the data of literature which found either positive or negative association 
between PC and LL or LV genotype, several authors have shown no association at all 
between these genotypes and PC risk. These reports were by Onen et al (2007) in Turkish 
population, Hayes et al (2007) in Australian Caucasians and Rajender et al (2009) in South 
Indians. Except for Hayes et al (2007), the other two reports were from small cohorts in 
their respective populations which might be one of the reasons for lack of associations. The 
other reasons for discrepancy of data of the literature could be age-differences of recruited 
patients, including PC patients with different stages of the tumour development and 
inconsistent use of controls (either BPH or healthy controls). In summary, the 261C>G 
polymorphism in SRD5A2 gene that results in Val to Leu substitution (i.e. LL genotype) is 
associated with increased risk of PC in Caucasian group. To the best of our knowledge our 
study is the first report which provides data on the SRD5A2 polymorphism in South-East 
Asian population. These data can form the basis for designing a larger study on the role of 
this polymorphism in PC risk in different ethnic groups in Malaysia.    
 
5.3.2.2 Polymorphism at position 140G→A 
Another important SNP in SRD5A2 gene is rs9282858 which was found in the exon 1 at 
codon 49. This SNP is a nucleotide substitution at the position 140G>A resulting in amino 
acid substitution (Ala (A) to Thr (T)) (Makridakis et al, 2000). Functionally, this amino 
acid substitution can increase the activity of the 5α-reductase enzyme, thus increasing the 
conversion of testosterone to DHT which can actively cause the cancerous changes in the 
prostate (Makridakis et al, 1997, Zeigler-Johnson et al, 2002). Hypothetically, frequency 
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of this polymorphism should be higher in a population with high incidence of PC and in 
individual with PC when compared to non-cancer cases.  
Our study did not establish presence of T genotype in either Caucasians or MC; or cancer 
and control groups. This is in agreement with other studies when T genotype was not 
present in cancer or control cases in Japanese (Yamada et al, 2001), Turkish (Onen et al, 
2007), Chinese (Hsing et al, 2001), or Italian populations (Margiotti et al, 2000) and in 
South Indian population (Rajender et al, 2009). 
In a study on mixed American population, where the T genotype was present, no 
association between frequency of this genotype and PC was established (Torkko et al, 
2008, Salam et al, 2005). This is consistent with data of a meta-analysis conducted by Li et 
al (2010) who did not find evidence of association between increased risk of PC and 
frequency of T genotype compared to A genotype.  
In contrast to the above, Makridakis et al (1999) demonstrated in a study on African-
American and Hispanic USA cohorts that  PC risk increases by 7.2-fold and 3.6-fold in 
both population respectively in the presence of T genotype compared to the A genotype. A 
contradicting report was presented by Hayes et al (2007) on Australian population where 
60% increased PC risk was observed in the presence of the A genotype compared to the T 
genotype.  
Similarly to 261C>G polymorphism reported in the previous chapter, there is very limited 
information on frequency of 140G>A polymorphism in the SRD5A2 gene and its 
association with PC risk and incidence in Asian population. Although our study did not 
find any polymorphism at position 140G>A in both Caucasians and MC groups or in PC or 
control groups, it will be interesting to investigate further whether this polymorphism is 
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present in other ethnic groups, such as Malays and Indians in the multi-ethnic Malaysian 
population.  
  
5.3.3 Polymorphism in AR gene in relation to prostate cancer 
The androgen receptor (AR) is activated by binding of testosterone and, to a greater extent, 
(Huang and Tindall, 2002). The AR gene is located on Xq11-12 (Kral et al, 2011, Brown 
et al, 1989). This study assessed the number of AR trinucleotide CAG-repeats in PC and 
control participants in Caucasians and MC ethnic groups. It has been reported in the 
literature (although not consistently) that an increased number of CAG-repeats is likely to 
decrease transactivation and binding activity of AR which can lead to reduction of PC risk 
(Chamberlain et al, 1994). In contrast, reduction in the number of CAG-repeats may 
increase the risk of PC (Ekman et al, 1999, Nicolaiew et al, 2009). It has been reported that 
African-Americans generally have shorter CAG-repeats and higher PC risk compared to 
the Whites and Asians (Kral et al, 2011, Coetzee and Ross, 1994). 
Our study demonstrated that the mean number of CAG repeats was slightly increased in 
the MC group compared to the Caucasians (both cancer and control participants) but 
statistical significance was not established. Our study also demonstrated a higher mean 
number of CAG-repeats in cancer patients compared to the control participants when data 
for all the men were pooled together. There was no interaction noted between the ethnicity 
and disease status of the participants which mean that there were no differences in the 
CAG repeat length between the 4 sub-groups (namely, Caucasian cancer, Caucasian 
control, MC cancer and MC control). Absence of ethnic differences in CAG repeat length 
in our study is consistent with data of the literature. Price et al (2010) did not find 
differences in CAG-repeat length between control and cancer groups in Hispanic White 
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population. In agreement with this study, Lange et al (2008) did not observe significant 
association between CAG repeat length less than 21 and PC incidence. Results of our study 
are also consistent with a report by Huang et al (2003) on Taiwanese population, and with 
a study by Edwards et al (1999) on British Caucasian populations who did not find 
differences in CAG repeat length between PC and control cases. Although all the studies 
above have shown no association between the CAG-repeat length and PC, there is 
significant number of studies that reported different results. One of the studies in Chinese 
population have shown that a smaller number of CAG-repeats (less than 22) (Zhai et al, 
2014) increases the risk of PC, and another Chinese study (Hsing et al, 2000) showed 
increased PC risk in case of CAG repeats of less than 23. It should be noticed that there is 
inconsistency regarding the number of CAG-repeats associated with PC (a cut-off for CAG 
repeats). It is also not clear how the cut-off number was determined. A study on a mixed 
American population (Giovannucci et al, 1997) reported a cut-off at  less than or equal to 
18 CAG-repeats , and a study in non-Hispanic Whites (Ingles et al, 1997) reported a cut-
off  at less than 20 CAG repeats. Both studies reported significant association between PC 
at these cut-off points. An Iranian population study (Ashtiani et al, 2011) reported that the 
average number of CAG-repeat in PC patients was significantly smaller than control 
group. Krishnaswamy et al (2006) also agreed with the above author in a study on South 
Indian population where a number of CAG repeat was smaller in PC patients than in 
control. However, the average CAG repeat length was different in both Iranian and South 
Indian PC patients and was 19.9 and 17.0 respectively for PC compared to 22.8 and 20.7 
respectively for controls.  
A recently published meta-analysis demonstrated that AR with over 20 CAG repeats have 
a protective effect on PC risk and incidence (Gu et al, 2012).  Taking into account 
controversial data of the literature on association between CAG repeats length and PC and 
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a relatively small number of participants in the present study, it will be interesting to 
evaluate further the above association on a larger group of patient across various ethnic 
groups using the same study protocol. This, in particular, refers to Malaysia, which is a 
multi-ethnic population. 
 
5.4 Relationship between genetic polymorphisms and steroid hormone 
concentration 
Rational for analysis of relationship between genetic polymorphisms and concentration of 
circulating hormones in this study was the hypothesis that increasing androgens and IGF-I 
concentration can increase risk of PC. It has been reported in the literature that -34T→C 
SNP in CYP17 gene can increase CYP17 activity in Caucasians thus, potentially 
increasing biosynthesis of testosterone (Carey et al, 1994). It was demonstrated in 
experiments on mixed-American ethnic groups in Los Angeles and Hawaii that SRD5A2 
gene polymorphism in the position 261C→G causes amino acid substitution from Val to 
Leu at codon 89, This amino acid substitution is associated with reduced 5ɑ-reductase 
enzyme activity, which could, in turn, reduce the production of DHT (Makridakis et al, 
1997). The other polymorphism in the SRD5A2 gene at position 140G→A has been 
reported to result in Ala to Thr amino acid substitution at codon 49. This substitution is 
associated with increase in 5ɑ-reductase enzyme activity and thus elevated DHT 
concentration is expected (Jaffe et al, 2000). Increase in CAG-repeat length in AR gene 
has been suggested to reduce the risk of PC by reducing transactivation activity of the AR 
after binding of DHT to AR (Brown et al, 1989).  Defective binding of DHT to AR due to 
the polymorphic CAG-repeat length might affect the signalling of androgen response 
elements like PSA and growth factors (Heinlein and Chang, 2004).  
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Our study did not find significant relationship between testosterone or DHT concentrations 
and CYP17 polymorphism at the position -34T→C in Caucasian and MC cancer and 
control groups. At the same time, the present study has noted a significant positive 
relationship between the above CYP17 polymorphisms and circulating IGF-I concentration 
in the Caucasian control group but not in the Caucasian cancer, MC control or MC cancer 
groups. Our results are in agreement with other study on a UK population which showed 
that serum testosterone concentration was not affected by CYP17 -34T→C polymorphism 
in men (Allen et al, 2001). This is consistent with report by Severi et al (2007) who found 
that serum testosterone concentration was not related to the CYP17 polymorphism at -
34T→C in Australian cancer and control cohorts.   
Similarly, a report from USA on a predominantly White population showed that the 
testosterone and DHT concentrations in participants with CYP17 A2 and/or A1/A2 alleles 
did not differ significantly between PC and control participants (Haiman et al, 2001). The 
research undertaken in this thesis demonstrated that there was no significant relationship 
between SRD5A2 gene polymorphism at the position 261C→G, circulating testosterone 
and DHT concentrations in Caucasian cancer, MC control and MC cancer groups. 
However, in case of Caucasian control group, we observed increased serum testosterone 
concentration in individuals with the mentioned above SRD5A2 polymorphism. This 
finding is consistent with a report by Hsing et al (2001) who also showed a higher 
testosterone concentration in the presence of the SRD5A2 polymorphism in control 
participants. This may be due to a lower rate of conversion of testosterone to DHT in the 
prostate gland. Testosterone that had not undergone the conversion in the prostate gland 
may leak back into circulation and increase serum testosterone concentration.  
Our results are not in agreement with study by Allen et al (2001) who did not observe 
significant relationship between SRD5A2 polymorphism at 261C→G and serum 
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testosterone concentration in UK control population. Hsing et al (2001) and Hayer et al 
(2006) did not find significant association between the SRD5A2 polymorphisms and DHT 
or testosterone concentrations either. Our study established that IGF-I concentration in the 
Caucasian cancer group were significantly elevated in the presence of SRD5A2 
polymorphism at the position 261C→G. We are unable to discuss this finding as, to the 
best of our knowledge, relationship between the above polymorphisms and IGF-I 
concentration has not been reported before. One of the reason for lack of information on 
this topic might be a low interest in looking at the relationship between IGF-I and the gene 
which is not directly involved in IGF-I biosynthesis.    
Our study, did not establish relationship between the mean number of CAG-repeats length 
and serum testosterone, DHT or IGF-I concentration. These results are consistent with the 
study by Platz et al (2005) who reported no association between testosterone or DHT and 
the length of CAG-repeats in USA healthy men. However, an earlier study in the USA by 
Krithivas et al (1999) showed that testosterone concentration declined in individuals with a 
shorter CAG-repeat length but the report did not elaborate on the repeat length. At the 
same time, the study by Krithivas et al. (1999) did not find any association between the 
number of CAG repeats and DHT concentration (Krithivas et al, 1999). It should be noted 
that there is very limited literature on association of CAG repeats with concentration of sex 
steroids and therefore it is not possible to have a more extensive discussion of this topic. 
 
5.5 Inferences and limitations of the study. 
Research undertaken in this thesis was performed on Bristol Caucasians and MC men, and 
it  is the first study which analysed a Malaysian ethnic group for all the parameters such as 
testosterone, DHT, IGF-I as well as genetic polymorphism in CYP17, SRD5A2 and AR in 
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comparison to a Caucasian group. This study was a prospective study designed carefully to 
include only cases selected using identical criteria in both populations. This study was also 
conducted using uniform blood storage and laboratory techniques to minimise potential 
effect of selection bias and heterogeneity of the study group.  
Although, overall participant number of 200 is quite high and statistically had sufficient 
power to generate valid data, it should be noted that the subgroups (i.e. various ethnicity 
and disease status) comprised of smaller numbers. Therefore interpretation of relationships 
between hormonal status, genetic polymorphisms and PC with ethnic groups must be 
treated with caution. Nevertheless, the data generated in this study provide important 
baseline data for designing future studies on other or larger ethnic groups.  
 One of the challenges in analysing results of this study in the light of data of the literature 
is the fact that majority of literature reports, especially studies on hormonal assessment, are 
nested case-control studies which analysed samples stored for a long period of time 
(Sawada et al, 2010, Price et al, 2012) whilst our study analysed samples that were 
obtained after the diagnosis of PC. The PC and control samples in our study were not 
stored for more than 6 months before analysis. Furthermore, the samples used in the 
literature reports were pre-diagnostic (Chen et al, 2003, Rowlands et al, 2012) in contrast 
to our study where the samples were obtained post-diagnosis. Research on stored samples 
has established that stability of bio-molecules will not be affected if the storage condition 
is ideal. The stability of inflammatory factors like interleukins and coagulation factors was 
not affected when stored at -70oC for a period of 6 years (Lewis et al, 2001). Samples that 
was stored at -20oC and -40oC showed degradation in some parameters like cholesterol, 
fibrinogen and creatinine compared to those stored at -80oC or -180oC (Elliott et al, 2008). 
Sex steroid hormones have been reported to be more stable than other proteins stored at -
70oC for up to 15 years (Barrett-Connor et al, 1990). Data of the literature with regards to 
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genetic studies were mainly case-control studies with blood sample collected from newly 
diagnosed PC cases similarly to the blood collection procedure in our study (Torkko et al, 
2008, Krishnaswamy et al, 2006). The genomic DNA in our study was isolated within 2 
weeks of blood collection which was similar to other studies and the genomic DNA stored 
at -20oC till ready for analysis.  Genomic DNA is known to be stable in blood stored at -
70oC giving good yield for up to 14 days (Polakova et al, 1989). Isolated DNA integrity 
has been reported to be stable for 7 years in solution form at -20oC (Madisen et al, 1987). 
As far as hormonal study is concerned, we are of the opinion that a pre-diagnostic serum 
sample may not reflect the changes due to the influence of environment and lifestyle that 
preceded the diagnosis of PC, therefore a prospective sample collected may be a better way 
to obtain reliable results.  
Another important aspect of our study is that during the participants’ selection stage, we 
aimed to achieve the best possible age-match between the cancer and control groups and 
between Caucasian and MC groups. However, in spite of all the effort, the MC cancer 
group had older participants when compared to Caucasians and MC control. This was due 
to cultural differences between Caucasians and MC with MC normally seeing the doctors 
at later stages of PC and at older age (Selvalingam et al, 2007). In our study we attempted 
to take into account potential effect of older age of MC cancer group by including age as 
confounding factor in statistical analyses. Nested case-control studies are usually well-
matched for age because the selection of controls is based on the average age of PC cases 
(Gann et al, 1996). When there is a discrepancy in the mean age between PC and control 
group, a statistical adjustment is made as reported by Giwercman et al (2005).  
Another important feature of our study is that our control groups comprised of Benign 
Prostatic Hyperplasia (BPH) cases in which the possibility of having PC is generally low. 
This low risk of PC is based on analysis of PSA level of < 4 ng/ml, outcomes of normal 
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digital rectal examination and absence of family history of PC (Heidenreich et al, 2011). 
This, however, does not discount a possibility of presence of occult cancer because a low 
PC risk is still possible even in cases with the mentioned above criteria (Schroder et al, 
1998, Schröder et al, 2000). Composition of our control group is quite different and, we 
believe, is more accurate and appropriate, when compared to control groups described in 
the literature. Some of the reported studies on PC use diverse control groups which include 
healthy individuals and some individuals with either symptomatic or asymptomatic BPH 
(Kehinde et al, 2005, Platz et al, 2005, Das et al, 2008).  It is important to note that studies 
using healthy controls could be misleading, because the age of these participants should be 
over 45 years. It is known that prostate gland starts naturally enlarging from the age of 45 
onwards and enlargement of the prostate gland itself does not mean predisposition to 
development of PC (Schatzl et al, 2002). It is very difficult to rule out BPH in these 
healthy individuals who are age-matched with the PC group, because prostatic enlargement 
invariably exists even when PC symptoms are absent as described by Lilja et al (2008). It 
is known that BPH is definitely not a risk factor for PC development (Lilja et al, 2008). 
Therefore, selection of BPH patient who have a low risk of occult PC is justified for their 
inclusion in control group in our study. 
Data of the literature contain controversial results on hormonal changes in PC patients as 
described in section 5.2.1 and 5.2.2 above. One of the reasons for this controversy might be 
the use of different analytical methods and approaches. Some of the studies used 
radioimmunoassay (RIA) method (Wu et al, 1995b, Gapstur et al, 2002, Nomura et al, 
1996)  whilst others analysed hormonal status by ELISA (Kehinde et al, 2006, Borugian et 
al, 2008).  ECLIA and IRMA methods were used by Sawada et al (2010) and Stattin et al 
(2004) respectively. This difference in the techniques used introduces a further variation 
factor and makes it difficult to conduct comparison of results obtained on different ethnic 
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groups. Our study ensured that the technique used for analysis of hormonal status in both 
ethnic groups was the same (ELISA).  
It should be mentioned that, in our study we were not able to obtain samples of prostate 
tissue and therefore we were not able to compare the serum hormone concentration with 
the concentration of the same hormones in the prostatic tissue. It has been reported that the 
tissue concentration of testosterone, DHT and even IGF-I may be a more sensitive 
indicator of the concentration within the glands compared to the serum concentration 
(Cardillo et al, 2003, Titus et al, 2005). Collecting sample tissues must be explored in the 
future in experiments on a larger number of participants and in a wider range of ethnic 
groups.   
The genetic studies conducted in this thesis were based on a relatively small number of 
polymorphisms that was identified based on their impact on PC in previous reports. Future 
studies should be directed to explore potential role of other genetic polymorphisms in 
various ethnic groups in relation to PC development. In particular, this refers to a multi-
ethnic population with low PC incidence in Malaysia. The genes which might be 
interesting in relation to PC are Vitamin D receptor (VDR). It has been reported that sun 
exposure and polymorphism at 3’ untranslated region in exon 2 of VDR gene may reduce 
the risk of PC in USA Hispanic and non-Hispanic (Caucasian and African descend) 
populations  (John et al, 2005). VDR gene study in Malaysian population may give 
important information on PC risk and incidence due to the tropical nature of the climate. A 
Japanese population study (Habuchi et al, 2000) also confirmed the protective nature of the 
VDR gene polymorphism against PC. . Further research on relationship between VDR 
polymorphism, differences in lifestyle and dietary habits is required. Identification of 
variations in the concentration of androgens, and growth factors as well as identification of 
SNPs in genes controlling androgen metabolism might be an important tool for detection 
 206 
 
of men with predisposition to PC, and for advocating any preventive medication or 
treatment strategy. It is rather surprising that studies in this field continue to produce 
conflicting data because there is very clear clinical evidence that patients with advance PC 
respond favourably to androgen deprivation therapy using either medical or surgical 
castration (Singer et al, 2008).  
Our research has found ethnic differences in testosterone, DHT/T as well polymorphisms 
in CYP17 and SRD5A2 in a study conducted under identical conditions for different ethnic 
groups. Therefore, we feel there is immense potential in studying further the androgen and 
growth factor related pathway and their relationship with genetic mutations in PC as 
potential ethnic group-specific biomarkers for PC.  
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6 Conclusions 
The main aim of the thesis was to investigate ethnic group-specific relationship between 
PC, androgens concentration and frequency of genetic polymorphism that play active role 
in androgen metabolism. The investigation focussed on the circulating concentration of 
testosterone and DHT as well as a growth hormone IGF-I. The genes studied were CYP17 
and SRD5A2 which encode for enzymes that play crucial role in androgen metabolism. 
This study also investigated polymorphisms in AR gene that determines functionality of 
AR. The key findings of this thesis are: 
1. The mean testosterone concentration did not differ significantly between Bristol 
Caucasian and MC ethnic groups (when PC and control data pooled together). To 
the best of our knowledge, this is the first communication based on direct 
comparison on the 2 ethnic groups in the same experiment.  
2. The mean testosterone concentration in the MC cancer group was significantly 
lower than in Caucasian cancer and MC control group.  Taking into account that 
MC group consisted of participants with a more advance stage of PC, the data 
suggest that an advanced cancer stage may result in reduction of testosterone 
concentration. 
3. The mean DHT concentration did not differ significantly between Bristol 
Caucasians and MC ethnic groups (when PC and control data pooled together). 
This suggests that ethnicity has no impact on circulating DHT concentration.  
4. Cancer group had a significantly lower DHT concentration than the control group 
(pooled data from Caucasian and MC group). However, this difference was not 
observed after taking into account the age factor.  
5. Data adjusted for age, showed that DHT/T was increased in MC group compared to 
Caucasians (when PC and control data pooled together). There was no difference in 
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DHT/T between MC control and Caucasian control groups. Ethnic group difference 
in DHT/T should be further investigated on a larger cohort to confirm impact of 
ethnicity on DHT/T. 
6. PC group had higher DHT/T when compared to control (when data from 
Caucasians and MC were pooled together) _. Sub-group analysis showed that MC 
cancer group had significantly higher mean DHT/T than Caucasian cancer and MC 
control groups. A larger number of cases with advanced PC stage in MC cohort 
might have contributed to these differences. These results suggest that PC grade 
may have an impact on the DHT/T ratio and therefore might be considered as a 
potential PC marker.  
7.  IGF-I concentration (unadjusted for age) was significantly higher in Caucasians 
than MC (when cancer and control were pooled together) but this difference was 
not observed for MC controls and Caucasian controls. This suggests IGF-I as a 
potential marker for PC. Caucasian cancer patients had higher IGF-I concentration 
compared to MC cancer group. MC cancer group had a significantly lower 
concentration of IGF-I than the MC control group.  
8. Frequency of A1, A2 and A1/A2 alleles of CYP17 gene did not vary between 
Caucasian and MC group and therefore it is unlikely to be linked to ethnicity. 
A1/A2 allele frequency was positively associated with PC risk in Caucasians but 
not in MC. This is an important finding which suggests that this polymorphism can 
be used an ethnic group-specific marker in PC risk assessment. A coincidental 
polymorphism at the position 135C→T of CYP17 gene was established. There was 
no significant association between frequency of this polymorphisms and PC risk. 
Further assessment of this SNP on a larger cohort is required. 
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9. The frequency of SRD5A2 LL and L/V genotypes were significantly higher in MC 
compared to Caucasians. The presence of these genotypes may explain the low 
incidence of PC in Asian community.   
10. An increased risk of PC was observed in the case of LL or LL + L/V genotypes and 
this risk was higher in the Caucasians compared to MC.  
11. In contrast to data of the literature, no polymorphisms were observed at the codon 
49 of SRD5A2 gene in both ethnic groups investigated. It was concluded that this 
polymorphism is a poor ethnic and PC marker in Caucasian and MC groups.  
12. No relationship was found between the mean numbers of CAG-repeats in AR gene 
and ethnicity or PC incidence.  
13. No significant relationship was found between CYP17 polymorphism at the 
position -34T→C and the concentration of testosterone and DHT in Caucasian or 
MC ethnic groups.  No association was found between the CYP17 polymorphism 
and PC either. IGF-I concentration was related to the above polymorphism in 
Caucasian control group. Further investigation is needed to assess relationship 
between the CYP17 polymorphism and PC.  
14. SRD5A2 polymorphism at the codon 89 was not related to testosterone and DHT 
concentration with exception of the Caucasian control group that needs further 
assessment. There was positive association between the SRD5A2 polymorphisms 
and IGF-I concentration in Caucasian cancer group.  
15. The number of CAG-repeats was not related to testosterone, DHT and IGF-I 
concentrations in both Caucasians and MC cancer and control groups. 
In conclusion, research presented in this thesis demonstrated ethnic groups- differences in 
the concentration of androgens and growth factor and ethnic-group-specific associations 
between these parameters and PC. The study also identified polymorphisms in CYP17 and 
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SRD5A2 that may play an important role in ethnic group-specific PC development. This 
study did not find significant relationship between a number of CAG-repeats in AR gene 
and PC in Caucasian or MC ethnic groups. Further evaluation of the results of this study on 
a larger cohort and in wider range of ethnic groups is needed 
It has been suggested that testosterone and DHT/T has good potential to be used as 
indicators of advanced PC. Polymorphisms in CYP17 (A2 and A1/A2) and the V89L 
variant of the SRD5A2 gene can be potentially used as an ethnic based markers for PC 
development, although further studies should be performed to compare larger multi-ethnic 
populations within the same environmental conditions.  
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7 Future work 
Findings of this research project will form the basis for future large-scale ethnic group-
specific studies on hormonal and genetic association with PC. This includes the study of 
circulating androgens, IGF-I concentrations and polymorphisms in CYP17, SRD5A2 and 
AR in larger study in Malaysia which would  involve all three major ethnic groups 
(Malays, Chinese and Indians) to establish variations within the same environmental 
conditions. Other future directions from this project would include:  
1. Analysis of androgens, IGF-I concentrations and expression of CYP17, SRD5A2 
and AR genes in prostatic tissues obtained by biopsy or surgical specimen from 
different ethnic groups in Malaysia. This will enable us to assess the intra-prostatic 
changes in the hormonal and genetic expressions that take place during cancerous 
changes of prostate gland. 
2.  To conduct analyses of genetic polymorphisms in CYP17, SRD5A2 and AR in PC 
patients facing multiple treatment options. This will assist with choosing the most 
effective treatment decisions.   
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Appendix A: Data for Caucasian prostate cancer patients. 
Patient DNA quality Test  
(ng/ml) 
DHT 
(ng/ml) 
DHT/T IGF-I 
(ng/ml) 
-34T→C V89L CAG 
Conc. 
(ng/µl) 
260/280 
CP1 42.90 1.85 2.91 0.74 0.26 75.60 A1 VV 20 
CP2 39.40 1.93 5.15 0.94 0.18 132.16 A1/A2 LL 25 
CP3 38.30 1.91 4.25 0.83 0.20 67.24 A1 LL 26 
CP4 41.90 1.95 1.36 0.27 0.20 44.45 A1/A2 VV 21 
CP5 69.90 1.81 3.44 0.87 0.25 100.19 A2 LL 29 
CP6 64.50 1.78 5.01 0.73 0.15 67.24 A1 LL 24 
CP7 129.50 1.90 3.14 0.38 0.12 70.04 A2 VV 25 
CP8 77.40 1.89 2.72 0.65 0.24 75.60 A1/A2 VV 22 
CP9 89.10 1.95 2.68 0.51 0.19 116.28 A1/A2 VV 20 
CP10 41.60 1.96 3.34 0.72 0.22 70.04 A1/A2 LL 21 
CP11 57.20 2.02 3.30 0.84 0.25 44.45 A1 LL 22 
CP12 89.60 1.81 3.68 0.46 0.13 44.45 A1/A2 VV 21 
CP13 63.60 1.85 3.34 0.54 0.16 150.47 A1 L/V 20 
CP14 81.40 1.86 5.54 0.64 0.12 231.93 A1/A2 LL 20 
CP15 174.80 1.91 3.26 0.81 0.25 97.49 A1/A2 LL 25 
CP16 59.40 1.89 2.95 0.17 0.06 41.53 A1 VV 20 
CP17 81.50 1.91 4.72 0.43 0.09 29.65 A1 VV 23 
CP18 44.40 1.99 2.65 0.54 0.20 94.78 A1 VV 26 
CP19 92.50 1.86 4.42 0.70 0.16 155.66 A1 VV 20 
CP20 45.60 1.86 3.12 0.39 0.12 209.33 A1/A2 LL 21 
CP21 77.00 1.87 3.22 0.61 0.19 143.13 A2 L/V 20 
CP22 69.30 1.90 2.07 0.29 0.14 43.00 A2 VV 22 
CP23 68.50 1.96 1.80 0.13 0.07 66.40 A1/A2 LL 26 
CP24 42.40 1.82 2.74 0.06 0.02 88.71 A1 VV 19 
CP25 57.50 1.93 2.99 0.27 0.09 107.25 A1 LL 18 
CP26 65.80 1.93 3.21 0.42 0.13 63.13 A1/A2 VV 25 
CP27 63.10 1.89 3.15 0.62 0.20 146.06 A1 VV 24 
CP28 64.80 1.94 1.89 0.62 0.33 119.36 A1/A2 VV 24 
CP29 56.70 1.85 4.54 0.56 0.12 379.75 A2 LL 23 
CP30 77.50 1.87 2.74 0.69 0.25 88.71 A1 VV 22 
CP31 35.60 2.01 2.78 0.52 0.19 91.83 A1 LL 21 
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Patient DNA quality Test  
(ng/ml) 
DHT 
(ng/ml) 
DHT/T IGF-I 
(ng/ml) 
-34T→C V89L CAG 
Conc. 
(ng/µl) 
260/280 
CP32 40.30 1.89 3.03 0.52 0.17 104.19 A1 LL 23 
CP33 54.00 1.81 2.26 0.63 0.28 69.64 A1 L/V 24 
CP34 79.40 1.90 7.33 1.06 0.14 113.33 A2 VV 23 
CP35 67.20 1.83 5.37 0.61 0.11 55.47 A2 VV 24 
CP36 80.70 1.91 3.68 0.80 0.22 63.92 A1 VV 20 
CP37 69.70 1.89 3.24 0.96 0.30 55.74 A1 LL 25 
CP38 42.60 1.87 2.79 0.83 0.30 35.18 A1/A2 VV 19 
CP39 68.50 1.88 2.07 0.60 0.29 158.62 A1 LL 18 
CP40 56.50 1.86 2.64 0.47 0.18 47.81 A1 LL 23 
CP41 48.60 1.73 2.47 0.35 0.14 81.70 A1 LL 24 
CP42 50.70 1.82 3.09 0.51 0.17 39.52 A1/A2 VV 24 
CP43 51.30 1.84 9.82 1.41 0.14 59.20 A1/A2 VV 27 
CP44 42.80 1.66 2.62 0.78 0.30 97.88 A1/A2 VV 21 
CP45 50.20 1.72 4.83 0.81 0.17 12.25 A1 VV 21 
CP46 39.30 1.81 3.83 0.48 0.12 100.68 A1/A2 VV 25 
CP47 63.40 1.82 4.28 0.54 0.12 58.82 A1 VV 23 
CP48 72.10 1.84 3.23 1.38 0.43 56.08 A1 LL 20 
CP49 71.00 1.90 1.72 0.20 0.11 37.90 A1 LL 24 
CP50 43.90 1.80 2.21 0.42 0.19 35.38 A1 VV 19 
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Appendix B: Data for Caucasian control patients. 
Patient DNA quality Test  
(ng/ml) 
DHT 
(ng/ml) 
DHT/T IGF-I 
(ng/ml) 
-34T→C V89L CAG 
Conc. 
(ng/µl) 
260/280 
CC1 84.80 1.77 3.45 0.70 0.20 140.03 A1/A2 VV 27 
CC2 41.20 1.88 5.50 1.07 0.19 116.28 A1 VV 24 
CC3 120.80 1.97 4.54 0.86 0.19 78.36 A1 LL 21 
CC4 76.80 1.86 4.47 0.89 0.20 121.59 A1 LL 23 
CC5 128.00 1.91 4.99 0.84 0.17 264.22 A1/A2 VV 20 
CC6 97.00 1.77 4.62 0.64 0.14 64.44 A1 VV 20 
CC7 107.50 1.85 3.14 0.42 0.13 97.49 A1/A2 LL 19 
CC8 109.30 1.91 4.47 0.96 0.22 189.05 A1/A2 VV 19 
CC9 107.80 1.94 2.97 0.70 0.24 102.89 A1/A2 VV 14 
CC10 68.40 1.94 3.60 0.78 0.22 113.61 A1 LL 18 
CC11 61.10 1.92 7.08 0.76 0.11 113.61 A1/A2 VV 23 
CC12 48.00 1.84 4.97 0.75 0.15 145.26 A1 VV 8 
CC13 55.00 1.85 2.76 0.54 0.19 47.00 A1 L/V 25 
CC14 64.80 1.85 5.33 0.64 0.12 41.53 A1 LL 19 
CC15 56.90 1.81 4.51 0.81 0.18 64.44 A1 VV 26 
CC16 87.00 1.91 4.70 0.47 0.10 55.95 A2 VV 23 
CC17 80.20 1.86 4.18 0.56 0.13 55.95 A1 VV 20 
CC18 85.60 1.82 4.69 0.85 0.18 70.04 A1 LL 19 
CC19 44.10 1.90 3.06 0.80 0.26 64.44 A1 LL 18 
CC20 81.30 1.85 4.39 0.63 0.14 75.60 2 VV 21 
CC21 49.70 1.79 2.27 0.85 0.38 49.83 A1 VV 21 
CC22 60.70 1.90 5.20 0.85 0.16 101.12 A1 VV 24 
CC23 61.10 1.85 3.11 0.21 0.07 69.64 A2 VV 18 
CC24 38.80 1.77 4.03 0.07 0.02 110.29 A2 VV 21 
CC25 72.60 1.89 6.05 0.39 0.06 110.29 A1 VV 23 
CC26 57.60 1.74 2.06 0.04 0.02 63.13 A2 L/V 20 
CC27 49.80 1.82 2.65 0.15 0.06 88.71 A1 L/V 25 
CC28 76.80 1.81 2.55 0.37 0.15 172.11 A2 VV 22 
CC29 63.20 1.76 4.38 0.56 0.13 94.94 A1 VV 26 
CC30 49.20 1.77 5.69 0.60 0.11 98.04 A1 L/V 24 
CC31 89.40 1.79 3.96 0.79 0.20 134.28 A1 VV 18 
CC32 31.60 1.75 5.53 0.99 0.18 113.33 A2 L/V 26 
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Patient DNA quality Test  
(ng/ml) 
DHT 
(ng/ml) 
DHT/T IGF-I 
(ng/ml) 
-34T→C V89L CAG 
Conc. 
(ng/µl) 
260/280 
CC33 48.50 1.79 0.52 0.17 0.32 143.13 A1 LL 18 
CC34 54.00 1.83 4.11 1.18 0.29 98.04 A1 L/V 24 
CC35 59.50 1.74 2.77 0.63 0.23 94.94 A1 LL 17 
CC36 65.00 1.82 4.60 0.81 0.18 72.86 A1 L/V 27 
CC37 71.90 1.91 5.03 0.93 0.18 119.36 A1 L/V 22 
CC38 79.80 1.86 8.44 1.03 0.12 91.83 A1 VV 26 
CC39 44.60 1.89 2.76 0.67 0.24 91.83 A1 L/V 18 
CC40 65.30 1.90 4.15 0.64 0.16 104.19 A2 L/V 24 
CC41 30.50 1.97 3.40 0.67 0.20 55.11 A1 VV 20 
CC42 54.90 1.90 4.60 0.78 0.17 66.31 A2 L/V 22 
CC43 54.80 1.88 2.44 0.50 0.21 129.41 A1 L/V 21 
CC44 52.00 1.90 3.36 0.40 0.12 63.14 A1 L/V 19 
CC45 44.90 1.89 5.44 0.70 0.13 35.14 A1 L/V 20 
CC46 31.00 1.88 4.45 0.67 0.15 115.58 A1 L/V 19 
CC47 69.00 1.89 3.28 0.76 0.23 62.40 A1 L/V 25 
CC48 57.30 1.86 3.18 0.66 0.21 80.58 A2 LL 19 
CC49 44.60 1.82 1.85 0.52 0.28 82.48 A1 LL 24 
CC50 68.20 1.82 1.80 0.51 0.28 100.73 A2 L/V 18 
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Appendix C: Data for Malaysian Chinese prostate cancer 
patients. 
Patient DNA quality Test  
(ng/ml) 
DHT 
(ng/ml) 
DHT/T IGF-I 
(ng/ml) 
-34T→C V89L CAG 
Conc. 
(ng/µl) 
260/280 
MP1 20.20 1.72 0.28 0.47 1.69 46.43 A2 LL 22 
MP2 21.60 1.82 0.42 0.78 1.84 98.04 A1 LL 24 
MP3 24.60 1.68 3.68 0.78 0.21 151.90 A1 VV 26 
MP4 17.60 2.04 4.45 0.78 0.18 104.19 A2 L/V 23 
MP5 20.10 1.84 7.26 1.10 0.15 49.83 A2 LL 18 
MP6 41.20 1.87 0.20 0.33 1.68 39.30 A1 LL 16 
MP7 23.10 1.97 3.28 0.19 0.06 86.25 A1 VV 24 
MP8 13.10 1.94 3.99 0.55 0.14 118.28 A2 LL 23 
MP9 15.60 1.84 3.37 0.65 0.19 94.09 A1 LL 15 
MP10 7.40 1.97 0.15 0.02 0.12 33.31 A1 LL 28 
MP11 33.20 1.59 0.72 0.10 0.14 86.19 A2 L/V 31 
MP12 19.80 1.91 0.09 0.17 1.82 50.13 A1 LL 22 
MP13 54.00 1.86 0.16 0.08 0.49 58.97 A1 LL 24 
MP14 43.40 1.88 3.35 0.21 0.06 71.26 A2 LL 20 
MP15 13.70 1.90 3.91 0.52 0.13 36.61 A1/A2 VV 27 
MP16 23.50 1.88 4.47 0.79 0.18 35.33 A1 L/V 25 
MP17 19.70 1.91 0.08 0.02 0.22 70.98 A2 L/V 23 
MP18 28.70 1.91 5.03 0.86 0.17 56.02 A1 LL 27 
MP19 31.80 1.85 0.27 0.34 1.26 23.05 A1 LL 22 
MP20 33.50 1.79 0.05 0.06 1.25 36.64 A2 LL 20 
MP21 32.70 1.92 0.55 0.09 0.16 83.92 A1 L/V 23 
MP22 17.70 1.90 0.06 0.20 3.59 27.99 A2 L/V 21 
MP23 30.30 1.76 5.31 0.66 0.13 39.35 A1/A2 LL 27 
MP24 19.40 1.61 0.27 0.18 0.66 22.91 A1 LL 17 
MP25 26.80 1.64 0.17 0.14 0.83 20.66 A1 L/V 21 
MP26 37.40 1.91 5.46 0.42 0.08 44.76 A2 L/V 24 
MP27 41.30 1.84 4.22 0.74 0.18 57.20 A1 L/V 16 
MP28 21.40 1.67 0.11 0.26 2.44 70.05 A1 L/V 22 
MP29 31.20 1.75 3.70 0.58 0.16 19.87 A2 VV 22 
MP30 33.50 1.76 4.74 0.75 0.16 39.47 A1 LL 19 
MP31 26.90 1.87 5.50 1.29 0.23 43.42 A2 LL 19 
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Patient DNA quality Test  
(ng/ml) 
DHT 
(ng/ml) 
DHT/T IGF-I 
(ng/ml) 
-34T→C V89L CAG 
Conc. 
(ng/µl) 
260/280 
MP32 51.20 1.79 0.14 0.31 2.28 50.49 A2 LL 23 
MP33 17.70 1.84 3.89 0.58 0.15 67.29 A1 LL 24 
MP34 47.60 1.83 1.47 0.28 0.19 94.34 A1 LL 24 
MP35 19.20 1.81 2.38 0.18 0.08 57.75 A1/A2 LL 24 
MP36 12.70 1.84 10.64 0.98 0.09 26.85 A1/A2 LL 24 
MP37 10.50 1.94 0.17 0.43 2.62 62.11 A1/A2 L/V 12 
MP38 31.60 1.75 0.33 0.56 1.72 52.69 A1/A2 L/V 22 
MP39 50.30 1.86 0.24 0.34 1.39 85.07 A1/A2 L/V 15 
MP40 13.70 1.71 2.86 0.52 0.18 133.05 A1 L/V 22 
MP41 19.60 1.57 1.73 0.30 0.18 134.29 A1 LL 22 
MP42 20.60 1.88 1.79 0.32 0.18 45.75 A1 LL 27 
MP43 19.50 1.78 4.14 0.28 0.07 36.66 A1 LL 22 
MP44 22.30 1.90 5.26 0.39 0.07 38.10 A1 L/V 21 
MP45 20.40 1.86 5.45 0.61 0.11 46.60 A1 LL 21 
MP46 9.40 1.69 3.52 0.79 0.23 72.26 A1 LL 26 
MP47 23.20 1.72 0.65 0.30 0.47 201.14 A1 L/V 25 
MP48 16.40 1.84 5.97 0.63 0.11 40.83 A1/A2 V 23 
MP49 25.40 1.84 2.18 0.29 0.13 81.85 A1 LL 27 
MP50 17.50 1.90 6.56 0.86 0.13 85.29 A1 L/V 19 
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Appendix D: Data for Malaysian Chinese control patients 
.Patient DNA quality Test  
(ng/ml) 
DHT 
(ng/ml) 
DHT/T IGF-I 
(ng/ml) 
-34T→C V89L CAG 
Conc. 
(ng/µl) 
260/280 
MP1 21.60 1.99 2.14 0.43 0.20 79.77 A1 LL 22 
MP2 12.90 1.68 3.78 0.45 0.12 38.16 A1 L/V 24 
MP3 17.00 1.90 3.30 0.25 0.07 82.31 A2 LL 20 
MP4 23.30 1.84 3.70 0.03 0.01 82.83 A1 LL 26 
MP5 21.30 1.93 3.14 0.44 0.14 104.13 A1 LL 23 
MP6 22.50 1.94 4.84 0.62 0.13 139.06 A1 LL 26 
MP7 14.90 1.95 2.88 0.07 0.03 133.06 A1 L/V 22 
MP8 30.70 1.91 8.05 0.56 0.07 175.74 A1 LL 22 
MP9 36.30 2.00 4.65 0.42 0.09 89.96 A1 LL 16 
MP10 16.70 1.96 3.97 0.15 0.04 58.97 A1 LL 22 
MP11 26.70 1.95 4.40 0.61 0.14 74.11 A2 L/V 24 
MP12 15.50 1.82 4.36 0.72 0.16 63.64 A1 LL 21 
MP13 30.60 2.03 6.60 0.87 0.13 75.21 A1 L/V 26 
MP14 27.60 1.98 4.73 0.63 0.13 77.13 A1 LL 22 
MP15 8.20 2.21 3.28 0.30 0.09 60.44 A1 L/V 24 
MP16 16.80 2.03 2.89 0.51 0.18 62.79 A1 L/V 24 
MP17 37.90 1.95 4.60 0.60 0.13 85.90 A1 L/V 22 
MP18 58.10 0.80 4.75 0.47 0.10 56.38 No DNA 
MP19 40.10 1.99 7.77 0.89 0.12 53.06 A1 L/V 21 
MP20 81.50 1.92 8.05 0.86 0.11 82.88 A1 LL 24 
MP21 10.70 1.90 6.38 0.83 0.13 69.93 A2 LL 17 
MP22 54.70 1.78 5.58 0.65 0.12 96.76 A2 L/V 20 
MP23 68.40 1.90 3.11 0.81 0.26 111.30 A2 L/V 21 
MP24 55.40 1.80 11.02 1.40 0.13 100.59 A1 LL 21 
MP25 32.80 1.94 7.12 1.08 0.15 36.86 A2 LL 27 
MP26 17.40 1.97 4.76 0.71 0.15 59.86 A2 VV 22 
MP27 18.10 1.84 4.80 0.64 0.13 71.81 A1 LL 20 
MP28 19.00 1.90 6.92 0.63 0.09 100.81 A1 LL 27 
MP29 40.10 1.91 6.92 0.61 0.09 88.48 A1 LL 27 
MP30 28.10 1.85 4.94 0.76 0.15 124.48 A1/A2 LL 22 
MP31 41.80 1.88 3.81 0.93 0.24 62.00 A1/A2 LL 30 
MP32 43.20 1.90 5.38 0.67 0.13 84.56 A1/A2 LL 26 
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Patient DNA quality Test   
(ng/ml) 
DHT 
(ng/ml) 
DHT/T IGF-I 
(ng/ml) 
-34T→C V89L CAG 
Conc. 
(ng/µl) 
260/280 
MP33 48.20 1.95 4.33 0.69 0.16 73.00 A1 LL 17 
MP34 64.10 1.88 3.82 0.95 0.25 119.68 A1 L/V 21 
MP35 60.40 1.89 2.52 0.86 0.34 92.97 A1/A2 LL 25 
MP36 44.40 1.97 4.43 0.50 0.11 77.31 A1 LL 19 
MP37 26.20 1.99 4.44 0.75 0.17 106.29 A2 LL 24 
MP38 63.00 1.94 1.69 0.27 0.16 109.81 A1 LL 23 
MP39 57.30 1.83 5.46 0.67 0.12 64.37 A1 LL 15 
MP40 19.50 2.02 4.88 0.72 0.15 58.31 A1 LL 24 
MP41 24.10 2.06 4.62 0.64 0.14 105.80 A1 LL 22 
MP42 29.10 1.99 7.00 1.00 0.14 142.69 A1 L/V 24 
MP43 59.90 1.86 2.85 0.74 0.26 107.83 A2 VV 21 
MP44 38.70 1.96 4.99 0.65 0.13 106.49 A1 LL 21 
MP45 35.90 1.86 4.29 0.59 0.14 103.51 A1 LL 18 
MP46 25.80 2.05 1.83 0.20 0.11 61.84 A1 VV 24 
MP47 47.40 1.83 1.77 0.63 0.35 202.64 A1 L/V 26 
MP48 25.50 1.62 3.20 0.76 0.24 60.15 A1 VV 23 
MP49 30.70 1.87 2.77 0.68 0.25 52.63 A1 LL 21 
MP50 70.40 1.86 5.24 0.62 0.12 111.25 A1 L/V 22 
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Appendix E: Sequence alignments 
(i) Alignment of CYP17 gene for 3 patients indicating the start codon (ATG) (red). 
  
 
 
Start codon -34T→C 
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(ii) Alignment of SRD5A2 gene for 2 patients indicating the start codon (ATG) (red) and Val to Leu substitution (green) at codon 89.   
 
  
 
 
 
Start codon 
Val to Leu substitution 
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(iii) Alignment of AR gene showing the number of CAG repeat in 2 samples. 
 
 
CAG repeat 
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Appendix F: Abstract 
 
33rd Congress of the Sociĕtĕ Internationale D’Urologie, Sept. 2013, Vancouver 
Convention Centre, Canada.  
UP.034  
 
Single Nucleotide Polymorphism (SNP) in CYP17A1 (rs743572) Gene as a Risk of 
Prostate Cancer Development – A Preliminary Report in Caucasian Group  
Kuppusamy S1, 2, 3, White P1, Razack A3, Gillatt D2, Rhodes A1, Doran O1  
1University of West of England, Bristol, UK; 2Bristol Urological Institute, Bristol, UK; 
3University of Malaya, Kuala Lumpur, Malaysia  
Introduction and Objectives: This study aims to sequence the established regions of 
CYP17A1 (rs743572) from Caucasians and to compare them with imported DNA from 
Malaysian Chinese group to investigate presence of ethnic-group specific single nucleotide 
polymorphism (SNP). This research will generate initial data for future clinical studies for 
development of biomarkers in ethnic-based prostate cancer screening.  
Materials and Methods: Blood sample obtained from newly diagnosed and biopsy 
confirmed prostate cancer patients from Caucasian men. Controls are confirmed Benign 
Prostatic Hyperplasia patients with normal digital rectal examination, with a PSA of < 
4.0ng/ml and with no family history of prostate cancer. Genetic polymorphisms were 
investigated by isolation of genomic DNA from whole blood and subsequent PCR ampli-
fication and DNA sequencing. Sequencing result aligned with reference gene using 
software (Geneious) to identify SNPs and anomalies in the translated protein.  
Results: A preliminary result for 40 prostate cancer and 25 control patients among the 
Caucasians showed polymorphic T to C substitution in the 5’-untranslated region of the 
CYP17A1 (rs743572) gene in 50% (n=20) and 36% (n=9) respectively. The mean age of 
participants in both groups was 66 years. The median PSA was 6.7 and 2.1 ng/ml 
respectively. This polymorphism was seen mainly in cancer cases with Gleason grade ≥7 
(n=15) (75%).  
Conclusion: The rs743572 polymorphism appears to be more common among the cancer 
group, however, statistical significance will only be ascertained once all the Caucasian 
samples has been analysed. Imported Malaysian samples will also be tested using similar 
protocol in order to provide further evidence in testing ethnic variation of the above 
polymorphism. 
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